2054
AZIMAT NUCLEAR MEDICINE B Y DR ZOOL HILMI 2012

AZIMAT NUCLEAR PDF .pdf

  • Upload
    rahmat

  • View
    261

  • Download
    10

Embed Size (px)

Citation preview

Page 1: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1/2049

AZIMAT NUCLEAR MEDICINE

BY

DR ZOOL HILMI2012

Page 2: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2/2049

SIMPLE PHYSIC

Page 3: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 3/2049

Radionuclide Decay mode Half time Energy (keV) Production

method

Thallium-201 Electron capture 73.1 hr 69-83(94%) ,

135(3%) 167(10%)

Cyclotron

Gallium-67 Electron capture 78.3 hr 93(37%),185(20%),3

00(17%),395(5%)

Cyclotron

Indium-111 Electron capture 2.8 d 171(90%),245(94%) Cyclotron

Iodine-123 Electron capture 13.2 hr 159 Cyclotron

Iodine-131 Beta minus 8 d 364 Reactor

Technetium-99m Isomeric

transition

6 hr 140 Generator

Cobalt-57 Electron capture 272 d 122 Cyclotron

Fluorine-18 Positron emitting 110 min 0.653 MeV Cyclotron

Gallium-68 Positron emitting 68 min 1.9 MeV Generator

Carbon-11 Positron emitting 20 min 0.96 MeV Cyclotron

Nitrogen-13 Positron emitting 10 min 1.19 MeV Cyclotron

Oxygen-15 Positron emitting 2 min 1.70 MeV Cyclotron

Rubidium-82 Positron emitting 1.3 min 3.15 MeV Generator

Page 4: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 4/2049

ɤ/xrayinteraction with

matter

Coherent/Rayleigh/

classical scatter

Pair production

Photodisintegration

Photo electric

Compton scatter

-Low energy photon excites atom but then

passes through without energy transfer

-High energy photon interact with nucleus

& converted to electron and photon-Positron and electron annihilation with

two 511 keV 180 degree

-High energy photon absorbed by nucleus

resulting disintegration of nucleus

-Energy threshold 15 MeV

-Photon interact with inner shell electron

-Photon energy totally absorbed by inner

shell electron

-Electron is ejected (photoelectron)

-Outer shell electron fill the inner shell-

characteristic radiation or Auger electron

-Energy of emitted photoelectron =

difference of incident photon energy and

electron binding energy-Low energy dominant

-PE∝ 3/³ 

-Photon interact with outer shell electron

-Loosely bound electron

-High energy photon – more straight scatter

-Compton ∝ electron density/ E

Page 5: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 5/2049

Decay

Alpha

Beta

Gamma

-Consist 2 neutrons and 2 protons = Helium

-Atomic no > 82

-In decay, atomic no decreases by 2 and mass

no decreases by 4

-Travel from 1 – 10 cm in air

-Travel < 0.1 cm in tissue

-High risk if ingested or injected

Electron

Positron

Electron

capture

Isomeric

transition

Internal

conversion

-Neutron rich

-n/p high

-n= p + ßˉ + v 

-High proton-n/p low

-n= n +ßᶧ + v

-High proton

-n/p low

-p + e = n + v

-Tc-99m = ɤ + Tc99

Page 6: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 6/2049

eˉ 

eˉ 

Q = EXPOSURE

AMOUNT OF ELECTRICAL CHARGE

PRODUCED BY IONIZING

ELECTROMEGNETIC RADIATION PER

MASS OF AIR

UNIT = C/Kg = Roentgen

1 R = 2.58 x 10 ˉ⁴ C/Kg

.SKIN DOSERADIATION EXPOSURE INCIDENT TO

PATIENT DUE TO RADIOLOGICAL

EXAMINATION

CHEST X RAY = 0.1 – 0.2 mGy

SKULL = 1.5 mGy

ABDOMEN = 3 mGy

LUMBAR = 10 mGy

K = KERMA

ENERGY CARRIED BY PHOTON (OR

OTHER INDIRECT IONIZING

RADIATION) TRANSFER ENERGY TO

CHARGE PARTICLE (

PE/COMPTON/PAIR PRODUCTION

UNIT = J/Kg OR Gray

D = ABSORB DOSE

DIRECTLY IONIZATION CHARGE

PARTICLE DEPOSIT ENERGY BY

(EXCITATION/IONIZING) PER UNIT

MASS

UNIT = J/Kg

1 Gray = 1 J/ Kg100 rad = 1 Gray

Rad = RADIATION ABSORB DOSE

E = EFFECTIVE DOSE

ICRP 1990

MEASURE OF RADIATION AND

ORGAN SYSTEM SPECIFIC DAMAGE

IN HUMAN

UNIT = Sievert

100 rem = 1 Sv = J/Kg

WT = TISSUE WEIGHTING FACTOR

GONAD = 0.2

BONE

MARROW/LUNG/STOMACH/COLON

= 0.12

BLADDER/BREAST/LIVER/THYROID

= 0.05

SKIN/BONE = 0.01

H = EQUIVALENT DOSE

ICRP 1990

MEASURE OF RADIATION SPECIFIC

BIOLOGIC DAMAGE IN HUMAN

UNIT = Sievert

100 rem = 1 Sv = J/Kg

WR = RADIATION WEIGHTING

FACTOR

XRAY/ɤ/ß/e  = 1

PROTON > 2 MeV = 5

NEUTRON = 5 – 20

ΑLPHA = 20

SOURCE

Page 7: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 7/2049

 

Page 8: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 8/2049

 PARATHYROID SCINTIGRAPHY

Page 9: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 9/2049

Pearls & Pitfalls

Parathyroid

imaging

• The most common indication for

parathyroid imaging is to localize thehyperfunctioning gland (adenoma) either

in the thyroid bed or in the ectopic

location (lower neck or mediastinum)

• Parathyroid adenomas are usually single

• Parathyroid imaging is usually performed

by using Tc-99m sestamibi withsequential images after 2 hours, whereas

parathyroid adenomas usually

hyperconcentrate Tc-99m sestamibi and

persist over time

Page 10: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 10/2049

PARATHYROID SCINTIGRAPHY

ANATOMY AND EMBRYOLOGY

Page 11: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 11/2049

ANATOMY

• 4 parathyroid glands

• Measuring 6mm x 3mm

• Weighing 35 – 40 gram

• Rarely, may be only 2 glands or as many as 8

glands

Page 12: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 12/2049

 

Page 13: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 13/2049

EMBRYOLOGY

• Inferior parathyroid glands arise from 3rd 

branchial pouch and migrate caudally with the

thymus

• Superior glands arise from 4th branchial pouch

and migrate with the thyroid

Page 14: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 14/2049

 

Page 15: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 15/2049

 

Page 16: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 16/2049

 

Page 17: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 17/2049

 

Page 18: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 18/2049

Type of cells in parathyroid

1. Chief cell  –  produces parathyroid hormone

(PTH) and it has little mitochondria orcytoplasma

1. Oxyphil cell – high number of mitochondria.

Page 19: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 19/2049

Pathophysiology

• Hyperpathyroidism :

1. Primary hyperpathyroidism

2. Secondary hyperpathyroidism

3. Tertiary hyperpathyroidism

Page 20: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 20/2049

 

Page 21: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 21/2049

Hyperparathyroidism

• Chief cells (single or multiple glands)synthesis

more and release more PTH

• PTH synthesize, stored and secreted by

parathyroid glands

• PTH responsible for calcium and phosphorus

homeostasis by its action on bone, small

intestine and kidneys

Page 22: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 22/2049

 

Page 23: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 23/2049

 

Page 24: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 24/2049

 

Page 25: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 25/2049

 

Page 26: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 26/2049

 

Page 27: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 27/2049

 

Page 28: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 28/2049

 

Page 29: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 29/2049

 

Page 30: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 30/2049

 

Page 31: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 31/2049

+

Page 32: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 32/2049

 

Page 33: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 33/2049

 

Page 34: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 34/2049

 

Page 35: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 35/2049

 

Page 36: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 36/2049

 

Page 37: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 37/2049

 

Page 38: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 38/2049

 

Page 39: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 39/2049

 

Page 40: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 40/2049

 

Page 41: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 41/2049

 

Page 42: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 42/2049

 

Page 43: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 43/2049

 

Page 44: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 44/2049

 

Page 45: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 45/2049

 

Page 46: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 46/2049

 

Page 47: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 47/2049

 

Page 48: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 48/2049

 

Page 49: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 49/2049

 

Page 50: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 50/2049

 

Page 51: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 51/2049

 

Page 52: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 52/2049

 

Page 53: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 53/2049

 

Page 54: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 54/2049

Scan of Tc-99m MIBI

Page 55: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 55/2049

Tc-99m MIBIHeart

GIKidney

Bladder 

Page 56: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 56/2049

Normal uptake for Tc-99m MIBI

Salivary gland

Parotid gland

Renal

Bladder

Heart

Intestine

Thyroid

Parathyroid

Concerning imaging of parathyroid

Page 57: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 57/2049

Concerning imaging of parathyroid

glands

A. Approximately 50% of cases of primaryhyperparathyroidism are due to a single functioningadenoma

B. The sensitivity of parathyroid scintigraphy in the

detection of adenomas within the gland approaches75%

C. In secondary hyperparathyroidism approximately 80%of hyperplastic glands will be visualized

D. The majority are parathyroid adenomas are

functioningE. False positive scans may occur in the presence of

coexisting thyroid disease

Concerning imaging of parathyroid

Page 58: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 58/2049

Concerning imaging of parathyroid

glands

A. F

B. T

C. F

D. T

E. T

Tc 99m sestamibi uptake may be found

Page 59: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 59/2049

Tc-99m sestamibi uptake may be found

in

A. Parathyroid hyperplasia

B. Parathyroid adenoma

C. Thyroid adenoma

Tc 99m sestamibi uptake may be found

Page 60: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 60/2049

Tc-99m sestamibi uptake may be found

in

A. T

B. T

C. T

In performing Tl 201/Tc 99m

Page 61: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 61/2049

In performing Tl-201/Tc-99m

pertechnitate parathyroid studies, it is

best perform the pertechnitate studyfirst

In performing Tl 201/Tc 99m

Page 62: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 62/2049

In performing Tl-201/Tc-99m

pertechnitate parathyroid studies, it is

best perform the pertechnitate studyfirst

• FALSE

Page 63: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 63/2049

What is the typical finding of

parathyroid adenomas on parathyroidimaging with Tc-99m sestamibi?

Page 64: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 64/2049

What is the typical finding of

parathyroid adenomas on parathyroidimaging with Tc-99m sestamibi?

• Parathyroid adenomas show delayed washout

compared with normal thyroid tissue

Page 65: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 65/2049

Page 66: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 66/2049

Hyperparathyroidism

1. Tc-99m sestamibi is taken up by thyroid and

parathyroid tissue, but wash out more rapidly

from the thyroid.

2. Parathyroid adenoma in the region of the leftlower lobe of the thyroid.

3. > 90% predictive value for preoperative

localization of parathyroid adenoma, lower testaccuracy for hyperplasia and small tumors.

4. Thyroid follicular adenoma.

Page 67: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 67/2049

Page 68: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 68/2049

Parathyroid adenoma

1. Dual isotope imaging with subtraction, in the past usingTl-201 and Tc-99m pertechnitate and recently using I-123and Tc-99m sestamibi

2. I-123 by mouth. After a delay of 2 to 3 hours, an anterior I-123 thyroid scan is obtained. Without moving the patient,

an image is obtained after IV injection of Tc-99m MIBI. TheI-123 image is computer subtracted from the Tc-99m MIBIimage.

3. The I-123 thyroid scan appears normal, although the leftlobe extends more inferiorly. The MIBI image shows an

asymmetrical bulbous configuration in the region of theright lower pole of the thyroid. Subtraction demonstratesfocal radiotracer compatible with parathyroid adenoma atthe lower pole of the right thyroid.

4. Parathyroid, thyroid adenoma, thyroid carcinoma and

metastatic carcinoma.

Page 69: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 69/2049

Page 70: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 70/2049

Mediastinal parathyroid adenoma

1. Parathyroid scan with Tc-99m sestamibi or Tc-

99m tetrofosmin.

2. Focal persistent uptake in the mediastinum,

normal salivary, liver, cardiac uptake. Axillaryuptake resolves with arm elevated, thus is

caused by skin folds.

3. Various benign and malignant neoplasm.

4. Mediastinal parathyroid adenoma.

Page 71: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 71/2049

ADRENAL SCINTIGRAPHY

Pearls & Pitfalls

Page 72: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 72/2049

Pearls & Pitfalls

Adrenocorticalimaging

• NP-59 is an adrenal cortical

imaging agent with imaging

performed at 4-5 days.

Unilateral adrenal uptake isusually an adenoma and

bilateral uptake is usually due

to adrenal hyperplasia

Page 73: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 73/2049

ADRENAL SCINTIGRAPHY

• Common indication is hypercortisolism

(Cushing’s syndrome)

• Less common :

a) Hyperaldosterolism (Conn’s syndrome)

b) Adrenal virilizing tumors

Page 74: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 74/2049

 

Page 75: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 75/2049

ADRENAL

CORTEX MEDULLA

ZONA

GLOMERULOSA

ZONA

FASCICULATAZONA

RETICULARIS

ALDOSTERONE CORTISOL ANDROGENS

CUSHING’S CONN’S 

EPINEPHRINE

Page 76: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 76/2049

 

Page 77: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 77/2049

 

Drugs that interfere with NP – 59

Page 78: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 78/2049

Drugs that interfere with NP   59

uptake

Drug MechanismSpironolactone Aldosterone receptor blocker

Ketoconazole Suppression of cortical biosynthesis

Diuretic/oral contraception Stimulate renin/angiotensin

Glucocorticoids Suppression of ACTH

Cholesterol lowering agents Decrease cholesterol

Hypercholesterolemia Decrease LDL receptor activity

Page 79: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 79/2049

 

HYPERALDOSTERONISM NP-59

Page 80: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 80/2049

HYPERALDOSTERONISM NP 59

PATTERN

SYMMETRICAL

BILATERALLY EARLY

IMAGING (BEFORE DAY 5)

SYMMETRICAL LATE

IMAGING (ON OR

AFTER DAY 5)

UNILATERAL EARLY

IMAGING (BEFORE

DAY 5)

-Bilateral autonomous

hyperplasia-Secondary

aldosteronism

-Conn’s tumor -aldosterone

secreting tumor

Normal adrenal

Page 81: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 81/2049

 

CUSHING’S SYNDROME NP-59

Page 82: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 82/2049

CUSHING S SYNDROME NP 59

PATTERN

ADRENALSCINTIGRAM

BILATERAL

VISUALIZATION

UNILATERALVISUALIZATION

BILATERAL NON

VISUALIZATION

SYMMETRIC

ASYMMETRIC

ADENOMA

CARCINOID

DRUG THERAPY

BILATERAL HYPERPLASIA

BILATERAL HYPERPLASIA

(SOME ASYMMETRY IS

COMMON)

BILATERAL HYPERPLASIA

ASSOSIATED WITH

UNILATERAL ADENOMA

ADRENAL REMNANTAFTER

ADRENALECTOMY

Page 83: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 83/2049

 

Page 84: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 84/2049

 

Page 85: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 85/2049

 

Page 86: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 86/2049

 

Page 87: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 87/2049

 

Page 88: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 88/2049

 

Page 89: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 89/2049

 

C i i ti h f th d l

Page 90: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 90/2049

Concerning scintigraphy of the adrenal

A. Asymmetrical uptake of NP 59 may be seen in twothirds in normal subject

B. Bilateral symmetrical uptake of NP 59 in the presenceof glucocorticoid excess is usually due to adrenalhyperplasia

C. Unilateral increased uptake following NP 59 is mostcommonly due to functioning adenoma

D. Bilateral non visualization of the adrenals in thepresence of endogenous glucocorticoid excess is most

likely to be due to adrenal carcinomaE. Unilateral non visualization exclude an adrenal

carcinoma

C i i ti h f th d l

Page 91: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 91/2049

Concerning scintigraphy of the adrenal

• TTTTF

In the scintigraphy assessment of

Page 92: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 92/2049

g p y

adrenal hypertension

A. Pretreatment with dexamethasone in patients withprimary hyperaldosteronism significantly improvesthe diagnostic accuracy of NP 59 scanning

B. Following dexamethasone suppression, a Conn’s adenoma will usually be seen before day five

C. NP 59 scintigraphy can distinguish ACTH dependentfrom ACTH independent Cushing’s syndrome

D. False negative results may be seen during MIBGscanning in patients with pheochromocytoma on

steroid therapyE. Activity in the normal gland is usually suppressed in

the presence of a unilateral pheochromocytoma

In the scintigraphy assessment of

Page 93: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 93/2049

g p y

adrenal hypertension

• TTTFF

Page 94: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 94/2049

Adrenocortical scintigraphy

Page 95: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 95/2049

Adrenocortical scintigraphy

1. A, Unilateral NP-59 uptake consistent with leftadrenal adenoma, concordant with the CT. B,Bilateral adrenal hyperplasia, discordant with CT.

2. Uptake in the right adrenal bed region indicating

adrenal remnant. Discordant with the negativeCT.

3. Transport and receptors system for serumcholesterol account for adrenal uptake.

Cholesterol is required for the production ofadrenal hormones.

4. Hyperaldosteronism (adrenal adenoma orhyperplasia) and hyperandrogenism.

Page 96: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 96/2049

ADRENOMEDULLARY

SCINTIGRAPHY

Pearls & Pitfalls

Page 97: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 97/2049

Adrenomedullary

imaging

• MIBG is a medullary adrenalimaging agent which effectivelylocalizes in pheochromocytoma

and neuroblastoma. It may alsolocalize in carcinoid, medullarythyroid carcinoma andparaganglioma.

Page 98: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 98/2049

 

Page 99: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 99/2049

Heart

Liver

Kidney

Bladder

MIBG scan

Page 100: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 100/2049

MIBG scan

Heart

Liver

Kidney

Bladder

Page 101: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 101/2049

Page 102: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 102/2049

Thyroid blockade

Page 103: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 103/2049

Thyroid blockade

• Potassium perchlorate for emergency andallergic to iodine= 400 mg

Compound Daily dose

Capsules

Potassium iodate 170 mg

Potassium iodide 130 mg

Solution

Lugol 1% 1 drop/kg max 40 (20 drops bd)

Oncology Committee of the EANM 

Page 104: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 104/2049

Page 105: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 105/2049

Page 106: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 106/2049

Page 107: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 107/2049

In-111 pentetreotide (octreoscan)

Page 108: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 108/2049

normal uptake at kidney, spleen, liver ,

thyroid and intestinal activity

Somatostatin analog limitations

Page 109: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 109/2049

Somatostatin analog limitations

False negative

Small &Few somatostatin receptors

Page 110: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 110/2049

Page 111: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 111/2049

Page 112: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 112/2049

Multiple endocrine neoplasia (MEN)

t 1

Page 113: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 113/2049

type 1• Dominantly inherited

• Mutation of MEN 1 gene on chromosomal region11q13

• Include :Parathyroid = hyperplasia or adenoma (90%)

Pancreatic islet = adenoma, carcinoma or

hyperplasia (80%)Anterior pituitary = adenoma (65%)

Adrenal cortex = hyperplasia or adenoma (40%)

Carcinoid tumors and lipomata

Multiple endocrine neoplasia (MEN)

Page 114: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 114/2049

type 2

Parafollicular cells of thyroid = Medullarycarcinoma (> 95%)

• Adrenal adrenal = pheochromocytoma (50%)

•Parathyroid = hyperplasia or adenoma (<25%)

Page 115: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 115/2049

The following tissues may show

d k f

Page 116: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 116/2049

increased uptake of MIBG

• TTFTT

The following are true concerning

Page 117: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 117/2049

MIBG scanning

A. Focal bone marrow activity in the presence of aknown neuroblastoma may be normal

B. The sensitivity of MIBG scanning in the detection ofneuroblastoma is approximately 90%

C. MIBG scanning is more accurate than CT or MRI in thedetection of primary adrenal pheochromocytoma

D. Increased adrenal uptake of MIBG in the MENsyndrome confirm the presence of

pheochromocytomaE. MIBG scanning accurately reflects the extent of bony

involvement in metastatic neuroblastoma

The following are true concerning

I G i

Page 118: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 118/2049

MIBG scanning

• FTFFF

A. I-131 NP 59

B In 111 Octreoscan

Page 119: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 119/2049

B. In-111-Octreoscan

C. I-131 MIBG1. Adrenal cortical adenoma

2. Pituitary adenoma

3. Medullary thyroid carcinoma

4. Pheochromocytoma

5. Carcinoid tumor

A. I-131 NP 59

B In 111 Octreoscan

Page 120: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 120/2049

B. In-111-Octreoscan

C. I-131 MIBG1. Adrenal cortical adenoma = A

2. Pituitary adenoma = B

3. Medullary thyroid carcinoma =B

4. Pheochromocytoma = C

5. Carcinoid tumor = B

Page 121: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 121/2049

Neuroblastoma

Page 122: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 122/2049

1. Bone scan shows uptake symmetrically in the distal

femurs, cranial and facial bones. I-131 MIBG shows a largearea of midline abdominal uptake. Inspection of the bonescan in the same area suggests a soft tissue left perirenaldensity, best seen in the anterior view. In addition, diffusemarrow/bone uptake is seen on the MIBG study.

2. The prominent mid line uptake on the MIBG is consistentwith neuroblastoma. Subtle bone uptake is seen in theregion. The symmetrical bone uptake in the distal femurs,cranial and facial bone is very suggestive of tumor. TheMIBG confirms metastatic disease with extensive tumor inthe marrow/ bone from skull to feet.

3. First, primary neuroblastoma. Osteosarcoma metastatic tothe lung is another. Metastases of various tumorsoccasionally are seen on bone scans, lung, colon andbreast.

4. Combination of Tc-99m bone scan and I-131 MIBG.

Page 123: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 123/2049

Octreoscan

Page 124: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 124/2049

1. In-111 octreoscan (octreotide), I-131 MIBG.2. Prominent liver, spleen and kidney uptake is

seen with In-111 octreoscan.

3. Focal abnormal uptake in the right temporalbone that correlates with CT.

4. Paraganglioma considering the patient’s 

history, also meningioma or NET metastasis.

Page 125: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 125/2049

Pheochromocytoma

Page 126: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 126/2049

y

1. I-131 MIBG2. Localization occurs through the norepinephrine

reuptake mechanism. It localizes incatecholamine storage vesicles in presynaptic

adrenergic nerve ending and cells of the adrenalmedulla.

3. Sensitivity: 90%, specificity, 95% for detection of

pheochromocytoma.4. Neuroblastoma (90%), carcinoid (50%) andmedullary thyroid carcinoma (25%).

Page 127: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 127/2049

NET

Page 128: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 128/2049

1. Peptide analogue of somatostatin and

octreotide. Binds to tumors with somatostatinreceptors.

2. NET

3. A, multiple metastases to both lobe of the liver.Two large foci and one small focus of uptakeconsistent with paraaortic tumor adenopathy.Possible small tumor in right hilum. B,

prominent irregular uptake in the anteriormediastinum and focal uptake in the lower lungposteriorly.

4. Kidney and spleen.

Page 129: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 129/2049

Infection and inflammation

Pearls & Pitfalls

Page 130: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 130/2049

Infection and

inflammation

• Gallium-67 citrate and In-111

leukocyte scans are usuallyphoton poor and the imagesare coarse or grainy.

• Tc-99m leukocyte scan have

more counts and the imagesappear less grainy andsmoother.

•Gallium-67 photon energiesare 90, 190, 290 and 390 keV.

• In-111 photon energies are 173keV and 247 keV.

Pearls & Pitfalls

Page 131: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 131/2049

Infection and

inflammation

• Gallium-67 activity is normally

seen in the skeleton, lacrimalglands, nasopharynx and liver.Liver activity is usually greaterthan spleen. Colon activity is

normal on delayed images.• Indium-111 leukocyte activity is

normally seen in the bonemarrow, liver and spleen with

spleen more intense than liver.• Patchy lung activity may be due

to leukocyte damaged duringlabeling.

Pearls & Pitfalls

Page 132: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 132/2049

Infection and

inflammation

• Colonic activity is normal on

Ga-67 and Tc-99m leukocytescans but not on In-111

leukocyte scans.

•Renal activity may be seennormally on Ga-67 images

during the 1st  24 hours and on

Tc-99m leukocyte images but

not on In-111 leukocyte scans.

Pearls & Pitfallsl f k

Page 133: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 133/2049

Infection and

inflammation

• Focal areas of uptake on Ga-67 scanare nonspecific and can represent

either tumor or inflammation.Indium-111 leukocytes have beenreported to localized in someneoplasms although this isuncommon occurrence.

• On Ga-67 imaging, sarcoidosis andlymphoma may have similarappearance. Both may showmediastinal and lymph node

involvement. Sarcoidosis issuggested by the presence of thelambda sign and the panda sign.Abdominal involvement is morecommon in lymphoma.

Pearls & Pitfalls

Page 134: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 134/2049

Infection and

inflammation

• Diffuse lung uptake on Ga-67

scan is often due to PCP inpatients with AIDS.

• Focal uptake in the abdomen on

leukocyte scan may be due to an

abscess or inflammatory bowel

disease (Crohn’s disease). Activity

in the colon can be seen in

ulcerative colitis or CMV.• Ga-67 is preferred to labeled

leukocyte in the setting of

suspected spinal osteomyelitis

Infection & inflammation

Page 135: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 135/2049

Gallium 67

citrate

Radiolabeled

leukocytes

Indium-111

oxine

leukocyte

Tc-99mHMPAO Tc-99m

Fenulesomab

F18 -

FDG

Tc-99mSulesomab

Page 136: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 136/2049

Page 137: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 137/2049

Page 138: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 138/2049

Page 139: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 139/2049

 

Radiopharmaceutical Gallium-67 Indium-111 Thalium-201

Half life 78 hours 67 hours 72 hours

Photo peak (KeV) 93, 185, 288, 394 173, 247 69-83, 135, 167

Normal Gallium-67 citrate Scan

Page 140: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 140/2049

Liver

SpleenMarrow

Bone

Gastrointestinal 

• liver/spleen/GI

marrow

Page 141: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 141/2049

Liver

Spleen

Marrow

Lung

*spleen intense than

liver/ marrow

Page 142: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 142/2049

(lungs)

• liver/spleen/ bladder

• marrow

Gallium-67 citrate imaging protocol

Page 143: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 143/2049

Patient preparation No recent barium contrast study

Radiopharmaceutical -Gallium-67 citrate

-5 mCi

-IV

Instrumentation Photopeak :20% window, 93, 285 and 300

KeV

Collimator: medium energy

Imaging procedure 24 hr images (optional):site of suspected

infection if early intervention considered.

48 hrs images : whole body imagingDelayed 72 – 96 hr images : differentiate

intraabdominal infection or normal bowel

clearance

Page 144: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 144/2049

Tc-99m HMPAO leukocyte protocol

Page 145: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 145/2049

Patient preparation Wound dressing should be changed priorimaging

Draw 50 ml blood and radiolabeled in

vitro

Radiopharmaceutical Tc-99m HMPAO labeled leukocyte in vitro

10 mCi

Given IV

Instrumentation Photopeak :20% window, 140 KeV

Collimator: low energy GP

Imaging procedure 1 - 2 hr images (mandatory):intra

abdominal imaging

4 hrs images : peripheral skeletal imaging:

osteomyelitis of feet

Whole body imaging

IndicationsGallium-67 In-111 oxine leukocytes Tc-99m HMPAO leukocytes

Page 146: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 146/2049

Gallium 67 In 111 oxine leukocytes Tc 99m HMPAO leukocytes

Severe leucopenia Intra abdominal infection Pediatric patients

Sarcoidosis Cardiovascular infection Inflammatory bowel disease

Idiopathic pulmonary fibrosis Diabetic mid foot and hind

foot osteomyelitis

Osteomyelitis of extremities

including feet in non diabetic

Pulmonary drug reactions(amiodarone, bleomycin)

Inflammatory bowel disease Diabetic forefoot osteomyelitis

Pneumocytic carinii Hip and knee prosthesis

FUO Orthopedic hardware, prior

fracture or infection

Immunosuppressed patient

with lung infections

Suspected low grade chronic

infections (fungal/protozoa)

Page 147: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 147/2049

 

Page 148: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 148/2049

 

Page 149: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 149/2049

 

Page 150: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 150/2049

 

Page 151: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 151/2049

 

Page 152: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 152/2049

 

Page 153: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 153/2049

 

Page 154: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 154/2049

 

Page 155: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 155/2049

Osteomyelitis

Page 156: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 156/2049

Type of study Sensitivity

%

Specificity

%

Three phase bone scan

(normal x ray)

94 95

Three phase bone scan

(underlying disease)

95 33

Gallium 67 81 69

Indium-111 oxine

leukocytes

88 85

Tc-99m HMPAO leukocytes 87 81

MRI 95 87

InfectionsRegions Scans

i b i f Di t l f t T 99 HMPAO l k t

Page 157: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 157/2049

Diabetic foot Distal foot – Tc-99m HMPAO leukocytes

Mid/hind foot – In-111 leukocytes

Vertebral osteomyelitis Ga-67/bone scanF18-FDG

Tc-99m infecton

Infected joint prosthesis In-111 leukocytes/ Tc-99m SC accuracy 90%

Intra abdominal infections In-111 leukocytes sensitivity 90% @ 24 Hr imaging

Tc-99m HMPAO leukocytes @ 2 Hr imaging

Tc-99m Fanolesomab for acute appendicitis

Inflammatory bowel disease Tc-99m HMPAO : Crohn’s small bowel involvement 

Ulcerative colitis = colonic involvement without small bowel

Cardiovascular Prosthetic graft – In-111 leukocytes d/t no blood pool

RenalGa-67 * increased uptake may due to renal/hepatic failure

and iron overload

Intra cerebral Tl-201 : increased uptake = malignant, no uptake = infection

FUO Ga-67

Post op fever=In-111 leukocytes

Malignant external otitisGa-67

Page 158: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 158/2049

Gallium-67 Thallium-201

Page 159: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 159/2049

- ve + ve Kaposi’ssarcoma

+ ve - ve Infection

+ ve + ve Lymphoma

Page 160: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 160/2049

 

Abnormal CXR

& NormalGallium-67

Kaposi’s sarcoma 

Pulmonary fibrosis

Treated

sarcoidosis

Inactive TB

  PCP

Page 161: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 161/2049

Normal CXR &

Abnormal

Gallium-67

CMVSarcoidosis

Pulmonary drugtoxicity

Lymphocytis

interstitialpneumonitis

Page 162: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 162/2049

 

Gallium scan

100% sensitivity

Burkitt’s

lymphoma

Pyogenic acute

osteomyelitisPyogenic acute

arthritis

Page 163: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 163/2049

 

Gallium-67 lung

uptake

associated with

drugs

Bleomycin

Amiodarone

Busulfan

Nitrofurantoin

Cyclophosphamide

Methotrexate

Ga-67 is taken up by the lungs due to

drug toxicity. Which drugs are the

Page 164: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 164/2049

g y g

culprits?

Ga-67 is taken up by the lungs due to

drug toxicity. Which drugs are the

Page 165: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 165/2049

g y g

culprits?• Bleomycin is the most common. Uptake can

be seen with cytoxin, nitrofurontoin and

amiodarone.

What is the role of Ga-67 in

sarcoidosis?

Page 166: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 166/2049

What is the role of Ga-67 in

sarcoidosis?

Page 167: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 167/2049

•Ga-67 lung uptake is a sensitive test for thediagnosis of active alveolitis of sarcoidosis. Ga-

67 may be markedly increased in the setting of

a normal CXR in early disease and may benegative in the setting of an abnormal CXR in

inactive disease.

Which leukocytes are labeled with In-

111 oxine and Tc-99m HMPAO?

Page 168: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 168/2049

Which leukocytes are labeled with In-

111 oxine and Tc-99m HMPAO?

Page 169: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 169/2049

•In-111 binds to neutrophils, lymphocytes,monocytes, erythrocytes and platelets.

• Tc-99m HMPAO binds to neutrophils.

Which of the following statements is

true regarding In-111 oxine

Page 170: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 170/2049

leukocytes?

A. It is diagnostically useful for evaluating

inflammatory lung disease.

B. It has a high sensitivity for detecting

osteomyelitis in the spine.

C. It should be used when the peripheralleukocyte count is less than 3000/mm³.

D. It is the radiopharmaceutical of choice for

intraabdominal infection.

Which of the following statements is

true regarding In-111 oxine

Page 171: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 171/2049

leukocytes?

• FFTT

What is the optimal imaging time for

In-111 leukocytes and Tc-99m HMPAO

Page 172: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 172/2049

leukocytes?

What is the optimal imaging time for

In-111 leukocytes and Tc-99m HMPAO

Page 173: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 173/2049

leukocytes?• In-111 labeled leukocytes are routinely imaged at 24

hours. Imaging at 4  –  6 hours is less sensitive fordetection of infection. The one exception is

inflammatory bowel disease in which imaging shouldbe done at 4 hours because intraluminal shedding ofinflammed cells may result in inaccurate localization at24 hours.

Tc-99m HMPAO leukocytes should be imaged at 1 -2hours for intraabdominal infection because of biliaryand renal clearance seen by 2 hours. Extra abdominalinfection can be imaged later, usually 4 hours allowingmore time for background clearance.

Regarding osteomyelitis, which of

these statements are true?

Page 174: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 174/2049

A. The three phase bone scan is sensitive testfor diagnosis.

B. The three phase positive scan is specific for

osteomyelitis.C. A negative flow phase study almost always

rules it out.

D. In patients with prostheses, a bone marrowscan can be useful to rule out a false positive

In-111 leukocyte study.

Regarding osteomyelitis, which of

these statements are true?

Page 175: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 175/2049

•TTTF

Which of the following statement are

true?

Page 176: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 176/2049

A. A negative three phase bone scan excludeosteomyelitis with high degree of certainty.

B. The specificity of bone scan is poor in patientswith underlying bone disease such as fractures,orthopedic hardware and neuropathic joints.

C. In-111 oxine and Tc-99m HMPAO leukocyteshave poor specificity for the diagnosis ofosteomyelitis in a patient with a hip prosthesis.

D. Because the three phase bone scan may bepositive in a patient with a Charcot’s  joint, aradiolabeled leukocyte study should beperformed.

Which of the following statement are

true?

Page 177: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 177/2049

A. TTTF

In the imaging of the lung infection

Page 178: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 178/2049

A. Gallium uptake is highly sensitive for PCPB. Localized uptake of Gallium is common in PCP

C. Uptake of Indium-111 labeled white cells in the

lungs is relatively non specific for infectionD. Unmatched defects of perfusion are the most

common abnormality seen on V/Q scan in

patients with bacterial infection

E. In patients with TB, only sites of active infection

are Gallium avid

In the imaging of the lung infection

Page 179: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 179/2049

•TFTFT

Concerning In-111 white cell scans

Page 180: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 180/2049

A. The white cells must be autologousB. Lung activity is pathological between 1 and 4

hours after injection

C. If a focus of increased uptake is seen on the

early images, the 24 hour images do not need tobe performed

D. In-111 white cell are more useful in chronic PUO

E. If the patient is on appropriate antibiotics, thewhite cell study is unlikely to be positive

Concerning In-111 white cell scans

Page 181: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 181/2049

•FTFFF

Concerning Tc-99m HMPAO and In-111

labeled white cell scans

Page 182: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 182/2049

A. Diffuse bowel activity on a Tc-99m HMPAO study at 24hrs indicates severe colitis

B. On a Tc-99m HMPAO labeled white scan, the typicalappearances of IBD is intense activity at 1 hour whichfades with time

C. Rectal disease can be distinguished from bladderactivity on a Tc-99m HMPAO

D. Activity is seen in the bowel in IBD because the

labeled WBC’s fix in the inflammatory bowel wallE. An abscess that communicates with the bowel can bedistinguish from one that does not

Concerning Tc-99m HMPAO and In-111labeled white cell scans

Page 183: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 183/2049

FFTFT

Concerning the imaging of theimmunosuppressed patient

Page 184: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 184/2049

A. In-111 labeled WBCs are sensitive as Galliumat detecting PCP

B. Tc-99m DTPA clearance is more useful thanGallium scanning in the following up of PCP

C. Gallium uptake in the colon is highlysuspicious for acute colitis

D. Kaposi’s lesions take up Tl-201

E. Active MAI infection in HIV positive patientshas specific appearance on Gallium scan

Concerning the imaging of theimmunosuppressed patient

Page 185: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 185/2049

FTFTF

The source of lectoferrin

Page 186: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 186/2049

A. LymphocytesB. Leucocytes

C. Bacteria

D. Fungus

E. Tissue macrophage

The source of lectoferrin

Page 187: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 187/2049

FTFFF

Page 188: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 188/2049

Page 189: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 189/2049

Lactoferrin is physiologically producedby certain organs that localize gallium

Page 190: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 190/2049

A. Lacrimal glandsB. Salivary glands

C. Lactating breast

D. Bone

E. Liver

Lactoferrin is physiologically producedby certain organs that localize gallium

Page 191: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 191/2049

TTTFF

Page 192: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 192/2049

Sarcoidosis

Page 193: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 193/2049

1. Patient A: lambda sign (hilar and paratrachealnodal uptake). patient B: diffuse pulmonaryuptake.

2. Classic panda sign.

3. Either A or B. The panda sign can be seen atany stage of the disease.

4. Sarcoidosis. Ga-67 scan is used to confirm the

clinical diagnosis and differentiate activealveolitis from inactive fibrosis.

Page 194: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 194/2049

Page 195: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 195/2049

Page 196: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 196/2049

Tc-99m HMPAO and osteomyelitis

1 A i b l li i i h

Page 197: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 197/2049

1. A negative bone scan rules out osteomyelitis with ahigh degree of certainty.

2. A bone marrow can improve the specificity of aleukocyte study if there is displaced normal marrow.This is most helpful in the hips and knees.

3. In-111 leukocytes can make same diagnosis. Thesuperior imaging resolution of Tc-99m HMPAO oftenbetter differentiates soft tissue and bone infection.Ga-67 is less specific because increased uptake occurswith bone remodeling from any cause.

4. Patient A: soft tissue uptake. No bone uptake rulesout osteomyelitis, consistent cellulitis. Patient B: softtissue and bone localization consistent withosteomyelitis.

Page 198: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 198/2049

Tc-99m HMPAO leukocytes free Tc-99m pertechnetate

Page 199: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 199/2049

1. Activity in the salivary glands, thyroid, stomach,bowel and bladder.

2. Free Tc-99m pertechnetate.

3. Gastrointestinal bleeding, swallowed leukocytes

from oropharyngeal, esophageal or lunginflammation/ infection, accessory spleen,uninfected postoperative surgical wounds,intestinal stomas.

4. Ga-67 = 48 hours, In-111 oxine leukocytes = 24hours, Tc-99m HMPAO = 1 to 4 hours.

Page 200: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 200/2049

Intraabdominal abscess

1 T 99 HMPAO bi d l t t hil I 111 i

Page 201: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 201/2049

1. Tc-99m HMPAO binds only to neutrophils. In-111 oxine

binds to mixed leukocytes.2. Normal bone marrow distribution of the radiolabeled

leukocytes.

3. Abdominal imaging: Tc-99m HMPAO images are acquiredat 1 to 2 hours because hepatobiliary, intestinal and renalclearance occurs subsequently, complicatinginterpretation. Extremity imaging: 2 to 6 hours. In-111leukocytes: 24 hours. Four hour imaging for inflammatorybowel disease because sloughing of intestinal mucosaleukocytes may occur and 24 hour may be misleading.

4. Infection in the right lower quadrant overlying thesacroiliac joint in the anterior view and lateral right of thespine. The patient had a perforated appendix.

Page 202: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 202/2049

Pericarditis – Ga-67

1 Ab l t k i di i di b th

Page 203: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 203/2049

1. Abnormal uptake in myocardium, pericardium or bothconsistent with pericarditis or myocarditis. Thepatient developed a pericardial fraction rub the dayafter the Ga-67 scan. Incidental note of normal liveruptake and transverse and left colon clearance.

2. Ga-67 shows uptake not only with inflammation andinfection, but also in tumors that can sometimes bethe cause of persistent fever e.g.. lymphoma.

3. Large bowel = 4.5 rads.

4. Most pulmonary inflammatory and infectiousdiseases. Uptake is nonspecific, although the patternof uptake and the clinical setting, e.g. AIDS may behelpful in determine the differential diagnosis.

Page 204: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 204/2049

Right ileum osteomyelitis

Page 205: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 205/2049

1. In-111 oxine or Tc-99m HMPAO leukocytes,Ga-67 could also be used. The intense spleenuptake is consistent with a radiolabeledleukocyte study. In-111 oxine leukocytes

were used. The image resolution is poorcompared with Tc-99m leukocytes.

2. Spleen, 15 – 20 rads.

3. Abnormal focal uptake in right groin and rightileum, indicating osteomyelitis.

4. 173, 247 keV. Physical half life is 77 hours.

Page 206: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 206/2049

Osteomyelitis of spine

1 Bone scan shows increased uptake of the T11

Page 207: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 207/2049

1. Bone scan shows increased uptake of the T11vertebrae. In-111 oxine leukocyte showsdecreased uptake in the same region. Ga-67shows increased uptake that matches the bonescan in relative intensity.

2. Osteomyelitis fracture, infarction, metastasis,orthopedic hardware, surgical defect, Paget’s disease, radiation therapy.

3. Osteomyelitis in this clinical setting. Many of the

diseases listed can be excluded by history andradiographs.

4. As high as 40%.

Page 208: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 208/2049

FDG PET paraspinal infection

Page 209: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 209/2049

1. Intense uptake involving the retroperitoneumanterior to the recent lumbar fusion surgery.

2. Consistent with postoperative infection.

3. Yes. Leukocytes and macrophages utilizeglucose.

4. All positron emitters have 511 keV

photopeak. F-18, C-11, N-13 , O15.

Page 210: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 210/2049

Knee athroplasty TRO infection

Page 211: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 211/2049

1. Increased blood flow in the right knee.2. Increased uptake in the proximal tibia on

both.

3. Serves as a template for normal marrowdistribution.

4. Negative for infected prosthesis.

Page 212: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 212/2049

Skeletal imaging

Pearls & Pitfalls• Common indications for bone

scans include evaluation of

Page 213: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 213/2049

Skeletal imaging

scans include evaluation ofprimary osseous or metastaticneoplasm, avascular necrosis,trauma, infection and less

commonly, arthritis or RSD.• When bone scans are

performed with Tc-99mdiphosphonate agents, normal

skeletal activity should bereasonably symmetric left andright sites.

Pearls & Pitfalls

• Look at the kidney activity for

Page 214: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 214/2049

Skeletal imaging

potential abnormalities. Alarge amount of activity of

diffuse soft tissue activity

remaining at 4 hours is

frequently due to renal

insufficiency.

• Activity in the lower cervical

region is frequently due tobenign causes such as

degenerative changes.

Pearls & Pitfalls

• A lesion that is hot all three

Page 215: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 215/2049

Skeletal imaging

phases of a bone scan can beosteomyelitis bit also may be

an acute fracture,

hypervascular tumor,

neuropathic joint or RSD.

• A flare phenomenon is most

likely seen within 1 to 3

months therapy completion.

Pearls & Pitfalls• Paget’s  disease is commonly

seen as intense activity in the

Page 216: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 216/2049

Skeletal imaging

seen as intense activity in theskull, femur, vertebral body orhalf of the pelvis. It is usuallypolyostotic but may be

monostotic and may causebowing of a femur.

• Good visualization of thebones and not the kidneys may

indicate a superscan due todiffuse metastases orhyperparathyroidism.

Pearls & Pitfalls• Focal hot lesions in multiple

adjacent ribs are essentially

Page 217: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 217/2049

Skeletal imaging

j y

always due to fracture.• Long lesions running along the

length of a rib are not usuallyfractures.

• Multiple sequential coldvertebral bodies are almost dueto radiation therapy.

• Tumors that commonly causecold (photopenic) metastaticlesions including kidney, lung,thyroid and breast tumors.

Pearls & Pitfalls

• Stress fractures usually occur

Page 218: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 218/2049

Skeletal imaging

in the pelvis and below theknees, they can be seen as

focal or fusiform primary

cortical activity.

• Bilaterally increased activity

along the cortex of the tibias

may be due to shin splints,

hypertrophic osteoarthropathyor periosteal reaction.

Pearls & Pitfalls• A loose hip prosthesis is

suggested by activity at the tip

Page 219: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 219/2049

Skeletal imaging

suggested by activity at the tip

and near the lesser trochanter.

•  An infected prosthesis usually

has activity all along the length of

the shaft.

• Postoperative activity around a

cemented prosthesis can

normally persist for 6 months to1 year and activity around a

noncemented prosthesis can

normally persist for 2 to 3 years.

Pearls & Pitfalls• Diffuse liver activity on a bone

scan is probably due to hepatic

Page 220: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 220/2049

Skeletal imaging

sca s p obab y due to epat cnecrosis orradiopharmaceutical problem.

• Focal liver activity is often due

to metastasis from colon,breast, ovary or lung.

• Diffused splenic activity due tosplenic infarction.

• Diffused renal parenchymalactivity is probably due tochemotherapy.

Pearls & Pitfalls• Increased activity in two

Page 221: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 221/2049

Skeletal imaging

adjacent vertebral bodies inthe absence of compression

fractures suggests diskitis

especially in a child.

• Osteomyelitis, acute fractures,

vascular tumors such as

Ewing’s  sarcoma and RSD are

hot on angiographic, bloodpool and delayed bone scan

images.

Pearls & Pitfalls• Cellulitis is hot on the 1st  two

phases but fades on delayed

Page 222: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 222/2049

Skeletal imaging

p y

images.• Shin splints have normal

angiographic and blood poolimages but are hot on delayedviews in the posteromedialaspect of the tibias.

• Osteomyelitis usually does not

cross joints.• Increased activity seen on both

sides of a joint is more likely dueto septic arthritis.

Page 223: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 223/2049

 

Page 224: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 224/2049

 

Page 225: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 225/2049

 

Page 226: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 226/2049

 

Page 227: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 227/2049

 

Page 228: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 228/2049

 

Page 229: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 229/2049

 

Page 230: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 230/2049

 

Page 231: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 231/2049

 

Page 232: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 232/2049

 

Page 233: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 233/2049

 

Page 234: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 234/2049

Page 235: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 235/2049

 

Page 236: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 236/2049

 

Bone pain for bone scan

Page 237: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 237/2049

Metastatic tumorsBenign bone tumor : osteoid osteoma

Trauma

Avascular necrosisInfection

Osteomalacia

Paget’s 

Page 238: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 238/2049

Page 239: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 239/2049

 

Page 240: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 240/2049

 

  Reduced hydrolyzed

technetium

Page 241: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 241/2049

Tc-99mpertechnitate

preparation,

there are 3 form

of technetium

Free pertechnetate

Chelated technetium

  Reduced hydrolyzed

technetium

Page 242: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 242/2049

Liver uptake in

bone scan

Excess amount of

aluminum in Tc-99m

MDP preparation

Excess amount ofstannous ion in Tc-

99m MDP

preparation

Excess amount of

Page 243: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 243/2049

aluminum in Tc-99m SCpreparation Lungs uptake

Tc-99m pertechnetate

Thyroid

Gastric mucosa

Page 244: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 244/2049

 

Page 245: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 245/2049

 

 

Page 246: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 246/2049

 

Page 247: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 247/2049

 

Page 248: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 248/2049

 

Page 249: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 249/2049

 

Page 250: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 250/2049

 

Page 251: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 251/2049

Page 252: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 252/2049

Metastatic bone disease

Bone tumors

Benign Malignant

Page 253: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 253/2049

Osteoid osteoma Osteosarcoma

Giant cell tumor Ewing’s sarcoma 

Fibrous dysplasia Chondrosarcoma

 

Page 254: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 254/2049

 

Bil t l

Urinary tract

obstruction

Acute tubular

i

Page 255: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 255/2049

Bilateralincreased

uptake of renal

in bone scan

necrosis

Chemotherapy

Radiation nephritis

Thalassemia

Hypercalcemia

NephrocalcinosisNephrotoxic

antibiotic

 

Bil t l

Tumors Non tumor

Prostate Renal failure

Page 256: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 256/2049

Bilateraldecreased

uptake of

renal inbone scan

“superscan” 

Lungs

carcinoma

Nephrectomy

Breast

carcinoma

Hyperparathyroidism

Bladder

carcinoma

Osteomalacia

Lymphoma

Fibrous dysplasia

Paget’s disease Renal osteodystrophy

  Breast carcinoma

Page 257: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 257/2049

Tumors that

metastasize to

bone

Lungs carcinoma

Prostate carcinoma

LymphomaThyroid carcinoma

Renal carcinoma

Neuroblastoma

  Multiple myeloma

Page 258: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 258/2049

Tumors falsely

normal in bone

scan

Severe anaplastic

tumors

Lytic lesions

 

Diff ti l

Metal artifact

Radiation changes

B i i b l

Page 259: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 259/2049

Differentialdiagnosis of

cold defect in

bone scan

Barium in bowelEarly avascular necrosis

Multiple myeloma

Benign tumorCysts

Osseous metastasis

Tumor marrow

involvement

Soft tissue calcification

Page 260: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 260/2049

Dystrophic

calcification

Metastatic

calcification

Heterotrophic

Bone

formation

Calcinosis

cutis

Calcification of

dying or dead

tissue

Normal tissue

with

hypercalcemia

-infection

-osteomyelitis

-cellulitis

-thrombophlebitis

-DVT

-osteosarcoma-osteochondroma

-calcinosis

cutis universalis

-calcinosis

cutis circumcripta

-calciphylaxis-rabdhomyolysis

Soft tissue accumulation ofdiphosphonate

Infarct

Page 261: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 261/2049

InfarctAmyloid

Muscle: myositis ossificans

FibroidsTumors: meningioma/neuroblastoma

Systemic sclerosis

Histocytosis X

• Disease in which there are focal accumulation

f h l d

Page 262: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 262/2049

of macrophages in various organs including

bones

• Triad:

1. Letterer-Siwe disease

2. Hand-Schuller-Cristian disease3. Eosinophilic granuloma of bone

  Fibrous dysplasia

Page 263: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 263/2049

Bone dysplasia's

a/w skeletal

tracer uptake

Osteogenic imperfecta

Albers-Schöenberg

Disease (Marble Bones)Englemann’s disease

Malorheosthosis

Ribbing’s disease 

Fibrous dysplasia

Page 264: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 264/2049

Osteogenic imperfecta

Page 265: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 265/2049

Osteopetrosis

• Albers-Schöenberg Disease (Marble Bones)

Page 266: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 266/2049

Englemann’s disease 

Page 267: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 267/2049

Ribbing’s disease (multiple diaphyseal sclerosis)

Page 268: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 268/2049

Melorheostosis

Page 269: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 269/2049

  Paget’s disease 

(osteitis deformans)

O i

Page 270: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 270/2049

Metabolic bone

disease

Osteoporosis

osteomalacia &

Rickets

Hyperparathyroidism

Renal osteodystrophy

Hypertrophicosteoathroplathy

DiseaseRenal

osteodystrophy

Primary

hyperparathyroidism

Osteomalacia Aluminum

induced

osteomalacia

Osteoporosis

Metabolic bone disease

Page 271: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 271/2049

Cause of +ve

bone scan Hyperparathyroid Hyperparathyroid Hyperparathyroid - Fracture

Differentiating

features

Metabolic features:

No tracer in bladder

Metabolic features:

Uncommon: brown

tumor & ectopic

calcification

Metabolic features:

pseudofractures

Long bone

uptake

High

background

activity

Intense linear

uptake at site of

vertebral

fracture

May be

low/patchy

uptake at axial

skeletal

Page 272: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 272/2049

Page 273: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 273/2049

Page 274: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 274/2049

Page 275: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 275/2049

Page 276: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 276/2049

Page 277: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 277/2049

Page 278: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 278/2049

 

Page 279: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 279/2049

 

Page 280: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 280/2049

Increased flow and

intense uptake around

the prosthesis’ stem

Focal skeletal phase uptake

At the tip of the hardware

Loosening Infection

Hip joint prosthesis

Page 281: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 281/2049

Blood pool image is

normal

Blood pool image is

increased vascularity

Discrete focus oftracer increased

uptake at the tip of

femoral prosthesis in

delayed image

Markedly increasedtracer uptake  in

delayed image

 

Page 282: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 282/2049

Stress fracture

Page 283: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 283/2049

Fatigue fracture Insufficient fracture

Cause by repeated

abnormal fractureon normal bone

Resulting from

normal stress onabnormal bone

 

Page 284: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 284/2049

 

Page 285: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 285/2049

 

Page 286: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 286/2049

Page 287: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 287/2049

 

Page 288: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 288/2049

 

Page 289: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 289/2049

 

Page 290: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 290/2049

 

Page 291: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 291/2049

 

Page 292: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 292/2049

 

Page 293: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 293/2049

 

Page 294: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 294/2049

 

Page 295: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 295/2049

 

Page 296: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 296/2049

 

Page 297: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 297/2049

 

Page 298: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 298/2049

Page 299: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 299/2049

 

Page 300: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 300/2049

Page 301: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 301/2049

 

Page 302: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 302/2049

 

Page 303: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 303/2049

 

Page 304: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 304/2049

 

Page 305: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 305/2049

 

Page 306: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 306/2049

 

Page 307: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 307/2049

 

Page 308: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 308/2049

 

Page 309: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 309/2049

 

Page 310: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 310/2049

 

Page 311: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 311/2049

 

Page 312: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 312/2049

 

Page 313: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 313/2049

 

Page 314: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 314/2049

 

Page 315: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 315/2049

 

Page 316: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 316/2049

 

Page 317: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 317/2049

 

Page 318: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 318/2049

 

Page 319: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 319/2049

 

Page 320: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 320/2049

 

Page 321: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 321/2049

 

Page 322: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 322/2049

 

Page 323: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 323/2049

 

Page 324: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 324/2049

 

Page 325: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 325/2049

L C l P th

Page 326: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 326/2049

FORM OF OSTEOCHONDRITIS DISEASES

CAUSED BY AN INFARCT IN THE CAPITALFEMORAL EPIPHYSIS

Legg-Calve-Perthes

 

Page 327: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 327/2049

 

Page 328: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 328/2049

 

Page 329: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 329/2049

 

Page 330: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 330/2049

 

Page 331: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 331/2049

 

Page 332: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 332/2049

 

Page 333: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 333/2049

 

Page 334: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 334/2049

 

Page 335: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 335/2049

 

Page 336: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 336/2049

 

Page 337: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 337/2049

4. Bone scan

• TTFTT

Page 338: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 338/2049

 

Page 339: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 339/2049

 

Page 340: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 340/2049

 

Page 341: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 341/2049

7. Indication for bone scan

• TTTTT

Page 342: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 342/2049

 

Page 343: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 343/2049

8. Bone scan

• TFFTT

Page 344: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 344/2049

 

Page 345: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 345/2049

 

Page 346: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 346/2049

 

Page 347: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 347/2049

 

Page 348: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 348/2049

 

Page 349: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 349/2049

 

Page 350: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 350/2049

 

Page 351: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 351/2049

 

Page 352: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 352/2049

 

Page 353: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 353/2049

 

Page 354: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 354/2049

 

Page 355: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 355/2049

15. Abnormal bone scan uptake inkidneys

• TTTTT

Page 356: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 356/2049

 

Page 357: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 357/2049

 

Page 358: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 358/2049

 

Page 359: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 359/2049

 

Page 360: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 360/2049

 

Page 361: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 361/2049

 

Page 362: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 362/2049

 

Page 363: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 363/2049

 

Page 364: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 364/2049

 

Page 365: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 365/2049

20. Cause of superscan

• FFFTT

Page 366: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 366/2049

 

Page 367: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 367/2049

 

Page 368: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 368/2049

Malignancy

A. In multiple myeloma the MDP bone scan is usuallyabnormal

B. Increased MDP bone scan uptake into metastaticdeposits 2 months after chemotherapy indicatesfailure of response and progression of disease

Page 369: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 369/2049

failure of response and progression of disease

C. A solitary rib hot spot in a cancer patient usually

represent benign diseaseD. A rib hot spot which is present over a year is likely to

represent a simple healing fracture

E. A solitary area of abnormal uptake is a patient with a

known primary cancer with normal plain filmappearances is likely to be benign

Malignancy

• TFFFT

Page 370: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 370/2049

Bone scanning in malignancy

A. A malignant superscan requires more time to

acquire the imageB. It is possible to distinguish a malignantsuperscan from one of metabolic bone disease

Page 371: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 371/2049

C. A superscan characteristically shows increased

bone and renal uptake of MDPD. Uptake of MDP into malignant bone diseaserelies solely on osteoblastic activity

E. It is not possible to distinguish benign from

malignant vertebral collapse

Bone scanning in malignancy

• FTFFT

Page 372: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 372/2049

Bone scan in Paget’s disease 

A. A bone scan may be normal in Paget’s disease

B. A bone scan is a method of choice to detectsarcomatous change in Paget’s disease

C Paget’s very rarely only involves a single bone

Page 373: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 373/2049

C. Paget s very rarely only involves a single bone

D. The appearance of new lesions in a patient withestablished Paget’s  disease is a commonrecognized finding

E. A bone scan is the method of choice in assessing

response to therapy in Paget’s disease

Bone scan in Paget’s disease 

• TFFFF

Page 374: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 374/2049

Bone scan in malignant disease

A. Patients with a known primary cancer and singleskeletal hot spot have a roughly equal chance that it isbenign or malignant

B. Patients with a known primary cancer and a singlevertebral hot spot are unlikely to have malignant

Page 375: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 375/2049

vertebral hot spot are unlikely to have malignantdisease

C. A bone scan is a useful routine staging procedure ofprostate carcinoma

D. A bone scan is a useful routine staging procedure forall patients with carcinoma of the cervix

E. A bone scan is a useful routine staging procedure forpatients with stage III and IV breast carcinoma

Bone scan in malignant disease

• TFTFT

Page 376: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 376/2049

Bone scan in trauma

A. Tibial stress fractures are indistinguishable fromshin splint on bone scan

B. Compartmental syndromes are indistinguishablefrom shin splint on bone scan

Page 377: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 377/2049

C. Reflex sympathetic dystrophy syndrome may

show reduced uptake of MDPD. 50% of non pathological rib fractures heal byone year

E. In talar coalition increased activity is usually at

the site of coalition

Bone scan in trauma

• FFTFF

Page 378: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 378/2049

Bone scan in avascular necrosis

A. Septic arthritis of the hip in children may cause absentuptake of MDP into the femoral head

B. Osteomyelitis and bone infarction are easilydistinguishable in sickle cell disease

Page 379: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 379/2049

C. Decreased MDP accumulation lasts for about 6 weeks

following bone infarction in sickle cell diseaseD. In chronic Perthes disease bone scan has a sensitivity

and specificity of over 90%

E. Bone scan a few weeks following femora; neck

fracture that is associated with higher uptake in thefemoral neck indicates a favorable prognosis

Bone scan in avascular necrosis

• TFFFT

Page 380: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 380/2049

Bone scan in infection

A. Labeled WBC scanning is the method of choice indiagnosing osteomyelitis in HIV patients

B. Tc-99m HMPAO labeled WBC are preferable to In-111labeled in detection of acute osteomyelitis ofextremities

Page 381: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 381/2049

extremities

C. Tc-99m HMPAO labeled are the method of choice in

diagnosing infection in childrenD. It is not possible to carry out WBC scanning in

severely neutropenic patients

E. WBC scanning is the method of choice indifferentiating acute infarct from osteomyelitis insickle cell disease

Bone scan in infection

• FTTFF

Page 382: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 382/2049

Increased uptake of MDP is seen in

A. Bone island

B. Osteopoikilosis

C. Fibrous dysplasia

Page 383: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 383/2049

D. Melorheostosis

E. Eosinophilic granuloma

Increased uptake of MDP is seen in

• FFTTT

Page 384: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 384/2049

Primary bone tumors

A. Vertebral hemangiomata may cause reduced orincreased uptake of MDP into a vertebral body

B. It is possible to differentiate benign from malignantbone tumors from the degree of uptake of MDP

Page 385: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 385/2049

C. Bone scan is a good method for assessing the extent

of involvement of a bone in osteogenic sarcomaD. Bone scan is a reliable method of detecting soft tissuemetastasis e.g.. lung in osteogenic sarcoma

E. Bone scan is a useful preliminary staging procedure in

Ewing's sarcoma

Primary bone tumors

• TFFFT

Page 386: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 386/2049

Metabolic bone disease

A. The tie sign is a recognized feature

B. Reduced uptake of MDP into the diaphyses oflong bones is a recognized feature

C. Osteomalacia causes a reduction in uptake ofMDP h i d i f b

Page 387: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 387/2049

MDP as there is reduction of bone mass

D. Aluminum osteomalacia in hemodialysispatients causes a metabolic superscan inadvanced disease

E. Treatment with biphosphonates may cause a

reduction in MDP uptake into the skeleton

Metabolic bone disease

• TFFFT

Page 388: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 388/2049

Infection

A. Both infection and loosening of a hip prosthesis will show

both increased vascularity and uptake on delayed images

B. Increased activity in relation to a knee prosthesis one year

after surgery nearly always signifies infection or loosening

C C ll li i i h li b i d k i b

Page 389: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 389/2049

C. Cellulitis in the limb may cause increased uptake into bone

on a bone scan

D. Uptake of Gallium into a bone at the site of increased uptake

on a bone scan nearly always signifies infection

E. Bone scan are less sensitive in detecting osteomyelitis in

neonates because of their small size

Infection

• FFTFF

Page 390: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 390/2049

Photon deficient bone scan lesionsmay be found in

A. Metastatic disease

B. Legg-Calve-Perthes disease

C. Infarct of sickle cell disease

Page 391: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 391/2049

Photon deficient bone scan lesionsmay be found in

• TTT

Page 392: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 392/2049

Pulmonary, gastric, and enhancedkidney activity on a bone scan is often

seen in patients with

A. Myelosclerosis

B. Histocytosis

Page 393: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 393/2049

y

C. Metastases from osteogenic sarcomaD. Hyperparathyroidism

E. Hyperthyroidism

 Pulmonary, gastric, and enhancedkidney activity on a bone scan is often

seen in patients with

• FFFTF

Page 394: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 394/2049

Spleenic uptake in bone scan is mostoften seen in

A. Cirrhosis with portal hypertension

B. Hypersplenism

C. Sickle cell disease

Page 395: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 395/2049

D. Lymphoma

E. Splenic abscess

Spleenic uptake in bone scan is mostoften seen in

• FFTFF

Page 396: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 396/2049

The following neoplasm does notfrequently metastasize to bone

A. Ovary

B. Prostate

C. Lung

Page 397: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 397/2049

D. Lymphoma

E. Breast

The following neoplasm does notfrequently metastasize to bone

• TFFFF

Page 398: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 398/2049

Which of the following commonly

cause photopenic lesions on a bonescan

A. Malignant melanomaB. Ewing’s sarcoma

Page 399: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 399/2049

C. Multiple myeloma

D. Hypernephroma

E. Colon carcinoma

Which of the following commonlycause photopenic lesions on a bone

scan

• FFTTF

Page 400: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 400/2049

What are the potential impurities in

Tc-99m labeled diphosphonatecompounds, based on their

biodistribution.

Page 401: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 401/2049

What are the potential impurities in

Tc-99m labeled diphosphonatecompounds, based on their

biodistribution.• Activity in the oropharynx, thyroid gland and

stomach suggestive of free pertechnetate.

Page 402: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 402/2049

gg p

Activity in the liver suggests of colloidalimpurity.

• Rarely, activity is seen in the gut, the result of

excretion of activity through the biliarysystem.

What is the distribution of metastatic

deposit from epithelial primary

malignancies in the skeleton?

Page 403: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 403/2049

What is the distribution of metastatic

deposit from epithelial primary

malignancies in the skeleton?•

80% at axial skeleton (spine, ribs, pelvis andsternum)

• 10% at skull

Page 404: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 404/2049

%

10% at long bones

What factors distinguish a superscan

resulting from metastatic disease or

from metabolic disease?

Page 405: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 405/2049

What factors distinguish a superscan

resulting from metastatic disease or

from metabolic disease?

• Metastatic disease: uptake seen at axial

skeleton and proximal parts of the femur and

humeri

Page 406: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 406/2049

humeri.

• Metabolic disease: entire skeleton is typicallyeffected with increased uptake seen at

extremities as well as in the axial skeleton.

What is the mechanism of the flare

phenomenon?

Page 407: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 407/2049

What is the mechanism of the flare

phenomenon?

• In some patients treated with chemotherapy

for metastatic disease, regression of thetumor burden is associated with increased

osteoblastic activity, presumably caused by

Page 408: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 408/2049

y, p y y

skeletal healing in response to chemotherapy.This can appear on bone scan as a paradoxical

increased “worsening” tracer uptake which up

to 6 months after therapy.

What factors contribute to prolonged

fracture positivity on bone scan?

Page 409: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 409/2049

What factors contribute to prolonged

fracture positivity on bone scan?

• Displaced or comminuted fractures and

fractures involving joints tend to haveprolonged tracer uptake. Elderly patients have

delayed healing.

Page 410: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 410/2049

y g

What is the scintigraphy pattern of

osteomyelitis in children

Page 411: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 411/2049

What is the scintigraphy pattern of

osteomyelitis in children

• Hot focus in metaphyseal region

Page 412: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 412/2049

What is scintigraphy finding in RSD

Page 413: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 413/2049

What is scintigraphy finding in RSD

• Increased blood flow and diffusely increased

periarticular activity in delayed images

Page 414: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 414/2049

What is the explanation for the

abnormal bone scan in RSD

• Loss of sympathetic stimulation

• Results in vasodilatation

• Increased blood flow and bone turnover

Page 415: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 415/2049

Synovitis contributing diffusely increasedperiarticular activity

What is shin splint

Page 416: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 416/2049

What is shin splint

• Periostitis along posteromedial angle of tibia

• Tear of tibialis posterior muscle or soleusmuscle tendon complex

Page 417: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 417/2049

What is scintigraphic appearance in

shin splint

Page 418: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 418/2049

What is scintigraphic appearance in

shin splint

• Longitudinal wavy irregular uptake in the

periosteal aspect of the posteromedial tibia

Page 419: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 419/2049

What is the three phase bone scan

finding in the acute phase of AVN

Page 420: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 420/2049

What is the three phase bone scan

finding in the acute phase of AVN

Diminish flow and cold defect in delayed view

Page 421: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 421/2049

What is the finding in the chronic

phase of AVN

Page 422: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 422/2049

What is the finding in the chronic

phase of AVN

• Increased or normal flow with increased

uptake

Page 423: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 423/2049

How is the bone marrow scan used in

AVN

Page 424: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 424/2049

How is the bone marrow scan used in

AVN

Page 425: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 425/2049

How is the bone marrow scan used in

AVN

• A cold defect in the region of increased uptake

in bone scan indicates the bone scanabnormality is due to infarct

Page 426: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 426/2049

What are the scintigraphic finding of

cellulitis

Page 427: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 427/2049

What are the scintigraphic finding of

cellulitis

• Increased flow and blood pool images in the

first and second phase• Delayed phase normal uptake

Page 428: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 428/2049

What are the scintigraphic finding of

osteomyelitis

Page 429: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 429/2049

Page 430: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 430/2049

Name four primary tumors causing

photopenic metastases

Page 431: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 431/2049

Name four primary tumors causing

photopenic metastases

• Renal

• Thyroid• Multiple myeloma

• Lung

Page 432: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 432/2049

Lung

Describe the scintigraphic pattern in

Paget’s 

Page 433: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 433/2049

Describe the scintigraphic pattern in

Paget’s 

• Expansile or thickening of the bone with sharpdemarcation of normal area

Page 434: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 434/2049

How does Paget’s affect the bone 

Page 435: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 435/2049

How does Paget’s affect the bone 

• Increased bone resorption accompanied by

bone formation

Page 436: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 436/2049

What is the scintigraphic finding of

radiation osteitis in bone scan

Page 437: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 437/2049

What is the scintigraphic finding of

radiation osteitis in bone scan

• Increased activity in the first few weeks,

followed by defect

Page 438: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 438/2049

What is the scintigraphic pattern of

early fracture in bone scan

Page 439: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 439/2049

What is the scintigraphic pattern of

early fracture in bone scan

• Cold defect in the first few hours

Page 440: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 440/2049

What are the reasons of cold defect in

first few hours of fracture in bone scan

Page 441: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 441/2049

What are the reasons of cold defect in

first few hours of fracture in bone scan

• Rupture of vascular supply from fracture andtoo early for reactive bone formation

Page 442: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 442/2049

How soon will fracture become

positive and what is the time course in

bone scan

Page 443: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 443/2049

How soon will fracture become

positive and what is the time course in

bone scan

• Cold defect in the first few hours

• Increasing activity up to few weeks or months

• Then tapering off until resolved

Page 444: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 444/2049

Then tapering off until resolved

Page 445: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 445/2049

Stress fractures

1. Increased activity in a linear pattern along theposterior and medial aspect of both mid tibias.

2. Shin splints

3. B , focal ovoid activity posteromedial right tibiaat the junction of the proximal 2/3 and distal

Page 446: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 446/2049

j p

1/3. C, focal fusiform activity posteromedially inthe right proximal tibia and linear activity alongthe posteromedial left tibia proximally and moreprominently distally.

4. B, stress fracture. C, stress fracture and shinsplints

Page 447: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 447/2049

Paget’s disease 1. Abnormal increased uptake in the entire left femur,

which appears bowed and widened and the distal

third of the left tibia, which tapers proximally.2. A sharp leading edge, referred to as “flame  shaped” 

or :blade of grass”, may be demonstrated on the lyticphase on radiograph and bone scan.

Page 448: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 448/2049

p g p

3. Paget’s  disease, fibrous dysplasia, chronicosteomyelitis, primary bone tumors.

4. High output congestive heart failure may occur. Oncebelieved to be the result of arteriovenous shunting

within the bone lesion, now hyperemia and increasedblood flow through the lesion and not shunting arelikely the causes.

Page 449: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 449/2049

Rib fractures1. Patient A; focal increased uptake in multiple ribs

posterolaterally and the costovertebral

 junctions. Patient B; increased vertical linearuptake in the sternum from the manubrium tothe xiphoid.

2. The uptake in adjacent (patient A) and the

Page 450: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 450/2049

p j (p )

vertical uptake in the sternum both have ageometric and characteristic pattern.

3. Trauma or surgery

4. Patient A; multiple rib fracture. Patient B;

median sternnotomy for coronary artery bypassgrafting (CABG)

Page 451: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 451/2049

Osteomyelitis1. First phase; arterial blood flow to the bone.

Second phase; blood pool. Third phase; delayed

phase or bone uptake at 3 hours after injection.All three phases are typically focally increasedwith osteomyelitis. With cellulitis only twophases are positive.

Page 452: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 452/2049

2. Increased flow, blood pool and delayed uptaketo the left first digit distal phalanx.

3. Consistent with osteomyelitis of the digit.

4. Sensitivity and specificity 95% if the radiograph

is normal or has only suggestive changes ofosteomyelitis.

Page 453: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 453/2049

Abnormal breast uptake

1. Nonuniform abnormal soft tissue uptake

exists in the soft tissue overlying the chest,likely the right breast.

2. Breast ca, aseptic mastitis or radiation

Page 454: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 454/2049

therapy.3. Breast examination, mammography and

possible biopsy.

4. To determine whether breast cancer bonemetastases are present.

Page 455: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 455/2049

Extra renal pelvis

1. Solitary right kidney with prominent renalpelvis. Incidental uptake at antecubitalinjection site

2. Ureteropelvic junction obstruction orobstruction secondary to other processes,

Page 456: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 456/2049

extrarenal pelvis.3. The renal pelvis has drained and the kidney is

now seen inferomedial to its prior location

4. Image B was taken with the patient erect,leading to gravity drainage of an extra renalpelvis. The kidney is mobile (ptotic)

Page 457: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 457/2049

Lymphedema

1. The soft tissues of the left arm enlarged and

show abnormal increased soft tissue activity,the left anterior ribs are uniformly more

intense than the right.

Page 458: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 458/2049

2. Venous or lymphatic obstruction, soft tissueneoplasm, soft tissue injury.

3. Breast cancer.

4. Lymphedema secondary to axillary lymphnode dissection and left mastectomy

Page 459: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 459/2049

Renal position1. The right kidney is not in the renal fossa.

Nonuniform activity is noted in the rightsacroiliac region, which extends beyond theexpected superior margin of the bone.

2. Congenital renal anomaly, pelvic kidney.

Page 460: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 460/2049

3. Anomalies of number (supernumerarykidney), position (malrotation) and fusion(horseshoe)

4. Yes. Ureteropelvic junction obstruction,vesicoureteral reflux, decrease function andincrease risk of trauma.

Page 461: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 461/2049

Metastatic prostate cancer1. Abnormal focal uptake throughout the axial

and appendicular skeleton stronglysuggestive of metastatic disease.

2. Greater than 20 ng/ml. the prevalence ofbone scan – evidence od metastases is < 1%.

Page 462: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 462/2049

3. Multiple myeloma, thyroid ca,, renal cell caand lymphoma

4. CT and MRI have poor sensitivity for

detection of prostate cancer soft tissue/nodalmetastases.

Page 463: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 463/2049

Fibrous dysplasia

1. A , shows increased uptake in the entire

mandible. B, shows intense increased uptakein the mandible and maxilla which appear

deformed and overgrown.

Page 464: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 464/2049

2. Check the rest of the bone scan for othersites

3. Fibrous dysplasia, cherubism.

4. Fibrous dysplasia.

Page 465: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 465/2049

Sacral insufficiency fracture

1. Patient A has increased blood pooling and

delayed uptake bilaterally in the region of thesacroiliac joints and across the sacrum (H

pattern). The bone scan for patient B.

2 Both of these are diagnostic of sacral

Page 466: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 466/2049

2. Both of these are diagnostic of sacral

insufficiency fractures.

3. Proximal femur, wrist and proximal humerus

4. Osteoporosis

Page 467: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 467/2049

Heterotopic ossification1. Intense activity is seen overlying the right

acetabulum with a separate area of uptake

overlying the proximal right femur.

2. Urinary contamination; fracture with exuberantcallus; heterotopic ossifican or myositis

Page 468: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 468/2049

ossificans; soft tissue injury (contusion).3. If urinary contamination is suspected; removeclothing and overlying bed sheets; wash thepatient’s  skin in the area of suspected

contamination.4. Heterotopic ossification.

Page 469: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 469/2049

Superscan

1. Increased tracer in the large majority of the

visualized bones, with nonuniforminvolvement in both femurs, both humeri and

skull.

2. Soft tissue and GI tract.

Page 470: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 470/2049

2. Soft tissue and GI tract.

3. The kidneys are not visualized, but faint

activity is seen in the urinary bladder. Little

soft tissue activity is seen.

4. Superscan.

Page 471: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 471/2049

hyperparathyroidism1. Abnormal diffuse uptake in the lungs and stomach.

Poor visualization of small kidneys and bladder,

increased uptake in the shoulders, hips, knees andankle.

2. Hyperparathyroidism, metastatic calcification causedby hypercalcemia, renal failure or metabolic bone

Page 472: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 472/2049

disease.3. This particular pattern of metastatic calcification is

characteristic of long standing hyperparathyroidism.

4. Free Tc-99m pertechnetate has gastric, thyroid and

salivary gland uptake. The latter two are not seen inthis patient, who also shows large uptake.

Page 473: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 473/2049

Reflex sympathetic dystrophy1. Three phase study demonstrate abnormal increased

blood flow and blood pool of the distal right upper

extremity. The delayed bone phase shows increasedactivity in the bones in the same distribution with astriking increased in periarticular activity causing the joints to stand out.

Page 474: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 474/2049

2. RSD. Disuse of a limb of new onset e.g.. recent strokeor immobilization by orthopedic cast or splint.

3. Shoulder hand syndrome, a frequently encounteredform of RSD

4. Neurogenic origin with loss of sympathetic autonomictone is the generally accepted explanation, althoughnot firmly establish.

Page 475: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 475/2049

Myocardial uptake1. Horseshoe pattern of uptake in the anterior

chest that does not correspond to normalbony anatomy and therefore is most likelyabnormal soft tissue uptake.

2. Cardiac uptake either the myocardium or

Page 476: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 476/2049

pericardium.3. Tc-99m pyrophosphate

4. Idiopathic or secondary cardiomyopathy e.g..

due to cardiotoxic drugs, myocarditis orpericarditis.

Page 477: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 477/2049

Avascular necrosis of femoral heads

1. Nonvisualization of the left ilium, leg lengthdiscrepancy as a result of high riding left hipand increased uptake both femoral heads,left worse than right.

2. The ilium has been surgically resected.

Page 478: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 478/2049

Femoral heads; avascular necrosis, fracture,osteotomies, slipped capital femoralepiphyses in the appropriate group.

3. Trauma, steroid, sickle cell disease, chronicrenal disease, alcoholism.

4. Humeral head and tarsal navicular.

Cardiac

Page 479: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 479/2049

Pearls & Pitfalls

Myocardialperfusion imaging

• The common indication for

MPI is to determine whether

there is normal perfusion,

ischemia or infarction.

• Tl-201 photon energy (69  – 81

keV)

Page 480: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 480/2049

• Myocardial uptake of Tl-201

chloride and Tc-99m

sestamibi/tetrofosmin is

proportional to regional blood

flow and requires cell viability.

Pearls & Pitfalls

Myocardialperfusion imaging

• Thallium is actively taken up by

Na/K pump in the cells.

Tc-99m sestamibi/tetrofosminpassively diffuse across the

membrane and localize in

cytoplasmic mitochondria.

Page 481: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 481/2049

• Thallium redistributes over

time, so post stress images

must be obtained immediately

after injection.

Pearls & Pitfalls

Myocardialperfusion imaging

• Tc-99m sestamibi/tetrofosmin

do not redistribute and best

images are made 30 to 90

minutes after injection to allow

clearance of interfering

background activity from the

Page 482: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 482/2049

liver but before the activityreaches the transverse colon.

• Infarcts and hibernating

myocardium produce perfusiondefects on the rest images.

Pearls & Pitfalls

Myocardialperfusion imaging

• Stress images are needed toelucidate ischemia with lesserdegree of stenosis (50 – 90%).

Stenosis less than 50% in diameterare not detected at rest and arevariably diagnosed with exerciseimaging.

Page 483: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 483/2049

Stress may be physical orpharmacologic.

• Physical stress should bediscontinued with patientexhaustion, claudication, severeangina or hypotension, arrhythmiaor severe ECG changes.

Pearls & Pitfalls

Myocardialperfusion imaging

• Dipyridamole and adenosine

are used instead of physical

stress to dilate normal

coronary arteries.

• Vessels in ischemic areas are

already maximally dilated and

Page 484: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 484/2049

do not dilate further.

• The adverse effect of the

dipyridamole are reversed with

100 to 200 mg IV

aminophylline.

Pearls & Pitfalls

Myocardialperfusion imaging

• Dipyridamole and adenosineshould not be used in patientswith asthma.

Dobutamine is inotropic andchronotropic and is used forpharmacologic stress.

• Adverse effects may be reversed

Page 485: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 485/2049

by using short acting betablocker.

• The most common cause of falsenegative is submaximal stress.

The most common cause of falsepositive is artifact.

Pearls & Pitfalls

Myocardialperfusion imaging

• The myocardium normally thins

at the apex, membranous

septum and base of inferior wall.

• A high degree of lung activity on

exercise Thallium images (>50%

of peak myocardial activity) is

Page 486: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 486/2049

related to poor prognosis, moreextensive disease and LV

dysfunction on exercise.

On Tc-99m sestamibi scans, lungactivity is uncommon.

Pearls & Pitfalls

Myocardialperfusion imaging

• Transient LV dilatation withexercise may be related tosubendocardial ischemia and less

often to real LV dilatation. It issign of poor prognosis.

• With adequate exercise, thesensitivity and specificity of MPI

Page 487: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 487/2049

are about 85%.• An occluded coronary artery with

adequate collaterals or balancedthree vessels disease canproduce an apparently normalscan

Pearls & Pitfalls

Myocardialperfusion imaging

• Real defects on MPI should be

seen on at least 2 views (e.g..,

short and vertical or horizontal

long axes)

• LBBB may produce myocardial

perfusion findings

Page 488: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 488/2049

indistinguishable from stressinduced reversible septal

ischemia.

A defect seen at the base of theheart is frequently artifactual

unless it extends to the apex.

Pearls & Pitfalls

Myocardialperfusion imaging

• Not all fixed defects are infarcts.They may also be soft tissueattenuation artifacts, hibernating

or repetitive stunnedmyocardium.

• Hybernating myocardium is achronically hypoperfused area

h h d d ll l

Page 489: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 489/2049

that has reduced cellularmetabolism.

• This area has decreasedcontractility andrevascularization is usuallyneeded.

Pearls & Pitfalls

Myocardialperfusion imaging

• Stunned myocardium is due to

an acute occlusion with

relatively rapid perfusion.

• These area have normal or

near normal perfusion and

decreased contractility and

Page 490: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 490/2049

revascularization is not usually

needed.

• LV walls that diverged towards

the apex should raisesuspicious of a LV aneurysm.

Pearls & Pitfalls

Myocardialperfusion imaging

• Diaphragmatic attenuation looks

like an inferior wall defect but it

goes away on prone images.

• Relatively intense GI activity

adjacent to the inferior wall can

cause an apparent inferior

di l d f S C

Page 491: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 491/2049

myocardial defect on SPECTstudies as a result of a

reconstruction artifact.

Breast attenuation usually causesan apparent defect in the

anterior or lateral LV wall.

Pearls & Pitfalls

Myocardialperfusion imaging

• Bull’s  eye plot underestimate

apical defect and overestimate

basal defects.

• The normal LVEF is 50 - 65%.

Page 492: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 492/2049

Page 493: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 493/2049

Cardiac Muscle Layers

Page 494: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 494/2049

parasympathetic sympathetic

SA NODES ↓ heart rate ↑ heart rate ( β receptor )

ATRIUM ↓ contractility  ↑ contractility and conduction

velocity ( β receptor )

AV NODES AND CONDUCTION

SYSTEM

↓ conduction velocity and 

block conduction

↑ conduction velocity ( β 

receptor )

VENTRICLE - ↑ contractility and conduction

l it ( β t )

Page 495: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 495/2049

velocity ( β receptor )

CORONARY ARTERY - Constriction (α receptor )

Dilatation ( β receptor )

Page 496: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 496/2049

Page 497: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 497/2049

Coronary artery

Right coronary artery (RCA) Left main artery (LMA)

Left circumflex (LCX) Left anterior

Descending (LAD)

Page 498: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 498/2049

AV node

branch

Acute marginal

Branch (AM)

Posterior

descending

Artery (PDA)

Descending (LAD)

Marginal

branches

Obtuse M1& M2 

Diagonal

branches

D1 & D

Septal

branches

CORONARY CIRCULATIONCORONARY ARTERY VASCULAR DISTRIBUTIONS

Left anterior descending ( LAD ) Septum

Anterior wallApex

Left circumflex ( LCX ) Lateral wall

Posterior wall

Posterior inferior wall

Apex

Right coronary ( RCA ) Inferior wall

Page 499: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 499/2049

Right coronary ( RCA ) Inferior wall

Posterior inferior wall

Right ventricular wall

Left main coronary Anterior wall

Septum

Posterolateral wall

Page 500: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 500/2049

Page 501: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 501/2049

Page 502: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 502/2049

Planes used for SPECT MPI

Page 503: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 503/2049

Page 504: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 504/2049

Page 505: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 505/2049

Page 506: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 506/2049

CONDUCTION SYSTEMSA ( sinoatrium node )• Pacemaker of heart

• Posterior wall of right atrium

• Depolarize spontaneously 70-80 time/ min

• Contraction of atrium

(interatrium septum)  AV ( atrioventricular node )

(interventricular septum) ( AV bundle )

Page 507: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 507/2049

( p ) ( AV bundle )

PURKINJE FIBRES

INNERVATIONparasympathetic sympathetic

SA NODES ↓ heart rate ↑ heart rate ( β receptor )

ATRIUM ↓ contractility  ↑ contractility and conductionvelocity ( β receptor )

AV NODES AND CONDUCTION

SYSTEM

↓ conduction velocity and 

block conduction

↑ conduction velocity ( β 

receptor )

VENTRICLE ↑ t tilit d d ti

Page 508: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 508/2049

VENTRICLE - ↑ contractility and conduction

velocity ( β receptor )

CORONARY ARTERY - Constriction (α receptor )

Dilatation ( β receptor )

STROKE VOLUME•  volume of blood pumped by left ventricle in 1

minute

• SV ( STROKE VOLUME ) x HR ( HEART RATE )

Page 509: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 509/2049

VENTRICLE CONTRACTILITYEF = EDV – ESV X 100

EDV

• Stroke volume = EDV – ESV

• EF = ejection fraction ( % )

Page 510: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 510/2049

EF = ejection fraction ( % )• EDV = End diastolic volume ( ml )

• ESV = End systolic volume ( ml )

ECG STAT

DR ZOOL HILMI

Page 511: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 511/2049

DR ZOOL HILMI

• ECG paper 25 mm/s

• Large square = 5mm = 0.2 s

• Each large square = 5 small square = 1 mm =

0.04 s

• 1 mV = 1 cm vertically

0 1 V 1 1 ll

Page 512: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 512/2049

• 0.1 mV = 1 mm = 1 small square

Page 513: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 513/2049

Page 514: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 514/2049

• 6 chest leads = V1 to V6

6 limb leads = I, II, III, aVR, aVL, aVF

- II, III, aVF = inferior

- V1 to V4 = anterior

Page 515: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 515/2049

- V1 to V4 = anterior- I, aVL, V5 to V6 = lateral

- V1 and aVR = right atrium and cavity of left ventricle

Page 516: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 516/2049

INTERPRETATION OF ECG• RATE

RHYTHM• AXIS

• P WAVE

• PR INTERVAL

• ST SEGMENT

T WAVE• QT INTERVAL

• U WAVE

Page 517: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 517/2049

PR INTERVAL• QRS COMPLEX

• Q WAVE

Page 518: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 518/2049

Page 519: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 519/2049

IMPORTANT• PR = 3 – 5 SMALL SQUARE / 0.12 – 0.2 SECONDS

• QRS ≤ 3 SMALL SQUARE / ≤ 0.12 SECONDS 

• BBB > 3 SMALL SQUARE

Page 520: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 520/2049

• QT < 11 SMALL SQUARE OR < 0.44 SECONDS OR

< 0.5 RR INTERVAL

CORRECTED QT = QT/√RR 

Page 521: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 521/2049

RHYTHM• Lead II

• Sinus rhythm = originates in the sinus node and

conduct to the ventricle

CARDINAL FEATURES OF SINUS RHYTHM

P wave is upright in leads I and II

Page 522: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 522/2049

P wave is upright in leads I and II

Each P wave is usually followed by QRS complex

Heart rate between 60 to 99

CARDIAC AXISNORMAL

AXIS

RIGHT AXIS

DEVIATION

LEFT AXIS

DEVIATION

LEAD I

+ - +LEAD II

+ +/

Page 523: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 523/2049

+ +/- -LEAD III

+/- + -

CARDIAC AXISLEAD I AVF

NORMAL + +

LEFT AXIS + & (LEAD II -) -

RIGHT AXIS - +

Page 524: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 524/2049

RIGHT AXIS +

INDETERMINATE - -

CARDIAC AXIS CAUSESLEFT AXIS RIGHT AXIS

LVH RVH

INFERIOR MI LATERAL MI

Page 525: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 525/2049

INFERIOR MI LATERAL MI

LEFT ANTERIOR

FASCICULAR BLOCK

LEFT POSTERIOR

FASCICULAR BLOCK

NORMAL FINDINGS ECG• Tall R waves

• Prominent U waves

• Exaggerated sinus arrhythmia• Sinus bradycardia

• Wandering atrial pacemaker

Wenckebach phenomenon• Junctional rhythm

Page 526: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 526/2049

Wenckebach phenomenon• Junctional rhythm

• 1st degree heart block

• ST segment elevation(high take off, benign early

repolarization)

P WAVE• Atrial depolarization

Characteristic of the P wave: positive in leads I and II

Best seen in lead II and V1

Commonly biphasic in lead V1

Page 527: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 527/2049

Commonly biphasic in lead V1< 3 small square (0.12s)in duration

< 2.5 small square (0.25mV) in amplitude

NORMAL ECG

Page 528: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 528/2049

P WAVE• Bifid P, in lead II , notch with peak to peak interval

of > 1 mm = mitral stenosis

Page 529: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 529/2049

P WAVE

• Large negativedeflection = left atrial

enlargement

Page 530: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 530/2049

PR INTERVAL• Electrical impulse conducted through the AV

node, the bundle of His and bundle branches

and the Purkinje fibers

• Beginning of the P wave to the 1st deflections

of QRS complex whether it is Q or R wave

Page 531: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 531/2049

of QRS complex, whether it is Q or R wave

3 to 5 small square (0.12 – 0.20 s)

Page 532: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 532/2049

QRS COMPLEX• Ventricular depolarization

• Not > 2 ½ small square (0.10 s)

• BBB > (0.12 s) wide QRS

Q wave : any initial negative deflection

R wave : any positive deflection

S wave : any negative deflection after R wave

Page 533: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 533/2049

S wave : any negative deflection after R wave

• Non pathological Q wave seen at: leads I, III,aVL, V5 and V6

Page 534: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 534/2049

ST SEGMENT• QRS complex terminates at the J point or ST

 junction

• ST segment lies between the J point and the

beginning of the T wave

• Period between the end of ventricular

depolarization and the beginning of the

Page 535: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 535/2049

depolarization and the beginning of the

repolarization

ST SEGMENT• Leads V1 to V3, rapidly S wave merges directly

with the T wave, making the J point indistinct

and the ST segment difficult to identify

• This produces elevation of the ST segment,

and this is known as high take off

Page 536: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 536/2049

and this is known as high take off

Page 537: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 537/2049

EARLY REPOLARISATION

Page 538: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 538/2049

Page 539: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 539/2049

T WAVE• Ventricular repolarization

• Normal T is ASYMMETRICAL

• SYMMETRICAL, Inverted T = myocardial

ischemia

Tall T wave = MI and hyperkalemia• T a e < 2/3 amplit de of R

Page 540: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 540/2049

yp• T wave < 2/3 amplitude of R

• T wave amplitude < 10 mm

Page 541: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 541/2049

QT INTERVAL• Total time for depolarization and

repolarization of the ventricle

• Beginning of the QRS complex to the end of

the T wave

• 0.35 – 0.45 s

Page 542: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 542/2049

Page 543: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 543/2049

Page 544: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 544/2049

PROMINENT U WAVE

Page 545: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 545/2049

CONDITIONS AFFECTINGTHE LEFT SIDE OF THE

HEART

Page 546: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 546/2049

CONDITIONING AFFECTING LEFT SIDE

OF THE HEART

1. Left atrial dilatation and

hypertrophy

2. LVH

Page 547: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 547/2049

LEFT ATRIAL ABNORMALITY• Atrial hypertrophy or dilatation or both

• P wave in lead V1 is often biphasic

• Early right atrial forces giving rise to an initial

positive deflection

These are followed by left atrial forcestravelling posteriorly, producing a later

Page 548: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 548/2049

travelling posteriorly, producing a later

negative deflection

LEFT ATRIAL ABNORMALITY

Page 549: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 549/2049

• Biphasic P wave in V1

LEFT ATRIAL ABNORMALITY• A large deflection (>1 small square) suggests a

left atrial abnormality

• Prolongation of P wave duration to greater

than 0.12 s is often found in association with

the left atrial abnormality

• Normal P wave may be bifid

Page 550: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 550/2049

LEFT ATRIAL ABNORMALITY• Any condition causing left ventricular

hypertrophy may produce left atrial

enlargement as a secondary phenomenon

• Causes of Left atrial enlargement :

Hypertension

Aortic stenosis

Page 551: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 551/2049

Mitral incompetence

Hypertrophic cardiomyopathy

LEFT ATRIAL ABNORMALITY

• P mitrale in lead II• Commonly seen in

mitral stenosis

Page 552: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 552/2049

LEFT VENTRICULAR HYPERTHROPHY

• Difficult to diagnose < 40 with ECG

• Causes:

1. Hypertension

2. Aortic stenosis

3. Co-arctation of aorta

Page 553: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 553/2049

LEFT VENTRICULAR HYPERTHROPHY

Page 554: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 554/2049

LEFT VENTRICULAR HYPERTHROPHY

Page 555: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 555/2049

LEFT VENTRICULAR HYPERTHROPHY

Page 556: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 556/2049

LEFT VENTRICULAR HYPERTHROPHY

Page 557: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 557/2049

TAHCYCARDIA

Page 558: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 558/2049

• HR > 100 bpm

TAHCYCARDIA

• Divided into 2:

1. Supraventricular

tachycardia

Page 559: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 559/2049

2. Ventricular

tachycardia

SUPRAVENTRICULAR TACHYCARDIA

(SVT)• From atria or sinoatrial node

1. Sinus tachycardia

2. Atrial fibrillation

3. Atrial flutter

• From atrioventricular node

Page 560: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 560/2049

1. Atrioventricular re-entrant tachycardia

2. Atrioventricular nodal re-entrant tachycardia

SUPRAVENTRICULAR TACHYCARDIA

(SVT)

• At the atrium

• Above bundle of

His

• Narrow complext h di

Page 561: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 561/2049

tachycardia

SUPRAVENTRICULAR TACHYCARDIA

(SVT)

Page 562: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 562/2049

SUPRAVENTRICULAR TACHYCARDIA

(SVT)

Page 563: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 563/2049

• SINUS TACHYCARDIA

SUPRAVENTRICULAR TACHYCARDIA

(SVT)

Page 564: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 564/2049

• SINUS TACHYCARDIA

SUPRAVENTRICULAR TACHYCARDIA

(SVT)• Normal P wave in

inferior lead II,III

and aVF• Atrial rate 100-200

bpm

• Regular ventricularrhythm

Page 565: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 565/2049

• SINUS TACHYCARDIA

rhythm

• Ventricular rate 100-

200 bpm

Page 566: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 566/2049

ATRIAL FIBRILATION

Page 567: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 567/2049

ATRIAL FIBRILATION

Page 568: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 568/2049

• NO P WAVES IN AF

ATRIAL FIBRILATION

• Mapping R waves

against a piece of paper

usually confirmdiagnosis

• May be paroxysmal,

persistent or

permanent

T Di i

Page 569: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 569/2049

• Treatment : Digoxin

ATRIAL FIBRILATION

Page 570: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 570/2049

Page 571: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 571/2049

ATRIAL FLUTTER

Page 572: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 572/2049

ATRIAL FLUTTER

• Re-entry circuit in the

right atrium with

secondary activation ofleft atrium

• Atrial contraction 300

bpm

• Broad and appear

t th b t t

Page 573: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 573/2049

sawtooth best seen at

inferior leads and V1

ATRIAL FLUTTER

Page 574: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 574/2049

JUNCTIONAL TACHYCARDIA

Page 575: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 575/2049

1. Atrioventricular re-entrant tachycardia

2. Atrioventricular nodal re-entrant tachycardia

JUNCTIONAL TACHYCARDIA

• Negative P waves in

inferior leads

Page 576: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 576/2049

JUNCTIONAL TACHYCARDIA

• PR interval < 3 ss

• P wave negative

deflection in lead II

Page 577: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 577/2049

ECTOPIC ATRIAL TAHYCARDIA

Page 578: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 578/2049

SUPRAVENTRICULAR TACHYCARDIA

(SVT)

Page 579: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 579/2049

JUNCTIONAL TACHYCARDIA

• WOLF PARKINSON

WHITE SYNDROM

• Atrioventricular re-

entrant tachycardia

• Electrical signal re-

enters the atria over

b l

Page 580: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 580/2049

an abnormal extra

pathway

JUNCTIONAL TACHYCARDIA

• WOLF PARKINSONWHITE SYNDROM

This extra pathwayallows electrical signalsto pass between theventricles and atria

Signals on this extrapathways causing theatria and ventricles to

Page 581: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 581/2049

atria and ventricles tobeat too fast

JUNCTIONAL TACHYCARDIA

• WOLF PARKINSONWHITE SYNDROM

• Short PR interval < 3small square

• Slurred upstroke to

the QRS indicatingpre-excitation (delta)

Page 582: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 582/2049

wave)

• Broad QRS

Page 583: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 583/2049

VENTRICULAR TACHYCARDIA

• At the ventricle

• Below bifurcation

bundle of His

• Broad QRS

complex

tachycardia

Page 584: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 584/2049

tachycardia

VENTRICULAR TACHYCARDIA

Page 585: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 585/2049

VENTRICULAR TACHYCARDIA

• Define as 3 or more ventricular extrasystoles insuccession at rate > 120 bpm

• Causes :

1. IHD

2. Cardiomyopathy

Page 586: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 586/2049

y p y

3. Myocarditis

4. Drugs: quanidine

ATRIOVENTRICULAR CONDUCTION

BLOCK• Delayed 1st degree block

• Intermittently blocked – 2nd degree block

Completely blocked – 3rd

 degree block

• Causes:

1. MI

2. Degeneration of His Purkinje system

3 Lyme disease diphtheria

Page 587: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 587/2049

3. Lyme disease, diphtheria

4. Surgery

5. Congenital disorder

1st DEGREE BLOCK

• A delay conduction of atrial impulse to ventricle

At level of atrioventricular node• Prolonged PR interval > 2.0 s

Page 588: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 588/2049

• A QRS complex follows each P wave, and PR

interval remains constant

1st DEGREE BLOCK

Page 589: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 589/2049

• Prolonged PR

2nd DEGREE BLOCK

•MOBITZ TYPE I BLOCK (WENCKEBACH

PHENOMENON)

• MOBITZ TYPE II BLOCK

Page 590: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 590/2049

2nd DEGREE BLOCK• At the level of

atrioventricular node

• Intermittent failure of

transmission of the atrial

impulse to the ventricles

• Initial PR interval is normal

but progressively lengthens

with each successive beat

until AV transmission is

blocked completely and the

Page 591: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 591/2049

P wave is not followed by

QRS complex

• PR interval then return tonormal and cycle repeats

MOBITZ TYPE I (WENCKEBACH)

i l i f i l

Page 592: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 592/2049

• Progressive prolongation of PR interval

within group

2nd DEGREE BLOCK

• Less common but is more likely to produce

symptoms

• Intermittent failure of conduction of P wave• PR interval is constant, though it may normal or

Page 593: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 593/2049

prolonged

Block is often at the level of the bundle brunches andis therefore associated with wide QRS complexes

MOBITZ TYPE II

• Constant PR interval in a group

Page 594: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 594/2049

3rd  DEGREE BLOCK

• Complete failure of conduction between atria

and ventricles

• Complete independence of atria and

ventricular contractions

b l i i h Q S l

Page 595: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 595/2049

• P waves bear no relation with QRS complexes

Usually proceed with faster rate

AV BLOCK SUMMURY

• 1st  DEGREE AV BLOCK

All P waves conducted with prolonged PR

• 2nd DEGREE AV BLOCK

Some P waves not conducted

Mobitz type I : Progressive PR prolongation

Mobitz type II : Constant PR interval

3rd DEGREE AV BLOCK

Page 596: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 596/2049

• 3rd DEGREE AV BLOCK

No P waves conducted

BUNDLE BRANCH BLOCK

• Right bundle branch block

• Left bundle branch block

Page 597: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 597/2049

Left bundle branch block

COMPLETE RBBB

• QRS prolongation (≥ 

0.12s)

• Slurred S  wave in

lead V6  and/or rSR

pattern in lead V1

• Overall positive QRScomplex in lead V1 

Page 598: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 598/2049

p

(a must)

RBBB

Page 599: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 599/2049

COMPLETE LBBB

• QRS prolongation (≥ 

0.12s)

• Broad R  waves in

lead I  and V6  with

no Q waves

• Broad S waves in theseptal leads

Page 600: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 600/2049

p

LBBB

Page 601: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 601/2049

HYPERKALAEMIA

• Potassium

concentration rises

above 5.5-6.5mmol/L

• Classic tall,

symmetricallynarrow and peaked T

Page 602: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 602/2049

waves

HYPOKALEMIA

• Serum potassium <

2.7 mmol/L

• Broad, flat T waves

• ST depression

• QT interval

prolongation

Page 603: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 603/2049

ACUTE CORONARY SYNDROME

Page 604: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 604/2049

STEMI

Page 605: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 605/2049

STEMI

Page 606: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 606/2049

STEMI

Page 607: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 607/2049

STEMI

Page 608: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 608/2049

STEMI

Page 609: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 609/2049

• Normal Q wave

STEMI

Page 610: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 610/2049

STEMI

Page 611: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 611/2049

• Viable myocardium

STEMI

ECG ONSET RESOLUTION

HYPERACUTE T WAVE

CHANGES

< 5 MINUTES HOURS

ST ELEVATION < 20 MINUTES HOURS TO 3 DAYS

TERMINAL PORTION QRS

CHANGES

HOURS HOURS

Q WAVE FORMATION 9 HOURS TO 2 DAYS PERMANENT

Page 612: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 612/2049

T WAVE INVERSION VARIABLE WEEKS

STEMI LOCALISATION

Page 613: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 613/2049

NSTEMI/UNSTABLE ANGINA

Page 614: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 614/2049

NSTEMI/UNSTABLE ANGINA

Page 615: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 615/2049

• T INVERSION

NSTEMI/UNSTABLE ANGINA

Page 616: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 616/2049

• ST SEGMENT DEPRESSION AND T INVERSION

NSTEMI/UNSTABLE ANGINA

Page 617: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 617/2049

SUMMARY

COMPLETE OCCLUSION

(STEMI)

PARTIAL OCCLUSION

(NSTEMI)ST ELEVATION ST DEPRESSION

Q WAVES T INVERSION

NO Q WAVES

FULL THICKNESS MI NON Q WAVE MI

Q WAVE MI PARTIAL THICKNESS MI

Page 618: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 618/2049

TRANSMURAL MI SUBENDOCARDIAL MI

Cardiac scan

Radionuclideventriculography

Myocardial perfusion

imaging (MPI)Infarct avid

Metabolic 

Neuronal

Single photon

PET

PET

Tetrofosmin 

Sestamibi

Thallium 

Teboroxime

NOET

Planar

O15

Rb82 

N13 

Pyrophosphate Antimyosin  Glucarate

FDG

Fatty acid

C11epinephrine

Tc-99m labeled

Tc-99m DTPA

Page 619: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 619/2049

MUGA First pass

Planar

MIBGC11phenylephrine

C11hydroxyephdrine

Tc-99m

pertechnitate

Tc-99m RBCTc-99m serum

Human albumin

Chemical, physical &

pharmacokinetic

Thalium-201 Tc-99m Sestamibi

( Cardiolite )

Tc-99m Tetrofosmin

( Myoview )

Chemical Element cation Isonitrile cation Diphosphine cation

Preparation cyclotron Generator/kit Generator/kit

Mode of decay Electron capture Isomeric transition Isomeric transition

Half life 73 H 6 H 6 H

Principle emissions Mercury x rays 69-

83KeV

Gamma rays 140KeV Gamma rays 140KeV

Mechanism of uptake Active transport Passive diffusion Passive diffusion

Myocyte localization Cytosol Mitochondria Mitochondria

Redistribution Yes No No

Extraction fraction 85% 60% 50%

Percent cardiac uptake 3% 1.5% 1.2%

Body clearance Renal Hepatic Hepatic

Highest radiation Kidney Colon Gallbladder

Page 620: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 620/2049

Highest radiation

absorbed dose

Kidney

( rads/3mCi )

Colon

( rads/30mCi )

Gallbladder

( rads/30mCi )

Imaging timeStress

Rest

10 min

3-4 hrs

15-30 min

30-90 min

5-15 min

30 min

Page 621: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 621/2049

Page 622: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 622/2049

Page 623: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 623/2049

Page 624: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 624/2049

WHAT IS REDISTRIBUTION?

Page 625: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 625/2049

REDISTRIBUTION

• Only occurs with Tl 201

• Is misnomer

• Tl 201 exits the myocardium more slowly from

ischemic segments

• In delayed imaging, more rapid exit of Tl 201

from normal segments result in equilibrium

among normal and ischemic segment

Page 626: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 626/2049

Page 627: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 627/2049

Page 628: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 628/2049

Page 629: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 629/2049

STUNNED MYOCARDIUM

• Myocardium with persistent contractile

dysfunction despite restoration of perfusion

after ischemia• Improves with time

• Normal by perfusion imaging

• Absence of ventricular contraction on wallmotion studies

Page 630: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 630/2049

• Increased uptake by FDG

WHAT IS HIBERNATING

MYOCARDIUM?

Page 631: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 631/2049

HIBERNATING MYOCARDIUM

• Chronically ischemic myocardium that is still

viable

• Appears cold on immediate Tl 201 imaging

• Absence of ventricular contraction on wall

motion studies

• Increased uptake of FDG compared toperfusion imaging

Page 632: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 632/2049

• Improved perfusion on reinjection of Tl 201

Normal scan

Stress (top) and rest (bottom) MPI images from normal male subject

Page 633: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 633/2049

ISCHEMIC MYOCARDIUM IMAGES?

Page 634: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 634/2049

ISCHEMIC MYOCARDIUM

• Reduced Tl 201 myocardial uptake on post

stress images

• Improves uptake on the rest images

Page 635: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 635/2049

Apical ischemia

Stress (top) and rest (bottom) MPI images from a subject with apical

ischemia

Page 636: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 636/2049

ischemia.

SCAR IMAGES ?

Page 637: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 637/2049

SCAR

• Reduced Tl 201 myocardial uptake post stress

images

• Reduced uptake on the rest images

Page 638: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 638/2049

Antero-apical infarct

Stress (top) and rest (bottom) MPI images from a patient with prior

Page 639: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 639/2049

extensive antero-apical MI and no residual ischemia.

MYOCARDIAL IMAGINGRADIOPHARMACEUTICAL DOSE ( mCi ) IMAGING TECHNIQUE TYPE OF STUDY

²⁰¹Tl Cl 2-3 Planar or SPECT Perfusion

Tc 99m sestaMIBI 10-30 Planar or SPECT Perfusion

Tc 99m teboroxime 15-30 Planar or SPECT Perfusion

Tc 99m PYP 10-15 Planar Infarct

¹¹¹In labeled antimyosin

antibody

2-3 Planar Infarct

⁸²RbCl  60 PET Perfusion

¹³NH₃  15-20 PET Perfusion

Page 640: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 640/2049

¹⁸F-FDG 5-10 PET Metabolism

Sensitivi ty & Specif ici ty  

Sensitivity Specificity

Myocardial

Perfusion Scan 93% 88%

Stress

Echocardiography 81% 82%

Exercise StressTest 68% 77%

Page 641: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 641/2049

INDICATIONS FOR MYOCARDIAL

PERFUSION SCAN• Detection of CAD

• Assessment of severity of myocardial ischemia orinfarction

• Assessment of myocardial viability• Evaluation for candidate of coronary bypass or

angioplasty

• Clinical indication of MI, chest pain and SOB

• ↑ CPK,LDH, +ve troponin and myoglobin• Detection of viable/hibernating myocardial tissue

• Evaluation of angioplasty/bypass surgery

Page 642: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 642/2049

• Evaluation of prognosis

CONTRAINDICATIONS FOR

MYOCARDIAL PERFUSION• Chest pain

• Ventricular arrhythmia at rest

• Very high BP

• Allergy to pharmacological stress drugs

• Third degree heart block

• Severe valvular disease ( aortic valve stenosis )

Page 643: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 643/2049

Selection of Stress Technique

Mean hyperemic flowMean resting flow

X 4

X 3

X 2

X 1

Restin blood flow

Treadmill exercise

Dobutamine

D iridamole/ Adenosine

Coronary flow disturbance vs diameter narrowing

Diff. btw.

sternotic

& non-

stenotic

counts.

Page 644: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 644/2049

% diameter narrowing50 100

STRESS PROTOCOLS

1. PHYSICAL EXERCISE

2. PHARMACOLOGICAL STRESS

Page 645: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 645/2049

STRESS TESTING INDICATIONS

• Diagnosis of CAD

• Evaluation of CAD, location and extent of ischemia

• Determine the cause for change in symptom pattern inpatients with known CAD

• Evaluate the effectiveness of medical therapy

• Risk stratification post myocardial infarction

Pre operative evaluation for major non cardiac surgeryin patient with known CAD

• Assessment after angioplasty or bypass

Page 646: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 646/2049

• Guide to rehabilitation therapy

STRESS TESTING CONTRAINDICATIONS

• Acute MI

• Unstable angina

• Severe tachyarrhythmias and bradyarrhythmias

• Uncontrolled symptomatic heart failure

• Critical aortic stenosis

• Acute aortic dissection

• Pulmonary embolism

l ll d

Page 647: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 647/2049

• Poorly controlled HPT

INDICATIONS FOR TERMINATING A

STRESS TEST• Patient’s request

• Inability to continue due to fatigue, dyspnea, orfaintness

• Moderate to severe chest pain• Dizziness, near syncope

• Pallor

• Ventricular tachycardia

• Atrial fibrillation• Third degree heart block

• ST segment depression > 3 mm

Page 648: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 648/2049

• Increased SBP > 240 mmHg or DBP > 120 mmHg

Myoview counseling

Stop medications:At the appointment date :

1. Aspirin

2. OHA/insulin

2 days prior :

1. Neulin (theophylline)

2. Beta blockers3. Viagra

Page 649: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 649/2049

3 days prior : 1. Nitrates/trimetazidine

Page 650: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 650/2049

CARDIAC STRESS TEST : EXERCISE AND

PHARMACOLOGY• LEG EXERCISE

• Treadmill

• Bicycle ergometer

• PHARMACOLOGIC STRESS

• Dipyridamole• Adenosine

• Dobutamine

Page 651: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 651/2049

• Dobutamine

STRESS PROTOCOLS

1.PHYSICAL EXERCISE

2. PHARMACOLOGICAL STRESS

Page 652: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 652/2049

PHYSICAL EXERCISE

• Treadmill or bicycle

• ECG 10-12 lead used

• Run baseline ECG

• Start exercise

• Monitor HR, BP, ECG changes till target HR is

achieved > 85% of ( 220-AGE )• Radiotracer is injected when target HR is reached

• Maintain exercise for 1 minute

Page 653: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 653/2049

• Maintain exercise for 1 minute

Page 654: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 654/2049

Page 655: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 655/2049

STRESS PROTOCOLS

1. PHYSICAL EXERCISE

2.PHARMACOLOGICALSTRESS

Page 656: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 656/2049

PHARMACOLOGICAL STRESS

1. ADENOSINE

2. DOBUTAMINE

3. DIPYRIDAMOLE

Page 657: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 657/2049

Page 658: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 658/2049

Page 659: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 659/2049

Page 660: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 660/2049

Page 661: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 661/2049

Page 662: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 662/2049

Page 663: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 663/2049

Dobutamine

✔β adrenergic agonist 

✔Synthetic catecholamine

✔β1 affinity

✔Short plasma half life

✔Cause ionotrophic/chronotrophic effect due

to high O2 demand cause by artery stenosis

✔Infusion rate (40-50 υg/kg/min) 

Page 664: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 664/2049

Dobutamine

✔Can be used in asthma patients

✔Side effect:Supraventricular and ventricular arrhythmia

Palpitation

SOBGI symptom

Chest pain

Page 665: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 665/2049

p

Dobutamine

✔Contraindications:

ST depression

Ventricular tachycardia

Systolic BP > 220 mmHg

Page 666: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 666/2049

Page 667: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 667/2049

Page 668: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 668/2049

Adenosine Dypiridamole Dobutamine

Mechanism of

action

Direct Indirect Indirect

Half life < 10 s 30 – 60 min 2 min

Onset of action Seconds 2 min 1 – 2 min

Patients with side

effect requiring

medical

intervention

0.6% 16% NA

Page 669: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 669/2049

ADVERSE EFFECTS: ADENOSINE AND

DIPYRIDAMOLEADVERSE EFFECT ADENOSINE ( % ) DIPYRIDAMOLE ( % )

Flushing 37 3

Dyspnea 35 3

Chest pain 25 20GI symptoms 15 6

Headache 14 12

Dizziness 9 12

A-V block 8 2

ST wave changes 6 8

Arrhythmia 3 5

Hypotension 2 5

h 0 1 0 1

Page 670: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 670/2049

Bronchospasm 0.1 0.15

MI 0.0001 0.05

Death 0 0.5

ARTIFACTS FOR MPI

• Patient motion

• Diaphragm in men and breast in female cause

attenuation artifacts• Medallion, necklaces, pacemaker or metallic

button

• Left arm of the patient, lying on the side maycause unwanted attenuation

• Gallbladder with sestaMIBI may causeproblems

Page 671: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 671/2049

problems

Breast attenuation effect

Stress (top) and rest (bottom) MPI images from a female subject

showing a reduction in counts anteriorly in both stress and rest

images

Page 672: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 672/2049

images.

Page 673: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 673/2049

Page 674: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 674/2049

Page 675: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 675/2049

Page 676: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 676/2049

Page 677: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 677/2049

Page 678: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 678/2049

Page 679: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 679/2049

Page 680: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 680/2049

Page 681: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 681/2049

Page 682: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 682/2049

Reporting MPI

Page 683: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 683/2049

Page 684: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 684/2049

Page 685: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 685/2049

Page 686: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 686/2049

Page 687: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 687/2049

Page 688: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 688/2049

Page 689: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 689/2049

Page 690: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 690/2049

Page 691: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 691/2049

Page 692: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 692/2049

Page 693: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 693/2049

Page 694: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 694/2049

Page 695: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 695/2049

Page 696: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 696/2049

Page 697: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 697/2049

Page 698: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 698/2049

Page 699: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 699/2049

Page 700: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 700/2049

Page 701: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 701/2049

Page 702: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 702/2049

Page 703: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 703/2049

Page 704: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 704/2049

Page 705: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 705/2049

Page 706: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 706/2049

Page 707: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 707/2049

Page 708: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 708/2049

Page 709: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 709/2049

PET Cardiac

Page 710: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 710/2049

Page 711: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 711/2049

Page 712: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 712/2049

Page 713: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 713/2049

Page 714: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 714/2049

Page 715: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 715/2049

Page 716: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 716/2049

Page 717: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 717/2049

Page 718: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 718/2049

Concerning the blood supply of the

normal heart

1. The right coronary artery supplies the AVnode

2. The anterior intraventricular artery is abranch of RCA

3. Arise from the inferior aspect of the aorticarch

4. The circumflex artery is a branch of the LCA

5. The great cardiac vein drains the territorysupplied by the RCA

Page 719: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 719/2049

Concerning the blood supply of the

normal heart

1. The right coronary artery supplies the AV node

2. The anterior intraventricular artery is a branch

of RCA3. Arise from the inferior aspect of the aortic arch

4. The circumflex artery is a branch of the LCA

5. The great cardiac vein drains the territorysupplied by the RCA

TFFTF

Page 720: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 720/2049

FOLLOWING ARE INDICATIONS OF

GATED BLOOD POOL STUDY

1. Measuring right ventricular ejection fraction

2. Quantifying shunts

3. Cardiotoxic drugs4. Extent of infarct

5. Myocardial reserve

Page 721: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 721/2049

FOLLOWING ARE INDICATIONS OF

GATED BLOOD POOL STUDY

1. Measuring right ventricular ejection fraction

2. Quantifying shunts

3. Cardiotoxic drugs4. Extent of infarct

5. Myocardial reserve

FFTFT

Page 722: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 722/2049

IMAGING OF INFARCT

1. Tc pyrophosphate is the infarct avid imagingprocedure of choice

2. Pyrophosphate uptake is taken more around the

infarct than in the infarct3. Myosin monoclonal antibody is useful only in

imaged within 2-3 days after administration

4. Pyrophosphate is taken up by bone5. Images are acquired after 48 hours in myosin

antibody

Page 723: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 723/2049

IMAGING OF INFARCT

1. Tc pyrophosphate is the infarct avid imagingprocedure of choice

2. Pyrophosphate uptake is taken more around the

infarct than in the infarct3. Myosin monoclonal antibody is useful only in

imaged within 2-3 days after administration

4. Pyrophosphate is taken up by bone

5. Images are acquired after 48 hours in myosinantibody

FTFTF

Page 724: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 724/2049

CONTRAINDICATION FOR

MYOCARDIAL PERFUSION IMAGING (

EXERSICE STRESS )

1. Sinus bradycardia

2. Third degree heart block3. Ventricular arrhythmias

4. Aortic stenosis

5. Unstable angina

Page 725: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 725/2049

CONTRAINDICATION FOR

MYOCARDIAL PERFUSION IMAGING (

EXERSICE STRESS )

1. Sinus bradycardia

2. Third degree heart block3. Ventricular arrhythmias

4. Aortic stenosis

5. Unstable angina

FTTTT

Page 726: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 726/2049

MYOCARDIAL PERFUSION IMAGING

1. Bulls eye maps are used to predict theprognosis of infarct

2. Stress images are acquired 30-60 mins afterinjection

3. GTN is administered when acquiring restimages

4. Rest images are acquired far later than stressimages

5. Injection is done at maximum stress

Page 727: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 727/2049

MYOCARDIAL PERFUSION IMAGING

1. Bulls eye maps are used to predict the prognosisof infarct

2. Stress images are acquired 30-60 mins after

injection3. GTN is administered when acquiring rest images

4. Rest images are acquired far later than stress

images5. Injection is done at maximum stress

TTTTT

Page 728: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 728/2049

STRESS IN MYOCARDIAL PERFUSION

IMAGING

1. Dipyridamole is the stress agent of choice

2. Systolic pressure less than 100mm is

contraindication for adenosine3. The aim of stress is to decrease the coronary

arterial flow

4. Adrenaline is the antidote to adenosinecomplication

5. Asthma is a contraindication to adenosine

Page 729: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 729/2049

STRESS IN MYOCARDIAL PERFUSION

IMAGING

1. Dipyridamole is the stress agent of choice

2. Systolic pressure less than 100mm iscontraindication for adenosine

3. The aim of stress is to decrease the coronaryarterial flow

4. Adrenaline is the antidote to adenosine

complication5. Asthma is a contraindication to adenosine

FTFFT

Page 730: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 730/2049

CARDIAC SCINTIGRAPHY

1. LAO best for left ventricle

2. RAO 30 best for right ventricle

3. For assessing RV ejection fraction, inject thetight bolus

4. For shunt quantification, inject over 3

seconds5. First pass takes 15 seconds

Page 731: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 731/2049

CARDIAC SCINTIGRAPHY

1. LAO best for left ventricle

2. RAO 30 best for right ventricle

3. For assessing RV ejection fraction, inject thetight bolus

4. For shunt quantification, inject over 3

seconds5. First pass takes 15 seconds

TTFFT

Page 732: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 732/2049

CARDIAC SCINTIGRAPHY

1. MIBI is more prone for liver uptake

2. Tetrofosmin is easier to prepare than MIBI

3. Stannous pyrophosphate and pertechnateare mixed before administrating in vein

4. MUGA scan are better than LIST studies

5. Acquisition begins with R wave of each cycle

Page 733: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 733/2049

CARDIAC SCINTIGRAPHY

1. MIBI is more prone for liver uptake

2. Tetrofosmin is easier to prepare than MIBI

3. Stannous pyrophosphate and pertechnateare mixed before administrating in vein

4. MUGA scan are better than LIST studies

5. Acquisition begins with R wave of each cycleTTFTT

Page 734: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 734/2049

THALLIUM 201

1. Decays by electron capture to Tl 203

2. Mainly produce gamma photon of 135 and

167 keV3. After IV administration 15% is localized in the

myocardium

4. All the thallium ions enter the myocytes bythe sodium potassium ATPase pump

5. Extraction of thallium is reduced in acidosis

Page 735: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 735/2049

THALLIUM 201

1. Decays by electron capture to Tl 203

2. Mainly produce gamma photon of 135 and 167keV

3. After IV administration 15% is localized in themyocardium

4. All the thallium ions enter the myocytes by the

sodium potassium ATPase pump5. Extraction of thallium is reduced in acidosis

FFFFF

Page 736: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 736/2049

FEATURES OF HIBERNATING

MYOCARDIUM

1. Reversible

2. FDG PET is the standard for assessing

myocardial viability3. Adverse cardiac events in these patients are

higher if treated with revascularization

4. Decreased uptake in FDG5. Decreased perfusion in thallium scans

Page 737: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 737/2049

Page 738: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 738/2049

MYOCARDIAL PERFUSION IMAGING

1. 2 separate injection are required for thallium,unlike for MIBI and tetrofosmin

2. ST segment depression more than 3mm is

indicator that dobutamine should be stopped3. Rest images are performed first, followed by

stress images

4. At least 2 days are required for satisfactory

testing using MIBI5. Infarcts will show decreased uptake during

stress and improved in rest images

Page 739: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 739/2049

MYOCARDIAL PERFUSION IMAGING

1. 2 separate injection are required for thallium, unlikefor MIBI and tetrofosmin

2. ST segment depression more than 3mm is indicatorthat dobutamine should be stopped

3. Rest images are performed first, followed by stressimages

4. At least 2 days are required for satisfactory testingusing MIBI

5. Infarcts will show decreased uptake during stress andimproved in rest images

FTFFF

Page 740: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 740/2049

THALLIUM 201 IMAGING

1. Taken up by infarcts

2. Left ventricular function can be assessed

using first pass studies3. Can be used to assess a left to right shunt

4. Normal to have a photon deficient area at

the apex5. Left ventricular failure is associated with

increased lung uptake

Page 741: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 741/2049

THALLIUM 201 IMAGING

1. Taken up by infarcts

2. Left ventricular function can be assessed usingfirst pass studies

3. Can be used to assess a left to right shunt

4. Normal to have a photon deficient area at theapex

5. Left ventricular failure is associated withincreased lung uptake

FTTTT

Page 742: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 742/2049

THALLIUM SCINTIGRAPHY

1. Involves a lower radiation dose than Tc99m

MIBI scanning

2. Reverse redistribution is commonly due toartifact

3. Injection is performed at peak exercise

4. There is increased uptake in areas ofmyocardial infarction

5. Is more sensitive than cardiac stress testing

Page 743: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 743/2049

THALLIUM SCINTIGRAPHY

1. Involves a lower radiation dose than Tc99m MIBIscanning

2. Reverse redistribution is commonly due to

artifact3. Injection is performed at peak exercise

4. There is increased uptake in areas of myocardial

infarction5. Is more sensitive than cardiac stress testing

FTTFT

Page 744: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 744/2049

THALLIUM 201

1. Kidney is the critical organ

2. Distribution is proportional to perfusion

3. Physical half life is 24 hours, making it lowdose

4. Images are of high resolution

5. High signal to noise ratio

Page 745: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 745/2049

THALLIUM 201

1. Kidney is the critical organ

2. Distribution is proportional to perfusion

3. Physical half life is 24 hours, making it lowdose

4. Images are of high resolution

5. High signal to noise ratioTTFFF

Page 746: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 746/2049

PET AGENTS USED IN HEART IMAGING

1. Nitrogen 13 ammonia

2. Rubidium 82

3. Potassium 384. Oxygen 15 labeled water

5. Inhaled 15 CO2

Page 747: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 747/2049

PET AGENTS USED IN HEART IMAGING

1. Nitrogen 13 ammonia

2. Rubidium 82

3. Potassium 384. Oxygen 15 labeled water

5. Inhaled 15 CO2

TTTTT

Page 748: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 748/2049

UPTAKE OF THALLIUM IS SEEN IN

FOLLOWING STRUCTURES

1. Kidney

2. Lungs

3. Salivary glands4. Skeletal muscle

5. Liver

Page 749: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 749/2049

UPTAKE OF THALLIUM IS SEEN IN

FOLLOWING STRUCTURES

1. Kidney

2. Lungs

3. Salivary glands4. Skeletal muscle

5. Liver

TTFTF

Page 750: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 750/2049

STRESS TESTING

1. Adenosine combined with exercise improves

detection of perfusion defects

2. Dobutamine avoided if patient has asthma3. Adenosine should be avoided if patient has

bifascicular block or LBBB

4. Bradyarrhythmia is reduced by exercise5. Dipyridamole has the highest sensitivity and

specificity among pharmacological agents

Page 751: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 751/2049

STRESS TESTING

1. Adenosine combined with exercise improvesdetection of perfusion defects

2. Dobutamine avoided if patient has asthma

3. Adenosine should be avoided if patient hasbifascicular block or LBBB

4. Bradyarrhythmia is reduced by exercise

5. Dipyridamole has the highest sensitivity andspecificity among pharmacological agents

TFFTF

Page 752: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 752/2049

MIBI CARDIAC IMAGING

1. Rescan is done at 4 hours as redistributionoccurs

2. 5% of negative studies go on to get MI within

one year

3. Increased uptake is seen in myocardialinfarction

4. Gated studies useful to look at wall motion5. Fatty meal should not be taken as it produces

hepatic uptake

Page 753: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 753/2049

MIBI CARDIAC IMAGING

1. Rescan is done at 4 hours as redistributionoccurs

2. 5% of negative studies go on to get MI within

one year3. Increased uptake is seen in myocardial infarction

4. Gated studies useful to look at wall motion

5. Fatty meal should not be taken as it produces

hepatic uptakeFFTTF

Page 754: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 754/2049

INCREASED UPTAKE OF THALLIUM

1. Graves’ disease 

2. Thyroid ca

3. Bronchogenic ca in lung4. Lymphoma of lung

5. Brain in encephalitis

Page 755: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 755/2049

INCREASED UPTAKE OF THALLIUM

1. Graves’ disease 

2. Thyroid ca

3. Bronchogenic ca in lung4. Lymphoma of lung

5. Brain in encephalitis

TTTTT

Page 756: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 756/2049

MYOCARDIAL PERFUSION

SCINTIGRAPHY

1. The physical properties of thallium 201 are such thatits use is preferable to that of Tc99m labeledcompounds in myocardial perfusion imaging

2. The effective dose from Tl 201 myocardial perfusionscan is one of the highest in diagnostic imaging androughly equates to 3 barium enemas

3. The uptake of Tl 201 relies solely on regional

myocardial perfusion4. Tl 201 is a Na analogue

5. Tl 201 remains irreversibly fixed to the myocardiumwithin a few minutes of injection

Page 757: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 757/2049

MYOCARDIAL PERFUSION

SCINTIGRAPHY1. The physical properties of thallium 201 are such that

its use is preferable to that of Tc99m labeledcompounds in myocardial perfusion imaging

2. The effective dose from Tl 201 myocardial perfusion

scan is one of the highest in diagnostic imaging androughly equates to 3 barium enemas

3. The uptake of Tl 201 relies solely on regionalmyocardial perfusion

4. Tl 201 is a Na analogue5. Tl 201 remains irreversibly fixed to the myocardium

within a few minutes of injection

FTFFF

Page 758: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 758/2049

THE FOLLOWING MAY CAUSE

REDUCTION IN Tl 201 UPTAKE TO THE

MYOCARDIUM

1. Myocardial infarction2. Hibernating myocardium

3. Cardiomyopathy

4. Cardiac sarcoidosis5. Dobutamine

Page 759: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 759/2049

THE FOLLOWING MAY CAUSE

REDUCTION IN Tl 201 UPTAKE TO THE

MYOCARDIUM

1. Myocardial infarction

2. Hibernating myocardium3. Cardiomyopathy

4. Cardiac sarcoidosis

5. DobutamineTTTTT

Page 760: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 760/2049

PROGNOSIS IN CORONARY ARTERY

DISEASE1. Increased uptake of Tl 201 into the lungs is a poor

prognostic indicator during myocardial perfusion imaging

2. Myocardial perfusion imaging may identify patients atincreased risk of cardiac events following major vascular

surgery3. Myocardial perfusion imaging has greater prognostic

power than exercise ECG

4. Myocardial perfusion imaging has less prognostic powerthan coronary arteriography

5. In a patient with a strongly positive ECG but a normalmyocardial perfusion scan, the perfusion scan is the mostappropriate for defining prognosis

Page 761: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 761/2049

PROGNOSIS IN CORONARY ARTERY

DISEASE1. Increased uptake of Tl 201 into the lungs is a poor

prognostic indicator during myocardial perfusion imaging

2. Myocardial perfusion imaging may identify patients atincreased risk of cardiac events following major vascular

surgery3. Myocardial perfusion imaging has greater prognostic

power than exercise ECG

4. Myocardial perfusion imaging has less prognostic powerthan coronary arteriography

5. In a patient with a strongly positive ECG but a normalmyocardial perfusion scan, the perfusion scan is the mostappropriate for defining prognosis

TTTFT

Page 762: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 762/2049

CONCERNING PHARMACOLOGICAL

STRESSOR AGENTS

1. Dipyridamole reduces uptake of myocardialperfusion agents to myocardial

2. Adenosine may be use as a cardiac stressor

3. Caffeine intake should be restricted before anexercise myocardial perfusion

4. Aminophylline may reverse chest pain caused

by dipyridamole5. Dipyridamole is a potent coronary

vasodilator

Page 763: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 763/2049

CONCERNING PHARMACOLOGICAL

STRESSOR AGENTS

1. Dipyridamole reduces uptake of myocardialperfusion agents to myocardial

2. Adenosine may be use as a cardiac stressor

3. Caffeine intake should be restricted before anexercise myocardial perfusion

4. Aminophylline may reverse chest pain caused by

dipyridamole5. Dipyridamole is a potent coronary vasodilator

FTTTT

Page 764: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 764/2049

Tc 99m LABELLED MYOCARDIAL

PERFUSION AGENTS1. Stress and redistribution images of Tc 99m SestaMIBI

accurately identify ischemic myocardium

2. Tc99m SestaMIBI is more suited to SPECT scanningthan Tl 201

3. A fatty meal is required following sestaMIBI injection4. Tc 99m SestaMIBI stress and rest myocardial perfusion

scans cannot be performed on the same day due tothe long redistribution time of this agent in

myocardium5. Tc 99m SestaMIBI imaging should be performed as

soon as possible following injection

Page 765: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 765/2049

Tc 99m LABELLED MYOCARDIAL

PERFUSION AGENTS1. Stress and redistribution images of Tc 99m SestaMIBI

accurately identify ischemic myocardium

2. Tc99m SestaMIBI is more suited to SPECT scanning than Tl201

3. A fatty meal is required following sestaMIBI injection4. Tc 99m SestaMIBI stress and rest myocardial perfusion

scans cannot be performed on the same day due to thelong redistribution time of this agent in myocardium

5. Tc 99m SestaMIBI imaging should be performed as soon as

possible following injectionFTTFF

Page 766: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 766/2049

EQUILIBRIUM GATED BLOOD POOL

IMAGING

1. Tc 99m DTPA is preferable to labeled red bloodcells in gated ventriculography asradiopharmaceutical preparation is easier

2. Red cells may be labeled with Tc 99m in vivo3. Concurrent ECG recording is only necessary ifthere is risk of arrhythmia

4. It is possible to assess regional wall motion

abnormalities of the left ventricle5. Background substraction is not usually requiredin measuring LV ejection fractions as activitywithin the adjacent lung is negligible

Page 767: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 767/2049

EQUILIBRIUM GATED BLOOD POOL

IMAGING1. Tc 99m DTPA is preferable to labeled red blood cells in

gated ventriculography as radiopharmaceuticalpreparation is easier

2. Red cells may be labeled with Tc 99m in vivo

3. Concurrent ECG recording is only necessary if there isrisk of arrhythmia

4. It is possible to assess regional wall motionabnormalities of the left ventricle

5. Background substraction is not usually required inmeasuring LV ejection fractions as activity within theadjacent lung is negligible

FTFTF

Page 768: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 768/2049

EQUILIBRIUM GATED BLOOD POOL

IMAGING1. Patients with coronary artery disease typically show an

increase in LV ejection fraction of only 5-10% on exercise

2. Regional wall motion abnormalities are more specific forcoronary artery disease than changes in ejection fraction

with exercise3. Patients receiving chemotherapy should be suspected of

having cardiotoxicity if the ejection fraction falls by morethan 10% on sequential scans

4. It is possible to differentiate alcoholic from viral

cardiomyopathy by gated blood pool imaging5. It is possible to differentiate ischemic cardiomyopathy

from dilated idiopathic cardiomyopathy with gated bloodpool imaging

Page 769: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 769/2049

EQUILIBRIUM GATED BLOOD POOL

IMAGING1. Patients with coronary artery disease typically show an increase in

LV ejection fraction of only 5-10% on exercise

2. Regional wall motion abnormalities are more specific for coronaryartery disease than changes in ejection fraction with exercise

3. Patients receiving chemotherapy should be suspected of havingcardiotoxicity if the ejection fraction falls by more than 10% onsequential scans

4. It is possible to differentiate alcoholic from viral cardiomyopathyby gated blood pool imaging

5. It is possible to differentiate ischemic cardiomyopathy from

dilated idiopathic cardiomyopathy with gated blood pool imagingFTTFT

Page 770: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 770/2049

RADIONUCLIDE VENTRICULOGRAPHY

1. Radionuclide ventriculography is a more accurate andreproducible method for measuring ejection fraction thanechocardiography

2. Assumptions for the calculation of ejection fraction are

greater for echocardiography than they are forradionuclide ventriculography

3. In severe left ventricular dysfunction the volume ofinjected radiopharmaceutical is reduced to avoid overload

4. Exercise ventriculography is not possible because there is

too much motion of the patient5. It is not possible to measure RV ejection fraction using

gated equilibrium technique

Page 771: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 771/2049

RADIONUCLIDE VENTRICULOGRAPHY

1. Radionuclide ventriculography is a more accurate andreproducible method for measuring ejection fraction thanechocardiography

2. Assumptions for the calculation of ejection fraction are

greater for echocardiography than they are forradionuclide ventriculography

3. In severe left ventricular dysfunction the volume ofinjected radiopharmaceutical is reduced to avoid overload

4. Exercise ventriculography is not possible because there is

too much motion of the patient5. It is not possible to measure RV ejection fraction using

gated equilibrium technique

TTFFF

Page 772: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 772/2049

FIRST PASS RADIONUCLIDE

ANGIOGRAPHY

1. It is possible to detect R to L cardiac shunts with thistechnique

2. It is possible to detect L to R cardiac shunts with this

technique3. As large a dilution of radiopharmaceutical as possibleshould be used in this technique

4. It is an accurate technique to quantify cardiac

shunting which coexist with coaortation of the aorta5. It is often not possible to accurately quantitate

cardiac L to R shunts in the presence of tricuspidregurgitation

Page 773: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 773/2049

FIRST PASS RADIONUCLIDE

ANGIOGRAPHY1. It is possible to detect R to L cardiac shunts with this

technique

2. It is possible to detect L to R cardiac shunts with thistechnique

3. As large a dilution of radiopharmaceutical as possibleshould be used in this technique

4. It is an accurate technique to quantify cardiacshunting which coexist with coaortation of the aorta

5. It is often not possible to accurately quantitatecardiac L to R shunts in the presence of tricuspidregurgitation

TTFFT

Page 774: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 774/2049

MYOCARDIAL INFARCT SCANNING

1. A myocardial infarction may be seen on an MDPbone scan

2. Tc 99m labeled pyrophosphate imaging may

detect myocardial infarction before cardiacenzyme changes

3. Rib fracture may give false positive results withpyrophosphate scanning

4. Positive antimyosin monoclonal antibodyscanning is specific for myocardial infarction

5. Rejection of heart transplants can be detectedwith antimyosin scanning

Page 775: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 775/2049

MYOCARDIAL INFARCT SCANNING

1. A myocardial infarction may be seen on an MDP bonescan

2. Tc 99m labeled pyrophosphate imaging may detectmyocardial infarction before cardiac enzyme changes

3. Rib fracture may give false positive results withpyrophosphate scanning

4. Positive antimyosin monoclonal antibody scanning isspecific for myocardial infarction

5. Rejection of heart transplants can be detected withantimyosin scanning

TFTFT

Page 776: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 776/2049

How does the percent extraction of

thallium-201 passing through the

myocardial capillary bed comparedwith the extraction of c-99m sestamibi

and Tc-99m teboroxime?

Page 777: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 777/2049

How does the percent extraction of

thallium-201 passing through the

myocardial capillary bed comparedwith the extraction of c-99m sestamibi

and Tc-99m tetrofosmin?• Tl-201 has a myocardial extraction fraction of

0.85 in normal subjects at a normal flow rates.

The myocardial extraction of Tc-99m sestamibiand Tc-99m tetrofosmin is considerably lower

0.5 and 0.6 respectively.

Page 778: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 778/2049

What percentage of Tl-201, Tc-99m

sestamibi and Tc-99m tetrofosmin

localizes in the heart?

Page 779: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 779/2049

What percentage of Tl-201, Tc-99m

sestamibi and Tc-99m tetrofosmin

localizes in the heart?

• Tl-201 : 3-4%

Tc-99m sestamibi : 1.5%• Tc-99m tetrofosmin : 1.2%

Page 780: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 780/2049

What are the advantages and

disadvantages of Tl-201 as perfusion

agent?

Page 781: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 781/2049

What are the advantages and

disadvantages of Tl-201 as perfusion

agent?Advantages

• Single injection because of

redistribution• Imaging within 10 – 15

minutes

• Can be used to assess

viability

Disadvantages

• High radiation

• Poor imaging characteristicswith a low photopeak of 69

 – 80 keV

• High scatter fraction

Page 782: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 782/2049

What quality control to detect patient

motion?

Page 783: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 783/2049

What quality control to detect patient

motion?

• Review raw data in cinematic display and

review of sonogram can confirm the extend of

the problem.

Page 784: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 784/2049

In what ways can the image

interpreter determine if fixed

decreased activity is due to artifact ordisease?

Page 785: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 785/2049

In what ways can the image

interpreter determine if fixed

decreased activity is due to artifact ordisease?

• Review the raw data in the cinematic display

to look for soft attenuation.

• Review the gated SPECT can help determine if

there is wall motion and thickening that

would indicate infarct or attenuation.

• Attenuation correction can be helpful.

• Prone can differentiate attenuation from

infarction in inferior wall.

Page 786: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 786/2049

Page 787: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 787/2049

What is the significant of lung uptake

on Tl-201 exercise study?

• Lung uptake on exercise stress images, but not

the delayed images is consistent with exercise

induced cardiac dysfunction.

• This finding is usually associated with three

vessel disease.

Page 788: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 788/2049

What other scintigraphic finding

suggest three vessel disease?

Page 789: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 789/2049

Page 790: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 790/2049

What is the mechanism of action of

dipyridamole?

Page 791: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 791/2049

What is the mechanism of action of

dipyridamole?

• Dipyridamole inhibits the action of adenosine

deaminase.

• By augmenting the effects of endogenous

adenosine, dipyridamole is a powerful

vasodilator.

Page 792: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 792/2049

What effect can a cup of coffee have

on dipyridamole or adenosine stress

test?

Page 793: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 793/2049

What effect can a cup of coffee have

on dipyridamole or adenosine stress

test?• Caffeine in coffee, tea, soft drinks or food such

as chocolate are chemically related to

dipyridamole and adenosine and can block theeffect of dipyridamole pharmacological stress

testing.

Page 794: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 794/2049

What percentage of stenosis at rest is

necessary in the coronary arteries for

resting blood flow to be effected?

Page 795: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 795/2049

What percentage of stenosis at rest is

necessary in the coronary arteries for

resting blood flow to be effected?•  > 85 – 90%

Page 796: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 796/2049

Why is imaging delayed for 30 – 90

minutes after administration of Tc-99m

sestamibi or tetrofosmin?

Page 797: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 797/2049

Why is imaging delayed for 30 – 90

minutes after administration of Tc-99m

sestamibi or tetrofosmin?• Lung uptake is also significant.

• The lung and liver clear with time and the

target to background ratio improves.

Page 798: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 798/2049

What pharmaceutical is administered

to allows the Tc-99m to bind to RBC?

Page 799: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 799/2049

What pharmaceutical is administered

to allows the Tc-99m to bind to RBC?

• Stannous (tin) pyrophosphate and stannous

chloride has been used.

Page 800: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 800/2049

What part of the RBC does the Tc-99m

label bind?

Page 801: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 801/2049

What part of the RBC does the Tc-99m

label bind?

• Beta chain of hemoglobin when the patient is

pretreated with stannous ion.

Page 802: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 802/2049

What do amplitude and phase images

portray?

Page 803: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 803/2049

What do amplitude and phase images

portray?

• Amplitude and phase images are parametric

or derived images.

• The amplitude images portrays the maximum

count difference at each pixel location during

the cardiac cycle. High EF areas have high

amplitude and background areas have low

amplitude.

• The phase images portrays the timing of

cyclical activity with respect to a reference

standard.

Page 804: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 804/2049

What is the hallmark of a ventricular

apical aneurysm by phase analysis?

Page 805: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 805/2049

What is the hallmark of a ventricular

apical aneurysm by phase analysis?

• Aneurysms demonstrate paradoxical motion.

• Activity in the area of the aneurysm is typically

180 degrees out of phase with the rest of the

ventricle.

Page 806: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 806/2049

Page 807: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 807/2049

LAD ischemia

1. Severe decreased perfusion in the majority of

the anterior wall, apex and septum which

normalizes on the rest image indicating

extensive severe ischemia.

2. LAD territory.

3. Transient cavity dilatation.

4. VT, angina related ST abnormalities,

decreased systolic pressure and level of

exercise achieved.

Page 808: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 808/2049

Page 809: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 809/2049

Apical infarct

1. Fixed stress and rest severe apical perfusion

defect. Heart and cavity size appear normal.

2. Myocardial infarction, apical thinning and

attenuation.

3. Small apical lateral scar.

4. Technical factors, operator error and

interpretation error

Page 810: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 810/2049

Page 811: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 811/2049

Breast attenuation

1. Mild fixed anteroseptal hypoperfusion thatdemonstrates uniform brightening on gatedSPECT, indicating normal myocardial wall

thickening on gated images.2. Apparent decreased tracer in the upper

portions of the heart is most obvious on theleft anterior oblique and lateral frames.

3. Normal perfusion study with normal wallthickening and breast attenuation.

4. Assessment of regional wall motion/ wall

thickening and LVEF

Page 812: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 812/2049

Page 813: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 813/2049

Inferolateral wall infarction

1. If the patient develops severe angina chest pain,a decrease in blood pressure, frequentpremature ventricular contraction or ST

elevation suggestive of acute infarct. Also ifpatient can walk no further on the treadmillbecause of general fatigue, leg pain or dyspnea.

2. Severe stress and rest fixed defect in the

basolateral, inferior and inferolateral walls,sparing the apex.

3. MI or possibly hibernation. Circumflex artery.

4. The exercise stress level.

Page 814: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 814/2049

Page 815: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 815/2049

Dipyridamole induced reversible

ischemia

1. A perfusion defect involving the entire

inferior wall extending to the apex shows

partial reversibility.

2. RCA

3. Inferior wall ischemia with incomplete

reversibility. The latter may represent scar or

hibernating myocardium.

4. The patient is at risk for further cardiac

event, either infarct or death.

Page 816: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 816/2049

Page 817: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 817/2049

Adenosine stress

1. A. adenosine is infused IV for 6 minutes (140μg/kg/min)  after 3 min the tracer is injected andadenosine is continued for 3 more minutes. B.adenosine is cleared from circulation <10 sec. return

to baseline blood flow levels occurs in 2 to 3 minutesafter stopping the infusion. C. stop infusion

2. Sinus node disease, 2nd  to 3rd  degree block,bronchospastic lung disease and adenosine allergy

3. Small to moderate severe fixed defect at the apex on

both stress and rest images consistent with infarct.Mildly improved perfusion of the anterior and lateralwalls at rest compared with stress consistent withmild anterolateral ischemia.

4. Whenever adequate exercise stress is not possible.

Page 818: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 818/2049

Page 819: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 819/2049

Viability

1. Extensive fixed defects involving the anterior

wall, apex, septum extending to the lateral

wall.

2. Myocardial infarction vs. hibernating

myocardium.

3. In hibernating myocardium, blood flow and

function e.g.. contractility are chronically

reduced.

4. Blood flow is normal with reduced function.

Page 820: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 820/2049

Page 821: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 821/2049

Bull’s eye 

1. A polar plot is constructed by layering short axis slicesone on top of the other with the apex forming thecenter and the base of the heart being the outermostportion.

2. Misregistration use of inappropriate referencedatabase.

3. Stress; hypoperfusion of the anterior, lateral andinferior walls. Rest; normalized perfusion of theanterior and lateral walls and incomplete

normalization of the inferior wall. Most consistentwith ischemia of the LCX and infarct of the right RCA.

4. Include location and extent, severity and reversibilityfor each perfusion abnormality. If gated SPECT is

performed, include LVEF, wall motion with or withoutwall thickening fractions.

Page 822: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 822/2049

Page 823: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 823/2049

Inadequate stress

1. Severe fixed defect involving the both entire

lateral wall

2. Dilated left ventricular cavity at both stress

and rest.

3. LCX artery

4. False negative studies for ischemia may result

Page 824: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 824/2049

Page 825: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 825/2049

LBBB

1. Dipyridamole or adenosine

2. Exercise or dobutamine. Methods of stress thatresult in increased heart rate can be associated

with false positive findings of septal reversibilityin patient with LBBB

3. These agents do not result in an increased inheart rate.

4. The mild decreased activity in the anterior wallappears fixed and likely is caused by breastattenuation in light of the reported normal wallmotion.

Page 826: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 826/2049

Page 827: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 827/2049

Dobutamine stress

1. Dobutamine stress; patients who are not

candidate for either exercise; asthma

2. Angina and inability to tolerate dobutamine

3. Mild fixed anteroseptal perfusion defect with

decreased wall thickening. Severe fixed

inferior defect with absent wall thickening.

Dilate LV. No reversibility. Myocardialthickening and wall motion signify

functioning viable myocardium.

Page 828: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 828/2049

Page 829: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 829/2049

Patient motion artifact

1. A. the first study shows an abnormal

configuration of the anterior wall; the repeat

study is normal. B, The initial sinogram shows a

discontinuity or break, the second is normal.2. To visually present the raw unprocessed

projection images to evaluate for patient

motion.3. Review SPECT projection, image by image or in

cinematic display.

4. Artifact caused by patient motion.

Page 830: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 830/2049

Page 831: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 831/2049

Breast attenuation

1. Tc-99m sestamibi, tetrofosmin and not Tl-201

because the GB is seen.

2. Mild fixed defect in the anterior wall.

Projection images; decreased uptake in the

half of the heart at stress and rest

3. Breast attenuation, anterior wall infarction.

4. Assessment of regional wall motion, wall

thickening and EF

Page 832: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 832/2049

Page 833: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 833/2049

Bowel activity

1. Dipyridamole inhibits the action of adenosinediaminase, increasing endogenous adenosine, apotent coronary artery vasodilatation. Coffee, tea,caffeine containing soft drinks or chocolate,theophylline and aminophylline.

2. Dipyridamole is infused for 4 minutes. Tracer is given3 minutes after completion of dipyridamole infusion.Side effects can be reversed with aminophylline.

3. Mild to moderate fixed defect of the anterior wall.

Severe, mostly fixed defect involving the entireinferior wall but small area of reversibility in theinferioapical region. Dilated LV.

4. Obtained delayed SPECT to allow additional hepaticclearance or movement of bowel activity, have thepatient drink water.

Page 834: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 834/2049

Brain scintigraphy

Page 835: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 835/2049

Pearls & Pitfalls

Brain imaging

• The commonest indications for brain imagingare perfusion abnormalities (stroke),dementia (Alzheimer’s  or multi infarct),epilepsy, brain death, and distinguishingrecurrent tumor from radiation necrosis.

• The radiopharmaceutical Tc-99m HAMPAO,

TC-99m ECD, N-13 PET.

• The radiopharmaceutical Tc-99m HAMPAO,TC-99m ECD are lipophilic, extracted on firstpass and reflect perfusion.

• Their uptake is highest in the cortical andsubcortical grey matter.

• On imaging, the central area of decreasedactivity is primarily white matter and shouldnot be mistaken for dilated lateral ventricle

Page 836: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 836/2049

Pearls & Pitfalls

Brain imaging

• The radiopharmaceuticals Tl-201

and FDG PET are metabolic agentsthat show activity in viablerecurrent and persistent tumors butnot in areas of radiation necrosis.

• Multi infarct dementia presentswith multiple asymmetric corticalperfusion defects.

• Multiple small perfusion defectscan also occur from cocaine abuseor vasculitis

Page 837: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 837/2049

Pearls & Pitfalls

Brain imaging

• Alzheimer's dementia classically

presents with symmetricallydecreased activity in the posteriorparietal-temporal lobes withpreserved activity in the calcarinecortex and basal ganglia and can be

also seen in Parkinson’s dementia.

• About 30% of Alzheimer's patientshave symmetrically decreased

activity.

• Herpes encephalitis can be seen asincreased activity in the temporal

lobe

l f ll

Page 838: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 838/2049

Pearls & Pitfalls

Brain imaging

• Epileptic seizure foci show increased

perfusion (Tc-99m HMPAO or Tc-99mECD) and metabolism FDG PET duringseizure activity but decreased or normalactivity interictally

• A normal radionuclide angiographicexamination of the brain presents atrident appearance of intracranial flow inthe anterior cerebral and right and leftmiddle cerebral territories.

• In brain death, there is no obvious arterialphase (the trident is absent) and onlyscalp activity is seen, which is often

accompanied by a hot nose sign.

l & f ll

Page 839: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 839/2049

Pearls & Pitfalls

Brain imaging

• These studies can also be

performed by Tc-99m HMPAOor Tc-99m ECD.

•A Diamox challenge studyevaluate cerebral vascularreserve.

• In areas of vascular disease,regional perfusion worsensafter Diamox compared with

perfusion without Diamox

l & i f ll

Page 840: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 840/2049

Pearls & Pitfalls

CSF imaging

• Common indications for CSF

imaging are for evaluation of a CSFleak or for differentiating normal-pressure hydrocephalus from othercauses of hydrocephalus.

• These study are done withintrathecal administration of In-111

DTPA

• Most CSF leaks occur in the ear,paranasal sinuses or nose

P l & Pi f ll

Page 841: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 841/2049

Pearls & Pitfalls

CSF imaging

• Substantial leaks can be

imaged by noting asymmetricactivity around the region ofthe ears on the frontal view oractivity in the nose on thelateral view.

• Some leaks are detected only

by removing and countingcotton pledgets that wereplaced in the area of concern

P l & Pi f ll

Page 842: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 842/2049

Pearls & Pitfalls

CSF imaging

• Cysternography images are

usually obtained anteriorly.

• Six hours after injection, these

images normally show a

trident appearance of activityproduced by labeled CSF in the

anterior interhemispheric,

right and left sylvian cisterns• Any abnormal entry into the

lateral ventricles is seen as

heart shape activity

P l & Pi f ll

Page 843: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 843/2049

Pearls & Pitfalls

CSF imaging

• Early ventricular entry with

stasis, accompanied by lack ofactivity over the superiorsurface of the brain after 24 to48 hours, support thediagnosis of normal pressurehydrocephalus.

• The classical clinical triad ofnormal hydrocephalus includesataxia, incontinence and

dementia

FDG

RADIOPHARMACEUTICALS F-18 FDG

Page 844: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 844/2049

RADIOPHARMACEUTICALS F-18 FDG

HOW THE STUDY IS

PERFORMED

- IV FDG (10-20 mCi)

- Imaged about 45 min later

- Patient sit in a quiet, darkened room

- EEG monitoring

PATIENT PREPARATION - Fasting except water- Withheld alcohol/caffeine/psychiatric medication

- Differ 4-6 weeks after RT

UNDERSTANDING THE

REPORT

FDG uptake dependent on blood flow & by active cells

Neoplasia

FDG is taken up by higher grade tumors

Most metastasis have increased uptake

Radiation necrosis have little or no uptake

Dementia

Alzheimer’s  dementia= decreased uptake in bilateral posteriortemporoparietal, posterior cingulate gyrus and frontal lobe if more

advanced

Prick’s disease = decreased uptake at frontotemporal

Lewy bodies = temporoparietal and more occipital

Parkinson’s dementia = temporoparietal and visual cortex

Vascular dementia = focal, asymmetric, wedge shape at cortical and

subcortical

AIDS dementia = multifocal cortical at frontal, temporal and parietal

Seizures Ictal = seizure = hyperperfusion

Interictal = after seizure = hypoperfusion

POTENTIAL PROBLEMS

Diaschisis phenomenon which abnormal in one segment will decreased uptake in

uninvolved region

False positive Inflammation / radiation necrosis with gliosis

False negative Steroid/ high glucose/ RT/ small lesion/ low histologic grade

Thyroid disease Hypothyroid may effect FDG uptake at parietal and temporal region

Brain perfusion SPECT imaging

Page 845: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 845/2049

RADIOPHARMACEUTICALS Tc-99m HMPAO / Tc-99m ECD / Xenon-133

HOW THE STUDY IS

PERFORMED

- IV RPC (15 – 30 mCi)

- Patient went in the dark room for 5 – 15 min

- For seizure, EEG is compulsory

PATIENT PREPARATION- Fasting except water

- Withheld alcohol/caffeine/psychiatric medication

- Differ 4-6 weeks after RT

UNDERSTANDING THE REPORT

Cerebrovascular disease

Brain perfusion highly sensitive to blood flow

Hemorrhagic stroke cannot be differentiated from other infarct

Lacuna strokes may be too small to detect

Dementia

Alzheimer’s  dementia= decreased uptake in bilateral posterior

temporoparietal, posterior cingulate gyrus and frontal lobe if more

advanced

Prick’s disease = decreased uptake at frontotemporal

Lewy bodies = temporoparietal and more occipital

Parkinson’s dementia = temporoparietal and visual cortex

Vascular dementia = focal, asymmetric, wedge shape at cortical and

subcortical

AIDS dementia = multifocal cortical at frontal, temporal and parietal

Seizures Ictal = seizure = hyperperfusion

Interictal = after seizure = hypoperfusion

POTENTIAL PROBLEMS

Diaschisis phenomenon which abnormal in one segment will decreased uptake in

uninvolved region

Age of infarct It is not possible to determine the age of infarct

Luxury perfusion Radiotracer may be deposited at an infarct due to increased flow, even

the brain cells are actually nonfunctioning. It’s seen with Tc-99m HMPAO

Page 846: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 846/2049

Blood Brain barrier protocol

Page 847: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 847/2049

SPECT cerebral perfusion imaging protocol

Brain death scan

Page 848: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 848/2049

RADIOPHARMACEUTICALS Tc-99m HMPAO / Tc-99m ECD / Tc-99m pertechnitate / Tc-99m DTPA

HOW THE STUDY IS

PERFORMED

- Tc-99m pertechnitate / DTPA bolus (20 mCi) for cerebral blood flow

- Tc-99m HMPAO / ECD (15 – 30 mCi), delayed images from 20 min to 2 hours postinjection

PATIENT PREPARATION - No specific preparation

UNDERSTANDING THE

REPORT

Absent of cerebral blood flow

Hot nose sign

POTENTIAL PROBLEMS

Barbiturates or

hypothermia

Barbiturate coma, taking phenobarbital or hypothermia

False negative Scalp blood flow may be increased due to inflammation

Continuum ofbrain death Ineffective blood flow can persist despite true brain death

Diamox Brain stress scan

Page 849: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 849/2049

Diamox Brain stress scan

RADIOPHARMACEUTICALS Tc-99m HMPAO / Tc-99m ECD

HOW THE STUDY IS

PERFORMED

- 1 g Diamox injected

- Rpc (9 mCi) injected 20 min later- The base line scan can be performed a day before or after

PATIENT PREPARATION - Contraindication for sulfa drug allergy

- Diamox is to be avoided within 3 days of acute stroke

UNDERSTANDING THEREPORT

Carotid arterystenosis

Decreased flow to the affected region onDiamox scan compared to base line

Multiinfarct

dementia or

Alzheimer’s

disease

MID = defect are often pronounced

following Diamox

AD = normal

POTENTIAL PROBLEMS

Side effect of Diamox = vertigo/ tinnitus/nausea/ postural

hypotension

Completely balanced bilateral lesion may give false negative

Thallium-201 or Tc-99m SestaMIBI Brain Scan

Page 850: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 850/2049

RADIOPHARMACEUTICALS

Tc-99msestamibi = localizes in mitochondria by active diffusion across

an interrupted BBB

Thallium 201 = concentrated like potassium in viable tumor, less in

inflammatory and no in necrotic tissue

HOW THE STUDY ISPERFORMED

- Tl-201 (2  –  4 mCi) IV , image at 10  –  30 min and delayed at 2  –  4hours

- Tc-99m SestaMIBI (10 – 30 mCi) IV an image at 10 min to 4 hours

PATIENT PREPARATION - No special preparation

UNDERSTANDING THE

REPORT

Normal brain Little or no thallium uptake

High grade gliomas

and lymphoma

Increased uptake “hot” 

Infection or radiation

necrosis

No significant increase from background

POTENTIAL PROBLEMS

False positive

There has been reports of thallium uptake with

abscess, certain infections, inflammatory

demyelinating disease and radiation necrosis

SestaMIBI less prone to false positive

False negative

If a lesion is necrotic, partially treated, near an

areas of normal uptake in the skull base or

scalp, or below the resolution of imaging

Radionuclide Cysternogram

Page 851: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 851/2049

RADIOPHARMACEUTICALS Indium-111 DTPA

3 days half life

Study requires 24 – 72 hours

HOW THE STUDY ISPERFORMED

- LP is performed- In-111 DTPA (9-18 MBq) into intrathecal

- Image at 1-4 hr, 24 hr, up to 48 – 72 hr

PATIENT PREPARATION - Lumbar puncture should be informed to patient before

procedure

- LP and radiotracer administration under fluoroscopic

guidance

UNDERSTANDING THE

REPORT

Normally radiotracer reaches basal cisterns by 1 hr,

frontal poles and Sylvian fissures by 2 – 6 hr

Convexity by 12 hr

Sagittal sinus by 24 hr

POTENTIAL PROBLEMS

Lumbar puncture Extravasation will manifest as persistent

activity at the lumbar puncture site and

slow or no progression to the cranium

Overlapping

patterns

Often there is overlap of finding

Page 852: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 852/2049

Cysternography protocol

CSF leak

Page 853: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 853/2049

RADIOPHARMACEUTICALS Indium-111 DTPA

3 days half life

HOW THE STUDY IS

PERFORMED

- Before the exam, labeled cotton pledgets are placed into the nasal

cavity and/or ears by ENT

- In-111 DTPA is introduced into the thecal sac via LP (9 – 18 MBq)

- Patient lies supine or in Trendelenberg

- Image at 1 – 4 hr

- Patient may be asked to Valsalva to increased CSF pressure

- The pledgets usually withdrawn when leak is detected or at 4 – 24 hr

and weighed and counted for radioactivity

- Plasma sample is collected to calculate a pledget to plasmaradioactivity ratio because CSF is absorbed into the blood stream

and will appear in normal nasal secretions

- Further delayed up to 72 hr

PATIENT PREPARATION - Informed for lumbar puncture

UNDERSTANDING THE

REPORT

A corrected pledget to plasma ratio > 2:1 indicates CSF leakage

POTENTIAL PROBLEMS

Lumbar puncture

Pledgets falling out

Nasal secretion radioactivity

Page 854: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 854/2049

CSF leak protocol

CSF Shunt Patency scan

Page 855: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 855/2049

RADIOPHARMACEUTICALS Tc-99m DTPA/ MAA

In-111 DTPA

HOW THE STUDY IS

PERFORMED

- Tc-99m DTPA or MAA (0.5  –  1 mCi) 0r In-111 DTPA (0.25  – 0.5 mCi)

injected into the shunt

- Image taken at 30 min to 2 hr

PATIENT PREPARATION - Aware type of shunt

UNDERSTANDING THE

REPORT

Normal flow through the tubing should be seen with significantreservoir clearance by 30 min

Ventriculoperitoneal shunt free distribution within abdominal cavity

If the tip is intra artrial – MAA is trapped in the lungs

Hold up of tracer at shunt tip in peritoneum indicates a loculation

Ventricular chemotherapy shunt – radiotracer appear at convexities by

24 hr if no obstruction

POTENTIAL PROBLEMS

Unfamiliar with shunt

Peri shunt injection  –  injecting not into reservoir will cause false

positive

Page 856: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 856/2049

Prick’s disease  Generalize cortical hypoperfusiond h t b li f i

Page 857: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 857/2049

and hypometabolism favoring

prefrontal regions

Multiinfarct dementia Scattered foci of decreased cortical

perfusion and metabolism

Alzheimer’s disease  Hypoperfusion and metabolism in

temporoparietal regions

Huntington’s disease  Decreased glucose metabolism and

perfusion in caudate nucleus and

putamen

Wilson’s disease  Severe depression of lenticularnuclei glucose metabolism

AIDS dementia Diffuse hypometabolism affecting

subcortical more than cortical gray

matter

Page 858: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 858/2049

Page 859: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 859/2049

Tc-99m HMPAO SPECT for brain in

Alzheimer's disease showing

posterior temporoparietal defects

Page 860: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 860/2049

Tc-99m HMPAO SPECT of the brain

in dementia of Lewy bodies showing

posterior perfusion defect withinvolvement of occipital cortex

Page 861: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 861/2049

Tc-99m HMPAO SPECT of the brain

in frontotemporal dementia(Prick’s  disease) of showing

anterior perfusion defect

Page 862: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 862/2049

Tc-99m HMPAO SPECT of the brain

in vascular dementia showing

multiple perfusion defects, with

generally reduced perfusion in the

right internal carotid territory

Page 863: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 863/2049

Page 864: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 864/2049

Page 865: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 865/2049

Page 866: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 866/2049

Page 867: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 867/2049

Page 868: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 868/2049

Page 869: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 869/2049

Page 870: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 870/2049

Page 871: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 871/2049

Page 872: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 872/2049

Page 873: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 873/2049

Page 874: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 874/2049

Page 875: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 875/2049

Language activation H215O study in a

patient with a left hemisphere

glioma. Activation during

articulation (red) and verb

generation (blue) is anterior to thetumor

Page 876: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 876/2049

Coronal a and b 11C methionine PET in

a patient with recurrent glioma in the

left temporal lobe

Page 877: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 877/2049

Stroke TumorBrain death

Page 878: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 878/2049

Stroke

Dimentia

Movement disorder

Lewi body

Tumor

TraumaTIA

Brain death

Epilepsy

Cortical cerebral imaging

AIDS

Alzheimer

Attention deficit

PSY

Obsessive compulsive

Schizo

Parkinson

Huntington’schorea

Multi infarct

Prick’s disease 

Page 879: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 879/2049

Page 880: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 880/2049

Brain

Blood brain barrier Brain perfusion MetabolismBrain tumors Cysternography

Tc-99m

glucoheptonate

Tc-99m DTPA

IMP

I-123 iodoamphetamine

Tc-99m ECD

Ethyl cysteinate dimer

Tc-99m HMPAO

F-18 FDG F-18 FDG Tc-99m DTPA

Tc-99m sestamibi

Thallium-201

Indium-111

DTPA

Indium-111 pentreotide

CNS

Page 881: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 881/2049

CNS

Blood Brain barrier

Diffusible lipophilic Non diffusible

Tc-99m DTPA

Tc-99m pertechnetate

F-Flurodopa

Tc-99m ECD

FDG

Tc-99m HMPAO

Page 882: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 882/2049

Tc-99m HMPAO Tc-99m ECD

Accumulation Frontalthalamus

cerebellum

parietaloccipital

Extraction 80% 60-70%

Dose remains in blood 1 hour < 12% 1 hour 5%

Good brain to background

ratio

Imaging time Can image until 24

hours

Superior quality 15-30 min

Suboptimal quality if delayed

Excretion Renal 40% and GI Renal and GI

Page 883: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 883/2049

Page 884: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 884/2049

Page 885: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 885/2049

Page 886: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 886/2049

Page 887: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 887/2049

Dementia

Page 888: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 888/2049

Temporoparietalhypoperfusion

Frontotemporalhypoperfusion

Multiplefocal defects

Lewy body

Frontotemporal

degeneration

Prick’s

Parkinson

Progressive

supranuclear palsy

Alzheimer

Pseudodepressive

Schizo

Normo pressure

hydrocephalia

Chronic alcoholism

Multi infarct

Creutzfeldt-Jakob

AIDS

Page 889: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 889/2049

 

Page 890: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 890/2049

 

Page 891: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 891/2049

 

Page 892: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 892/2049

 

Page 893: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 893/2049

 

Page 894: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 894/2049

 

Page 895: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 895/2049

 

Page 896: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 896/2049

 

Page 897: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 897/2049

 

Page 898: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 898/2049

 

Page 899: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 899/2049

 

Page 900: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 900/2049

 

Page 901: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 901/2049

 

Page 902: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 902/2049

 

Page 903: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 903/2049

 

Page 904: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 904/2049

 

Page 905: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 905/2049

 

Page 906: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 906/2049

 

Page 907: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 907/2049

Page 908: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 908/2049

 

Page 909: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 909/2049

 

Page 910: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 910/2049

 

Page 911: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 911/2049

 

Page 912: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 912/2049

 

Page 913: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 913/2049

 

Page 914: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 914/2049

 

Page 915: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 915/2049

 

Page 916: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 916/2049

 

Page 917: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 917/2049

 

Page 918: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 918/2049

 

Page 919: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 919/2049

 

Page 920: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 920/2049

 

Page 921: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 921/2049

 

Page 922: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 922/2049

 

Page 923: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 923/2049

 

Page 924: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 924/2049

 

Page 925: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 925/2049

 

Page 926: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 926/2049

 

Page 927: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 927/2049

 

Page 928: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 928/2049

 

Page 929: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 929/2049

 

Page 930: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 930/2049

 

Page 931: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 931/2049

 

Page 932: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 932/2049

 

Page 933: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 933/2049

 

Page 934: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 934/2049

 

Page 935: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 935/2049

 

Page 936: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 936/2049

 

Page 937: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 937/2049

 

Page 938: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 938/2049

 

Page 939: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 939/2049

Page 940: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 940/2049

Page 941: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 941/2049

Page 942: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 942/2049

 

Page 943: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 943/2049

 

Page 944: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 944/2049

 

Page 945: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 945/2049

 

Page 946: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 946/2049

 

Page 947: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 947/2049

 

Page 948: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 948/2049

 

Concerning Tc-99m HMPAO

Page 949: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 949/2049

A. Tc-99m HMPAO crosses BBBB. Regional uptake of Tc-99m HMPAO is

proportional to regional cerebral blood flow tothe same area

C. Distribution of Tc-99m HMPAO in the brain siindependent of brain maturation

D. Diffuse lung uptake of Tc-99m HMPAO is seenonly in people with a history of smoking

E. Focal cerebral uptake is seen in herpes simplexencephalitis

Concerning Tc-99m HMPAO

Page 950: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 950/2049

• TTFTT

Brain SPECT

Page 951: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 951/2049

A. The distribution of Tc-99m HMPAO reflects regionalglucose metabolism

B. Tc-99m HMPAO has to be used within 30 min of beingprepared

C. It is helpful to create images in the axis of temporallobes when investigating temporal lobe epilepsy

D. Bright light or loud sounds at the time of injectionmay alter the distribution of Tc-99m HMPAO

E. It is possible to accurately assess the size of lateralventricles with brain blood flow tracer

Page 952: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 952/2049

Concerning dementia

Page 953: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 953/2049

A. Increased accumulation of cerebral blood flow traceris seen in the frontal lobes in Prick’s disease

B. Abnormalities in Alzheimer’s  disease are oftenbilateral and predominantly effect temporal andparietal lobe

C. AIDS dementia complex usually shows noabnormalities on brain SPECT imaging

D. Typical blood flow changes are seen in the basalganglia in asymptomatic patients with Huntington’s 

choreaE. A characteristic pattern of reduced rCBF is seen inidiopathic Parkinson’s disease

Concerning dementia

Page 954: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 954/2049

• FTFTF

Concerning brain scintigraphy

Page 955: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 955/2049

A. In the initial stage of cerebral ischemia, regionalcerebral blood flow increases.

B. In the initial stage of cerebral ischemia, regionaloxygen extraction fraction increases.

C. With cerebral infarction, cerebral metabolic ratefor glucose increases.

D. Following cerebral infarction, local cerebralblood flow increases.

E. In Parkinson’s  disease, PET perfusion studiesdemonstrate decreased perfusion to the basalganglia contralateral to the affected limb.

Concerning brain scintigraphy

Page 956: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 956/2049

•FFFTF

Concerning brain scintigraphy

Page 957: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 957/2049

A. In Parkinson’s  disease, there is increased F-18 flourodopauptake by the stratum (caudate and putamen nuclei).

B. Concerning brain tumors, an advantage of PET is that it canimage metabolically active cells versus gadoliniumenhanced MRI and contrast enhanced CT, which imageareas where there is blood brain barrier breakdown.

C. Gadolinium enhanced MRI and F-18 FDG PET imaging areequally capable of distinguishing between recurrent braintumor and radiation necrosis.

D. All malignant brain tumors demonstrate hypermetabolism

over F-18 FDG.E. In differentiating between infectious and neoplastic brain

lesions, the presence of hypermetabolism is not useful.

Concerning brain scintigraphy

Page 958: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 958/2049

•FTFFF

Concerning brain scintigraphy

Page 959: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 959/2049

A. F-18 FDG freely crosses the BBB via the same carriermediated transport system as glucose

B. Local cerebral metabolic rates of glucose (specificareas of the thalamus, basal ganglia, lobes) can be

determined through PET studiesC. Approximately 20  –  30 mCi of FDG PET should beadministered for a brain study

D. A routine FDG study can be performed 5 minutes

after radiopharmaceutical administrationE. External stimuli can increased regional glucose

metabolism within particular areas of the brain

Concerning brain scintigraphy

Page 960: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 960/2049

•TTFFT

Concerning brain scintigraphy

Page 961: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 961/2049

A. Global glucose metabolism compared with normaldecreases to a greater degree in multiinfarctdementia than in Alzheimer’s dementia

B. Small white matter lacunar infarcts are much moreeasily identified with FDG PET than with CT

C. CT can reliably distinguish Alzheimer’s  disease frommultiinfarct dementia

D. In Huntington’s disease, changes in the caudate nucleican be observed on PET earlier than the CT

E. Persistent ventricular filling on a radionuclidecisternogram is diagnostic of communicatinghydrocephalus

Concerning brain scintigraphy

Page 962: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 962/2049

•FFFTT

Concerning Tc-99m DTPA in brain

scintigraphy

Page 963: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 963/2049

A. Does not cross the BBBB. Redistribute over several hours

C. In subacute stroke appears as an area of

increased uptakeD. Is the current agent of choice for

radionuclide cisternography

E. Requires preparation with oral perchlorate toblock the unwanted choroid plexus uptake

Concerning Tc-99m DTPA in brain

scintigraphy

Page 964: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 964/2049

•TFTFF

Which radiopharmaceuticals havebeen used for blood brain

scintigraphy?

Page 965: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 965/2049

scintigraphy?

Which radiopharmaceuticals havebeen used for blood brain

scintigraphy?

Page 966: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 966/2049

scintigraphy?

• Tc-99m pertechnetate, Tc-99m DTPA and Tc-

99m GH. The letter two were preferred

because of their faster background clearance,lack of choroid plexus uptake and lower

radiation dose.

What is the ‘flip-flop’ phenomenonseen in the cerebrovascular

i i h d h i h

Page 967: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 967/2049

scintigraphy and what is the

significance?

What is the ‘flip-flop’ phenomenonseen in the cerebrovascular

i ti h d h t i th

Page 968: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 968/2049

scintigraphy and what is the

significance?

• On the flow phase, parenchymal flow is

delayed on the abnormal side compared withthe contralateral normal side. Thus, as thenormal cortex clears, uptake in the abnormal

side peaks. This may be seen with the highgrade carotid artery stenosis with or withoutcerebral infarction. Delayed carotid flow isseen concomitantly.

Pearl

Page 969: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 969/2049

•A ‘hot  nose’  may be seen on the flow phaseimages and delayed images as a result of

shunting of the blood from the internal to the

external carotid system that supplies the face

and the nose in patients with severe carotid

stenosis, brain death, psychoactive drug use

and use of other drugs that cause nasal

congestion.

What is luxury perfusion?

Page 970: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 970/2049

What is luxury perfusion?

Page 971: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 971/2049

•Increased perfusion may be seen in the regionof an infarct after a recent stroke (1 to 10

days) cause by an uncoupling of blood flow

from metabolism and oxygen demand.

How is brain death diagnosed?

Page 972: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 972/2049

How is brain death diagnosed?

Page 973: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 973/2049

The diagnosis is primarily by clinical. The patientmust be in deep coma with total absence ofbrainstem reflexes and spontaneous respiration.Reversible causes (drug or hypothermia) must be

excluded; the cause of the dysfunction must bediagnosed (trauma or stroke); and the clinicalfindings of brain death must be present for adefined period of observation (6 to 24 hours).

Confirmatory EEG and radionuclide must be usedto increased diagnostic certainty, but thediagnosis is primarily clinical. The radionuclidestudy is more specific than EEG.

Which radiopharmaceuticals are used

to evaluate brain death and what are

Page 974: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 974/2049

the advantages of each?

Which radiopharmaceuticals are used

to evaluate brain death and what are

Page 975: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 975/2049

the advantages of each?• Tc-99m flow agents such as DTPA are inexpensive.

The 60 second flow study can be interpreted at

the bed side. Because Tc-99m HMPAO and Tc-99m ECD fixes in the cortex, delayed static images

can be obtained and interpreted for diagnosis.

The clinician is not dependent on a flow study,which demand a good bolus and good timing

with proper computer acquisition. However it is

more expensive.

What is the difference in mechanism

of uptake between F-18 FDG and Tc-

Page 976: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 976/2049

99m cerebral perfusion imaging

What is the difference in mechanism

of uptake between F-18 FDG and Tc-

Page 977: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 977/2049

99m cerebral perfusion imaging

• F-18 FDG is a glucose analog and its uptake

represent regional glucose metabolism. It’s metabolically trapped intracellularly.

• Tc-99m HMPAO and Tc-99m ECD are lipid

soluble cerebral perfusion agents taken up inproportion to regional cerebral blood flow.

They fixed intracellularly.

How can SPECT brain perfusion or PETFDG imaging can be useful in the

differential diagnosis of dementia?

Page 978: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 978/2049

differential diagnosis of dementia?

How can SPECT brain perfusion or PETFDG imaging can be useful in the

differential diagnosis of dementia?

Page 979: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 979/2049

differential diagnosis of dementia?

• Multiinfarct dementia is characterized by multipleareas of past infarct, recognized as areas of decreaseduptake that correspond to the vascular distributions.

• Alzheimer’s  disease exhibits characteristic pattern ofbitemporal and parietal hypoperfusion andhypometabolism.

• Pick’s disease is associated with decreased frontal lobeuptake.

• AISS dementia complex is associated with a pattern ofmultifocal or patchy cortical regions of decreaseduptake seen particularly in the frontal, temporal andparietal lobes and the basal ganglia

What is the purpose of cerebralperfusion imaging in patients with

i d h t i th t d PET

Page 980: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 980/2049

seizure and what is the expected PET

or SPECT pattern?

What is the purpose of cerebralperfusion imaging in patients with

i d h t i th t d PET

Page 981: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 981/2049

seizure and what is the expected PET

or SPECT pattern?

• PET F-18 FDG and SPECT cerebral perfusionstudies can often localize the seizure focus inpatients requiring surgery (typically temporallobectomy) for seizure control.

• Interictally, a seizure focus shows decreased

metabolism (FDG) on PET and decreasedperfusion on SPECT.

• Ictally there is increased activity is seen during aseizure.

Which radiopharmaceuticals havebeen found useful in imaging brain

tumors and what is their clinical

Page 982: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 982/2049

tumors and what is their clinical

utility?

What is the purpose of cerebralperfusion imaging in patients with

seizure and what is the expected PET

Page 983: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 983/2049

seizure and what is the expected PET

or SPECT pattern?

• F-18 FDG imaging demonstrates increased uptakein tumors owing to increased glycolysis. Uptake of

FDG is proportional to the malignant grade ofglioblastomas.

• SPECT with Tl-201 and Tc-99m sestamibi can beused in similar manner. Both Tl-201 and PET can

differentiate lymphoma from infection, mostoften toxoplasmosis in AIDS patients.

• Uptake of Tl-201 or FDG is indicative oflymphoma.

Name the radiopharmaceutical usedfor cysternography and the most

common clinical indication in this

Page 984: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 984/2049

common clinical indication in this

study

Name the radiopharmaceutical usedfor cysternography and the most

common clinical indication in this

Page 985: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 985/2049

common clinical indication in this

study

• In-111 DTPA. The most common use of this

radiopharmaceutical in modern practice is toconfirm the diagnosis of normal pressure

hydrocephalus (NPH). The next common use is

for (CSF) leaks.

What is the pattern of NPH oncysternography?

Page 986: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 986/2049

What is the pattern of NPH oncysternography?

Page 987: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 987/2049

• Persistent ventricular filling and evidence of

convexity block.

• The symptoms of NPH are incontinence,

dementia and gait disturbance.

Page 988: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 988/2049

Primary brain tumor

Page 989: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 989/2049

1. Low grade gliomas typically have poor or nouptake

2. Intense uptake in the large temporoparietalmass

3. Transformation of a low grade to a high gradeglioma

4. No. malignant tumors usually do not have

receptor for binding of RP, which is necessarybefore intracellular incorporation

Page 990: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 990/2049

Brain death

Page 991: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 991/2049

1. Flat EEG :hypothermia/ barbiturates/ depressivedrugs

2. Deep coma/ no spontaneous breathing/ no

brain stem reflex

3. Tc-99m DTPA/ Tc-99m pertechnetate or Tc-99m

HMPAO/ Tc-99m ECD

4. Tc-99m DTPA – no blood flow to cerebral cortex,

Tc-99m HMPAO  –  shows salivary gland/ normalbrain perfusion – cerebral cortical activity seen

Page 992: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 992/2049

Cerebral infarct

Page 993: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 993/2049

1. F18- FDG is dependent on glucose metabolism2. SPECT Tc-99m HMPAO/ ECD are cerebral

perfusion agents that are lipid soluble, distribute

according to blood flow (gray to white matter

ratio, 3:1 to 4:1) and fix intracellularly

3. Wedge shape severe decreased metabolism in

the left posterior parietal region

4. Cerebral hemorrhage/ infarct/ neoplasm

Page 994: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 994/2049

Seizure disorder

Page 995: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 995/2049

1. Decreased metabolism in the left temporal lobe.2. Temporal lobe infarct, benign mass or lower

grade tumor, post RT changes, interictal left

temporal lobe seizure focus.

3. Interictal left temporal lobe seizure focus.

4. Conformation of the location of the seizure

focus in a candidate for temporal lobe

lobectomy. Study is an alternative to surgicaldepth electrode placement.

Page 996: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 996/2049

Alzheimer’s disease 

Page 997: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 997/2049

1. Multiinfarct, Alzheimer's disease, AID’s  related,substance abuse, alcoholism, Parkinson’s disease, Prick’s,  Creutzfeldt-Jacob disease,depression, metabolic.

2. Diagnostic pattern using Tc-99m HMPAO, ECD orFDG PET: multiinfarct dementia or Alzheimer’s.

3. Hypometabolism (decreased FDG uptake) of theposterior parietal and temporal lobes bilaterally

and to a lesser extent the frontal lobes.4. Alzheimer’s disease > 80%

Page 998: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 998/2049

 

Prick’s disease 

1 Alzheimer’s disease multiinfarct late stage

Page 999: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 999/2049

1. Alzheimer s  disease, multiinfarct, late stageParkinson’s disease, metabolic, drug related anddepression.

2. The lipophilic Tc-99m HMPAO or ECD, cross theintact BBB and have rapid intracellular uptake inproportion to cerebral blood flow. They are fixedintracellularly. Subsequent imaging provide asnapshot of the blood flow pattern at the timeof injection.

3. Alzheimer’s, multiinfarct or Prick’s disease4. Decreased blood flow in the frontal cortex

bilaterally as a result of frontal lobe dementia.

Page 1000: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1000/2049

 

Page 1001: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1001/2049

 

Page 1002: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1002/2049

Herpes Encephalitis

Page 1003: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1003/2049

1. Increased uptake in the temporal lobe2. Increased blood flow in this region

3. Seizure focus (ictal injection), infection or

tumor4. Herpes encephalitis

Page 1004: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1004/2049

Normal pressure hydrocephalus

Page 1005: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1005/2049

1. In-111 DTPA administered intrathecally bylumbar puncture

2. Ventricular reflux and convexity block with no

flow over the cerebral hemispheres abovethe sylvian fissure

3. Communicating hydrocephalus, in this case is

normal pressure hydrocephalus

4. Triad of dementia, ataxia and incontinence

Page 1006: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1006/2049

 

Huntington’s disease 

Page 1007: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1007/2049

1. Hypometabolism of the basal ganglion2. Progressive motor abnormalities of

involuntary choreiform movements and

akinetic rigidity with progressive cognitivedeteriotion

3. Neuronal degeneration in the striatum, with

the caudate more involved than the putamen

4. Huntington’s disease

Page 1008: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1008/2049

 

CSF leak

Page 1009: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1009/2049

1. In-111 or Tc-99m DTPA2. Intrathecal injection

3. Activity in the region of the nose, indicating

CSF leak, probably at the cribriform plate4. Anterior views. With the use of nasal

pledgets placed in the superior, middle and

inferior nasal turbinates

Page 1010: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1010/2049

Thyroid

Pearls & Pitfalls

• A normal 24-hour iodine

Page 1011: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1011/2049

Thyroid

uptake in most lab rangesbetween 10% and 30% to 35%.

• Common indications for

radionuclide thyroid imaging

are to differentiate between

various types of hyperfunction

(Grave’s disease, toxic MNG or

autonomous adenoma) and toassess nodularity (cold or hot)

and ectopic tissue.

Page 1012: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1012/2049

Pearls & Pitfalls• A thyroid gland with an

Page 1013: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1013/2049

Thyroid

organification defect is usuallyseen as a normal gland on a Tc-

99m pertechnetate scan but

manifests no activity on an

iodine scan in a child with ahigh TSH level.

• A large gland with intense

homogenous activity is usuallyGrave’s disease.

Pearls & Pitfalls• A large gland with patchy

Page 1014: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1014/2049

Thyroid

activity is usually a MNG butcould also be chronic

thyroiditis or an infiltrative

process.

• Most hot nodules are benign

hyperfunctioning adenomas.

They can be single or multiple

and can suppress the normalportions of the glands.

Pearls & Pitfalls• Subacute thyroiditis classically

presents with a markedly

Page 1015: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1015/2049

Thyroid

p y

depressed radioiodine uptakeand nonvisualization of thegland in a patient with

thyrotoxicosis and a tender,swollen thyroid.

• Chronic thyroiditis can mimicnumerous thyroid conditions

but on imaging is usuallypatchy and decreased inactivity.

Pearls & Pitfalls• Thyroid cancer is usually a

single focal cold lesion and

Page 1016: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1016/2049

Thyroid

single focal cold lesion and

only rarely is seen to be diffuse

or multifocal on thyroid scan.

• Thyroid cancer can concentrate

Tc-99m sestamibi and persist

on delayed images. They are

typically cold on Tc-99m

pertechnetate scans.

Pearls & Pitfalls• Activity in the bladder,

stomach and bowel and diffuse

Page 1017: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1017/2049

Thyroid

stomach and bowel and diffuse

activity in the liver is usually

normal on a WBS of I-131.

• After successful RAI ablation of

residual thyroid tissue, serum

Tg are sensitive to detect

recurrent thyroid cancer.

Page 1018: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1018/2049

 

Page 1019: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1019/2049

 

Page 1020: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1020/2049

 

Page 1021: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1021/2049

 

Page 1022: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1022/2049

 

Page 1023: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1023/2049

 

Page 1024: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1024/2049

 

Page 1025: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1025/2049

 

Page 1026: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1026/2049

 

Page 1027: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1027/2049

 

Page 1028: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1028/2049

 

Page 1029: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1029/2049

 

Page 1030: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1030/2049

 

Page 1031: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1031/2049

 

Page 1032: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1032/2049

 

Page 1033: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1033/2049

 

Page 1034: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1034/2049

 

Page 1035: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1035/2049

 

Thyroid

function

Increased

thyroid

uptake

Normal

thyroid

uptake

Decreased thyroid

uptake

Thyrotoxicosis Grave’s disease  Antithyroid drugs

PTU/CBZ

Expended iodide pool

Page 1036: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1036/2049

Thyrotoxic phase ofsubacute thyroiditis

Hashitoxicosis Thyrotoxicosis factitia

Antithyroid drugs

Struma ovarii

Euthyroid Rebound after

antithyroid drug

withdrawal

Recovery from

subacute

thyroiditis

Hypothyroid Hashimoto’sdisease Hashimoto’sdisease after RAI

therapy

Hypothyroidism:primary/secondary

Subacute

thyroiditis

 

Page 1037: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1037/2049

 

Page 1038: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1038/2049

The following may cause a solitary cold nodule

in thyroid sca

  Thyroid adenoma

h d d

Page 1039: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1039/2049

Solitary cold

nodule inthyroid scan

Parathyroid adenomaLymphoma

TB

Colloid cyst

Metastatic carcinoma

Primary thyroidcarcinoma

ld

Percentage to become thyroid carcinoma

Page 1040: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1040/2049

 

Nodules

Cold 15 – 20%

Indeterminate 15 – 20%

MNG 5%

Hot <1%

20% malignant = trapping but not organified

Page 1041: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1041/2049

 

Discordantnodule

(thyroid

adenoma)

Hot nodule of Tc-99m

Cold nodule of I-131

Small amount of functioning thyroid tissue

with intact trapping and organified

Page 1042: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1042/2049

Reverse discordant

nodule(thyroid adenoma/

Hashimoto’s

thyroiditis/

thyroglassal duct)

Cold nodule of Tc-99m

Hot nodule of I-131

 

O l’ i

Photopenic area in center of

functioning autonomous thyroid

d l ti d ti ithi

Page 1043: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1043/2049

Owl’s eye sign  nodule = cystic degeneration within

solitary functioning thyroid nodule

Fish eye sign

Central core of functioning tissue

surrounded by a rim of decreased

uptake = functioning adenoma with

cystic degeneration at periphery

Page 1044: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1044/2049

Page 1045: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1045/2049

Page 1046: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1046/2049

Page 1047: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1047/2049

Page 1048: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1048/2049

Page 1049: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1049/2049

Page 1050: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1050/2049

Page 1051: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1051/2049

Page 1052: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1052/2049

Page 1053: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1053/2049

Page 1054: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1054/2049

Page 1055: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1055/2049

Page 1056: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1056/2049

Causes of

hyperthyroidism

Grave’s Disease 

Toxic multinodular Goitre

Toxic adenoma

Antithyroid drugs

Surgery

Radioiodine

Page 1057: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1057/2049

Toxic adenoma

Thyroiditis

• Hashimoto’s 

 Subacute (De Quervain’s) • Silent (post partum)

Factitious

Iodine and iodine-

containing drugs agentsDrugs - amiodarone 

Trophoblastic disease

Radioiodine

Self limiting

Symptomatic

Treatment of causes

Treatment Choices 

Antithyroid drugs (thionamides)

• inhibit thyroxine production

Page 1058: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1058/2049

• inhibit thyroxine production • immunomodulation 

Surgery• reduce thyroid bulk to decrease thyroxineproduction

Radioiodine• same principle as surgery 

Physical Characteristics of 131Iodine

•reactor produced

Page 1059: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1059/2049

reactor produced• T ½ 8.02 days

• ßeta and gamma emitter

•ßeta - 606 keV max, 191 keV mean

• Beta-particle emission tissue range – 0.8mm (local therapeutic effect)

gamma - 364 & 637 keV• Clinical Form : Sodium Iodide

131I concentrated by the cellsAdministration of oral

Sodium iodide

Physiological Basis of Radioiodine Treatment

Page 1060: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1060/2049

Reduce thyroid mass/size

Decreased thyroxine

production

High local radiation (beta

particle emissions)

cytotoxic effect

Page 1061: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1061/2049

Contraindications

• Pregnant women

a cross the placenta – accumulate in the

Page 1062: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1062/2049

a. cross the placenta   accumulate in the

fetal thyroid gland – severe neonatal

hypothyroidism

b. irradiation –  risk of thyroid cancerc. retained activity in maternal bladder – direct

exposure to the fetus

• Lactating mother

Page 1063: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1063/2049

Patient’s Preparation 

• No solid foods or drink dairy products for at least two

hours before and after treatment.

Page 1064: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1064/2049

• Low iodine diets for about 3 - 7 days

• GD patients should be counseled regarding the risks of

ophthalmopathy.

• Render patients euthyroid before treatment with 131I

or thyroidectomy.

- older patients (> 50 –60 years old)

- very thyrotoxic patients (symptomatic)

- patients with cardiac problems.

Page 1065: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1065/2049

Patient’s Preparation 

• Follow drug interactions notes

Page 1066: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1066/2049

• Antithyroid drugs - resumed 3 to 10 daysfollowing

treatment, or earlier, if clinically necessary

• Beta blockers medications - to reduce symptoms

which may occur during treatment:

propranolol, 80 –160 mg/day, oratenolol, 50 –150 mg/day, or

diltiazem 30 – 180mg/day (bronchospasm)

Doses

Two common approaches:

Page 1067: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1067/2049

1. Fixed Dose

2. Calculated Dose - based on the size of the

thyroid & percentage uptake at 24 h.

• Although treatments based on dose calculations

Doses

Page 1068: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1068/2049

 Although treatments based on dose calculations

appear efficacious, they have not proven superior to

the use of empirically selected administered

activities.

• Fixed dose advantages – simple & successful

outcome in an acceptable number of patients.

Initial Therapy

Grave’s

Disease

Subacute

Thyroiditis

Toxic adenoma

(Plummer Disease) 

Hyperfunctioning

Multinodular

Goiter

Page 1069: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1069/2049

Β-block

Antithyroid

Β-block

Steroids until

resolution of

symptoms

Β-block

Antithyroid

Β-block

Antithyroid

Grave’s Disease 

Page 1070: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1070/2049

Β-blockers

Carbimazole or PTU

Modulate therapy

until normalization

of TSH, FT3, FT4

(18 – 24 months)

Withdrawal of Β-blocker

Progressively reduce

Carbimazole or PTU

Check TSH, FT4, FT3

Every 3 month

Grave’s Disease - 1° relapse

Page 1071: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1071/2049

Β-blockers

Carbimazole or PTU

• Inform the pt on alternative

advantages and limitations of13I I therapy and surgery

• Needs of substitutive Tx in

both cases

• Pt’s age and gender • Size of goiter

• Tracheal compression

• Narcosis risks

• Complications of thyroid surgery

Fixed dose

• Vary but are commonly in the range of

185–555 MBq (5–15 mCi)

Page 1072: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1072/2049

185  555 MBq (5  15 mCi)

• Depending on the size of the gland

Calculation of Administered Activities for Treatment of Benign Thyroid

Diseases

Page 1073: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1073/2049

Use the following equation to correct for 24-hour RAI

uptake in target thyroid tissue:

Administered activity = Thyroid tissue mass (g) x Activity per g

tissue/RAI uptake at 24 hours

with RAI uptake expressed as a fraction of 100% uptake.

Page 1074: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1074/2049

Toxic adenoma

(Plummer

Disease) 

Hyperfunctioning

Multinodular

Goiter

Long Term Therapy

Page 1075: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1075/2049

131I THERAPY vs. SURGERY

• Pt’s age and gender 

• Size of goiter

• Tracheal compression

• Narcosis risks

• Complications of thyroid surgery

Toxic Nodular Goitre

• Definitive treatment is more commonly accomplishedwith RAI or surgery

• > RAI resistant than GD

• Large doses

Page 1076: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1076/2049

Large doses

• Standardized administered activities:

740 – 1110 Mbq (20 - 30 mCi)

• Administered less than 370 MBq (10mCi)

 – common Tx failure

(Estour B, Millot L, Vergely N, et al. Efficacy of low doses of radioiodine in the treatment of autonomous

thyroid nodules: importance of dose/area ratio. Thyroid 1997; 7(3):357 –361.)

• Large solitary nodules – percutaneous ethanol injection. (Del Prete S, Caraglia M, Russo D, et al. Percutaneous ethanol injection efficacy in the treatmentof large symptomatic thyroid cystic nodules: ten-year follow-up of a large series. Thyroid 2002;12(9):815 –821.)

Total thyroidectomy for clinically benign disease ofthe thyroid gland

Incidence of:

Page 1077: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1077/2049

Incidence of:

• temporary recurrent laryngeal nerve palsy 2.3%

• temporary hypoparathyroidism 14.4%

• Permanent recurrent laryngeal nerve palsy 1.1%• permanent hypoparathyroidism 2.4%

• Neither the initial clinical diagnosis nor a history of previous

treatment significantly influenced the rate of complications.

Bron LP, O'Brien CJ. Br J Surg. 2004 May;91(5):569-74.

Euthyroid Multinodular Goitre

• Surgery – first-line treatment esp. for enlarged goiter

• Preferable for patients > 65 years old

• > 90% of patients demonstrate a decrease in goiter size

Page 1078: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1078/2049

- Average reduction of 40% at 1 year .(Freitas JE. Therapeutic options in the management of toxic and nontoxicnodular goiter.

Semin Nucl Med 2000; 30(2):88 –97. )

• A small percentage may developed transient

hyperthyroidism

• Approximately 4% developed autoimmune thyroiddisease.(Huysmans AK, Hermus RM, Edelbroek MA, et al. Autoimmune hyperthyroidism occurring late after radioiodinetreatment for volume reduction of large multinodular goiters. Thyroid 1997; 7(4):535 –539.)

• RAI > effective than L-thyroxine suppression for reducingthe size of nontoxic goitre

Goals and outcomes• 80% response rate should be expected.

• Primary goal of treatment is to resolve

hyperthyroidism

Page 1079: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1079/2049

hyperthyroidism

• Hypothyroidism is preferable to persistent

hyperthyroidism - if not optimally treated, may

produce significant morbidity.• Hypothyroidism tends to occur more frequently

in patients with small thyroid glands & lower 24-

hour uptake measurements• Significantly reduce thyroid gland size in patients

with GD - 50% to 80% reduction in gland volume

Outcomes

• Euthyroid

• Hypothyroid

Page 1080: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1080/2049

Hypothyroid

 – transient

 – permanent early

late

• Hyperthyroid

Side Effects

Generally it is mild, infrequent and self-limiting.

GeneralTh id t d

Page 1081: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1081/2049

• Thyroid tenderness

• Salivary gland swelling

• Nausea

• Vocal cord paresis – extremely rare

Hormonal related

• Transient hypothyroidism, permanent hypothyroidism

• Transient hypoparathyroidism

• Exacerbation of hyperthyroidism – Beta blockers

• Thyroid storm is uncommon

NSAIDs

Side EffectsSevere side effects > likely in patient with large goitre – risk of

tracheal compression.

Ophthalmopathy

Page 1082: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1082/2049

p p y• Ophthalmopathy may be particularly severe in 3%

to 5% of patients with GD.

• Progression of ophthalmopathy - approximately

15% of patients especially:

- who smoke

- have pre-existing eye disease

- high levels of TSH-receptor antibody- severe manifestations of thyroid disease

Side Effects

• Prednisone, 0.4 –0.5 mg/kg per day,

beginning immediately after radioiodined f h

Page 1083: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1083/2049

g g ytreatment, continued for one month,and then tapered over three months,has been shown to be effective in arandomized controlled trial.(Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism andthe course of Graves’ ophthalmopathy. N Engl J Med 1998; 338(2):73–78. )

• Referral to Ophthalmologist isrecommended.

Side EffectsCancer Risk

• remains controversial

• Ron et al, a study of >35,000 hyperthyroidi f d h h i id f

Page 1084: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1084/2049

, y , yp ypatients found that the incidence ofthyroid cancer in RAI-treated patients overa 27-year period was not significantly

different from its incidence in the generalpopulation.

Genetic Effects to Offspring

• no evidence that exposure to radioiodineaffects the long-term outcomes ofsubsequent pregnancies and offspring.

Patient’s Instruction & Precautions • First 72 hours after treatment:

• Drink plenty of fluids.

Do not spend prolonged periods of time closer than 3 feet to anyadult or within the same room as any child

Page 1085: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1085/2049

adult, or within the same room as any child.

• For the next 4 –7 days:

• Void as often as possible. Flush toilet twice after use.

• Wash hands thoroughly and routinely.• Do not share eating utensils or towels. Wash utensils or clothing

separately.

• Avoid close contact with children and pregnant women (not

closer than 2 feet) for long periods of time.• Sleep in a separate bed.

• Avoid kissing and sexual intercourse.

Follow up

• To assess the need for

- further 131Iodine treatment

- L-thyroxine replacement

Page 1086: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1086/2049

y p

• Symptoms of uncontrolled hyperthyroidism

should be described, and patients should beinformed to seek medical attention if suchsymptoms occur.

4 to 6 weeks and at regular intervalsthereafter.

Children with hyperthyroidism

• Incidence of side effects from antithyroid

medications is higher & less consistent in taking themedications remission rates are lower

Page 1087: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1087/2049

medications remission rates are lower.

• Surgery - may have the highest cure rates butthyroidectomy is technically more difficult in young

children.• Several authorities have promoted the

administration of 131I earlier in the management ofpediatric patients and even as the primarytreatment.

• Children as young as 3 year old can be treated.

 

Chronic Renal Failure and DialysisPatients

• Holst et al. reviewed the medical literature

and concluded that:

Page 1088: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1088/2049

and concluded that:

131

I dose does not need to be adjusted.However, recommended 131I administration

as soon as possible after dialysis and a

delay in subsequent dialysis until the

maximum 131I uptake has occurred in the

thyroid.

 

Temperature

37.2-37.6 5

37.7-38.2 10

38.3-38.7 15

38.8-39.3 20

39.4-39.9 25

>40 30

CNS

Mild agitation 10

Moderate delirium/psychosis 20

Page 1089: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1089/2049

Seizure/coma 30

GI/liver dysfunctionDiarrhea/vomiting/abd pain 10

Unexplained jaundice 20

Cardiovascular dysfunction

99-109 5

110-119 10

120-129 15

130-139 20

>140 25

Heart failure

Pedal edema 5

Bibasilar rates 10

APO 15

AF 20

Precipitant historynegative 0

positive 10

Score >45 suggestive of thyroid storm, 25 – 44 supports the diagnosis and < 25 unlikely thyroid storm

Molecular genetic of thyroid

Page 1090: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1090/2049

Molecular genetic of thyroid

carcinoma

Introduction

• Thyroid cancer- most common malignant

tu of endocrine system & accounts for 1%of all newly diagnosed cancer cases.

Page 1091: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1091/2049

of all newly diagnosed cancer cases.

• Most thyroid cancers originate fromthyroid follicular cells .

• Type of thyroid malignancy :

• papillary ca 80%,

• follicular ca 15% may be of conventionalor oncocytic (Hurthle cell) type.[4] 

• Follicular ca develop either from pre-existing benign follicular adenomas ordirectly, bypassing the stage of adenoma.

2%

Page 1092: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1092/2049

Schematic representation of thyroid ca origin and its putative progression. Oncocytic adenoma

and ca are considered to be variants of follicular adenoma and ca. Papillary ca may be of the

classical type or manifests as one of its variants, including oncocytic variant of papillary ca

3%

Page 1093: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1093/2049

Papillary Ca• Activating mutations of BRAF, RET or RAS genes

seen in 70% papillary ca.

• Genes mutations rarely overlap in the same

Page 1094: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1094/2049

y p

tumor, suggesting that activation MAPK signaling

is essential for tumor initiation

• Alteration of a single effector of the pathway is

sufficient for cell transformation

 

BRAF

Page 1095: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1095/2049

Mol p/way in thyroid papillary ca & typical microscopy & clin feat of tu assoc with specific

mutations

BRAF mutation• Involve nucleotide 1799 and result in a val-to-glut

substitution at residue 600 (V600E).

• Other mech include K601E point mut, small in-

Page 1096: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1096/2049

frame insertions or del surrounding codon 600,[14 –

16] & AKAP9-BRAF rear which is more common in

papillary ca a/w radiation exposure.[17] 

With BRAF mutation…. 

• Extrathyroidal extension , advanced tu stage

@ presentation, tu recurrences & lymph nodedi t t t

Page 1097: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1097/2049

or distant mets.

• BRAF V600E is independent predictor of tu

recurrence even in stage 1-2.• Decreased ability of tu to trap radioiodine &

dysregulation of function of Na iodidesymporter ( NIS) & other genes metabolizing

iodides in follicular cells

BRAF mut as therapeutic target….. 

• BRAF inhibitors like BAY 43-9006, a multikinase

inhibitor with potent activity against RAF & otherprotein kinases.

Page 1098: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1098/2049

protein kinases.

• BAY 43-9006 effectively blocks the wild-typeBRAF and the mutant V600E BRAF kinase

activity.[13,31]

 • Sudies showed that BAY 43-9006 inhibit BRAF

signaling and growth of all thyroid cancer celllines carrying mutant BRAF   and it impair the

growth of the cell line xenografts in nude mice.[32]

 

RET/PTC rear in papillary thyroid ca

Page 1099: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1099/2049

RET/PTC• Fusion between the 3´-portion of the RET  

receptor tyrosine kinase gene and the 5´-portion

of various genes.

Page 1100: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1100/2049

• Two most common rear types, RET/PTC1  and

RET/PTC3, are paracentric inversions, because

both RET  and its respective fusion partner, H4 orNCOA4 (ELE1), reside on the long arm of

chromosome 10.[36 –39] 

 

Page 1101: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1101/2049

RET/PTC 1

Two most common rear types RET/PTC 1 & RET/PTC 2 areparacentric inversions bcoz both RET & its respective fusion

patner, H4 or NCOA4(ELE1), reside on the long arm of chr 10

Page 1102: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1102/2049

RET/PTC 3

 

RET/PTC 3

Page 1103: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1103/2049

RET/PTC

• Most of these rare RET/PTC   seen in papillary

ca fr pts with a h/o environmental or[40

Page 1104: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1104/2049

therapeutic exposure to ionizing radiation,[40 –

46] & in children & young adult.

• In papillary ca assoc/w exposure to ionizingradiation (i.e. post Chernobyl), RET/PTC1 a/w

classic papillary histology, RET/PTC3 more

common in solid variant

RET/PTC 2 t(10;17)(q11.2;q23)

Page 1105: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1105/2049

RET/PTC2 and nine more recently identified types of

RET/PTC  are all interchromosomal translocations

 

RET/PTC 2 t(10;17)(q11.2;q23)

Page 1106: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1106/2049

Page 1107: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1107/2049

RET/PTC 5 t(10;14)(q11.2q32)

 

RET/PTC 5 t(10;14)(q11.2q32)

Page 1108: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1108/2049

Page 1109: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1109/2049

RET/PTC 6 –

 t(7;10)(q32;q11.2)

 

RET/PTC 6  – t(7;10)(q32;q11.2

Page 1110: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1110/2049

Page 1111: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1111/2049

RET/PTC 7 –

 t(1;10)(p13;q11.2)

 

RET/PTC 7  – t(1;10)(p13;q11.2

 

Page 1112: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1112/2049

Page 1113: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1113/2049

RET/PTC 8 –

 t(10;14)(q11.2;q22.1)

 

RET/PTC 8 t(10;14)(q11.2q22.1)

Page 1114: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1114/2049

 

Page 1115: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1115/2049

RET/PTC 9 –

 t(10;18)(q11.2;q21)

 

RET/PTC 9  – t(10;18)(q11.2;q21)

Page 1116: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1116/2049

Page 1117: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1117/2049

PCM 1/ RET  – t(8;10)(p21;q11.2)

 

PCM 1/ RET  – t(8;10)(p21;q11.2)

Page 1118: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1118/2049

Page 1119: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1119/2049

RFP/RET –

 t(6;10)(p21;q11.2)

 

RFP/RET  – t(6;10)(p21;q11.2)

Page 1120: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1120/2049

RET/PTC

• ELKS-RET  and HOOK3-RET  fusions identified in

papillary ca with no apparent h/o of radiationexposure [47 48]

Page 1121: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1121/2049

exposure.[47,48] 

Page 1122: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1122/2049

ELKS/RET - t(10;12)(q11.2;p13.3)

 

ELKS/RET - t(10;12)(q11.2;p13.3

 

Page 1123: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1123/2049

Page 1124: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1124/2049

HOOK3/RET –

 t(8;10)(p11.21;q11.2)

 

HOOK3/RET  – t(8;10)(p11.21;q11.2)

Page 1125: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1125/2049

• All fusions leave the tyrosine kinase domain of

the RET receptor intact and enable theRET/PTC oncoprotein to bind SHC and activate[ ]

Page 1126: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1126/2049

the RAS-RAF-MAPK cascade.[49] 

RET/PTC mut as therapeutic target…. • ZD6474, orally active low m.w receptor kinase

inhibits VEGVR-2 & blocks RET tyrosine

kinase.• ZD6474 block phosphorylation and signalling

Page 1127: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1127/2049

p p y g g

from RET/PTC3 in vitro, induce growth arrest

of human papillary ca cell lines carryingRET/PTC1 and prevent growth of RET/PTC3-

transformed fibroblasts in nude mice.[64,65] 

RET/PTC mut as therapeutic target…….. 

• SU 12248 (multikinase inhibitor - sunitinib)

effectively inhibit signalling from RET/PTCkinase in the experimental models and has

Page 1128: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1128/2049

kinase in the experimental models and has

been tested in Phase II clinical trial in

radioiodine-refractory, unresectabledifferentiated thyroid cancer.[66] 

RAS• RAS  genes (HRAS, KRAS  and NRAS) encode G-proteins

important in the intracellular transduction of signals arisingfrom cell membrane receptors.

• In its inactive state, RAS protein is bound to GDP.

• Upon activation it releases GDP and binds GTP activating

Page 1129: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1129/2049

Upon activation, it releases GDP and binds GTP, activatingMAPK and PI3K/AKT.

• Normally, the activated RAS-GTP protein becomesquickly inactive due to its intrinsic GTPase activity andthe action of cytoplasmic GTPase-activating proteins.

Page 1130: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1130/2049

• Point mut in the discrete domains of the RAS 

gene either increase its affinity for GTP (mut incodons 12 and 13) or inactivate its

Page 1131: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1131/2049

autocatalytic GTPase function (mut in codon61).

• As a result, the mutant protein becomespermanently switched in the active positionand continuously activates its downstream

targets

Follicular Ca & Adenoma

• RAS

• PAX8-PPAR

Page 1132: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1132/2049

• PIK3CA

• PTEN

 

Page 1133: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1133/2049

Mol p/way in follicular thyroid ca

Foll Ca & Adenoma - RAS• Mutations found in 40 to 50% conventional

foll ca & in 20 to 40% adenomas.

Hotspots – NRAS codon 61 & HRAS codon 61.• Mutations seen in 15 to 25% oncocytic cell ca.

Page 1134: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1134/2049

y

• Mut correlates with tu dedifferentiation &

metastasis

Foll Ca & Adenoma - PAX8-PPARy• Due to t(2,3)(q13;p25)

• Leads to fusion of PAX8 & PPARy genes.

• 35% of conventional foll ca & lower in hurtlecell ca.

Page 1135: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1135/2049

• A/w younger age, smaller size, solid/nested

growth pattern & vas invasion• If seen in adenoma –  ? Insitu (preinvasive foll

ca, ?invasion overlooked in histo)

Foll Ca & Adenoma – other mut

• P13K/AKT pathway mut seen in 6-13% foll ca

& 0-6% of foll adenoma

In exons 20 & 9 of PIK3CA genes.•  LOH in regions harboring different tu supp

Page 1136: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1136/2049

genes..

Del of 2p, 3p, 9q,10q,11p,15q & 17p.• LOH assoc/w aggressiveness & recurrences

Oncocytic Ca• LOH on chr 3q,18q,1p,2p,8q,14q

• Mut of GRIM-19 in 15% oncocytic ca

• GRIM-19 encodes a protein linked to retinoid-interferon-induced p/way of cell death &

Page 1137: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1137/2049

p y

involved in mitochondrial met.

Poorly diff & Anaplastic Ca

• TP53

• CTNNB1 ( Beta catenin)

RAS

Page 1138: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1138/2049

• RAS

• BRAF

• PIK3Ca

PTEN

Poorly diff Ca & Anaplastic Ca-TP53• Point mut of TP53 are late events

• Most involve exons 5-8 of gene & alter DNA

binding properties

A / l t d ll th & i

Page 1139: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1139/2049

• Assoc/w accelerated cell growth & progressive

This is the neck after removal

of the cancerous lymph nodes

Medullary Thyroid Ca

• RET   is activated by point mutation vs chr rear in

papillary ca.• Germline mutations in specific functional regions of

RET found in almost all pts with familial medullary ca

Page 1140: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1140/2049

RET   found in almost all pts with familial medullary ca.

• MEN 2A & familial medullary ca, mutations are

typically located in the extracellular domain, within thecysteine-rich region.[124] 

• 90% of MEN 2A mutations affect a single codon 634,whereas in familial medullary ca they are more evenly

distributed along the cysteine rich region.[125]

 

In MEN 2B, the majority of germlinemutations occur in codon 918 in the

intracellular tyrosine kinase domain of RET .

This alter the substrate specificity of RETkinase, resulting in phosphorylation of

l i t ll l t i [126]

Page 1141: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1141/2049

unusual intracellular proteins.[126] 

This CT scan shows a thyroid cancer

tu in the throat, encircling,narrowing,

& displacing the windpipe(trachea)

Page 1142: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1142/2049

• RET kinase inhibitors ZD6474 and SU12248

(sunitinib), now in Phase II clinical trials in ptswith familial & sporadic medullary thyroid

Page 1143: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1143/2049

p y y

cancer.[63,66] 

Summary

• FNA dx of thyroid nodules can be improved by

testing for BRAF , RET/PTC  and other mutations.• BRAF , RET/PTC  and RAS mutations correlate with

Page 1144: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1144/2049

, /

specific phenotypical features of papillary ca.

• BRAF   is a reliable diagnostic marker formalignancy and an independent prognostic

marker for tumor recurrence and more

aggressive behaviour of papillary carcinomas.

These are lymph nodes that

received cancer cells fr the

primary ca in the thyroid gld

Summary• PAX8-PPAR γ  & RAS mut correlate with specific

phenotypical feat of follicular ca.

• Limitations…..Papillary ca (~30%),

conventional follicular cas (~20%) & oncocytic

Page 1145: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1145/2049

conventional follicular cas ( 20%) & oncocytic

follicular ca (>50%) do not harbour any of the

known mutations.

Black discoloration of cancerous

lymph nodes.Papillary ca is

sometimes black in color especially

afer having spread to lymph nodes

Page 1146: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1146/2049

Page 1147: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1147/2049

Page 1148: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1148/2049

Page 1149: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1149/2049

Page 1150: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1150/2049

 

Page 1151: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1151/2049

Page 1152: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1152/2049

Page 1153: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1153/2049

Page 1154: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1154/2049

Page 1155: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1155/2049

Page 1156: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1156/2049

Page 1157: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1157/2049

Page 1158: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1158/2049

Page 1159: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1159/2049

Page 1160: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1160/2049

Page 1161: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1161/2049

Page 1162: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1162/2049

Page 1163: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1163/2049

Page 1164: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1164/2049

Page 1165: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1165/2049

Page 1166: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1166/2049

Page 1167: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1167/2049

Page 1168: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1168/2049

Page 1169: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1169/2049

Page 1170: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1170/2049

Page 1171: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1171/2049

Page 1172: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1172/2049

Page 1173: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1173/2049

Page 1174: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1174/2049

Page 1175: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1175/2049

Page 1176: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1176/2049

Page 1177: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1177/2049

Page 1178: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1178/2049

Page 1179: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1179/2049

Page 1180: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1180/2049

Page 1181: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1181/2049

Page 1182: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1182/2049

Page 1183: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1183/2049

Page 1184: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1184/2049

Page 1185: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1185/2049

Page 1186: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1186/2049

Page 1187: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1187/2049

Page 1188: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1188/2049

Page 1189: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1189/2049

Page 1190: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1190/2049

In the investigation of hyperthyroidism

A. In Grave’s  disease, uptake of Tc-99m is usuallyuniform

B. If, after 2 years following I-131 treatment for Grave’s disease the patient is still euthyroid, the incidence ofsubsequent development of hypothyroidism is

li ibl

Page 1191: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1191/2049

negligible

C. A normal isotope scan exclude Grave’s diseaseD. Hypothyroidism following I-131 treatment of a

solitary hyperfunctioning nodule is more commonthan in Grave’s disease

E. Low tracer uptake into the thyroid gland may occur inuntreated hyperthyroidism

In the investigation of hyperthyroidism

• TFFFT

Page 1192: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1192/2049

The following are true

A. About 25% of toxic nodules are palpable

B. The scan appearances of Grave’s disease may beconfused with toxic MNG

C. Thallium-201 may be used to demonstratethyroid tissue in which uptake but not metabolic

Page 1193: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1193/2049

thyroid tissue in which uptake but not metabolicactivity has been diminished

D. Almost 10% of patients with Grave’s disease willrelapse following a prolonged course ofantithyroid drugs

E. RAI therapy for thyrotoxicosis is contraindicatedin pregnancy

The following are true

• FTTFT

Page 1194: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1194/2049

Concerning thyroid imaging in

thyroiditis

A. Thyroid uptake usually diffusely decreased inacute(supurative) thyroiditis.

B. Uptake in the early phase of subacute (deQuervian’s)thyroiditis is usually increased

C Scan appearances in Hashimoto’s thyroiditis may

Page 1195: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1195/2049

C. Scan appearances in Hashimoto s thyroiditis maybe difficult to distinguish from Grave’s disease

D. Radiation induced thyroiditis is commonly seenfollowing external radiation therapy

E. RAI uptake in Reidel’s thyroiditis is increased

Concerning thyroid imaging in

thyroiditis

• FFTFF

Page 1196: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1196/2049

In the investigation of solitary thyroid

nodules

A. A single warm nodule is likely to be an adenoma

B. The risk of carcinoma in a hot nodule is 10%C. The risk of carcinoma in a cold nodule is at least

10%

Page 1197: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1197/2049

D. The risk of carcinoma in the dominant nodulewithin MNG is approximately 1%

E. A history of childhood of head and neckirradiation substantially increases the risk of

malignant change in solitary thyroid nodule

In the investigation of solitary thyroid

nodules

• TFTFT

Page 1198: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1198/2049

The following are true

A. The commonest site for ectopic thyroid tissue isthe base of tongue

B. I-123 is superior than Tc-99m in confirming thepresence of a lingual thyroid gland

C Isotopes of Iodine are superior than Tc-99m for

Page 1199: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1199/2049

C. Isotopes of Iodine are superior than Tc 99m forlocalizing retrosternal thyroid tissue

D. Absence of activity below the sternal notchexcludes an intrathoracic goitre

E. Ectopic thyroid tissue may be found in up to 50%

of cases of neonatal hypothyroidism

The following are true

• TTTFT

Page 1200: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1200/2049

Concerning malignancy of the thyroid

gland

A. The majority of tumors are follicular type

B. Most tumors are well differentiatedC. Most thyroid tumors are detected following

demonstration of an area of increased uptake

Page 1201: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1201/2049

prelative to normal thyroid on Tc-99m scan

D. Anaplastic carcinoma never takes up I-131

E. Screening of relatives is mandatory inanaplastic carcinoma

Concerning malignancy of the thyroid

gland

• FTFTF

Page 1202: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1202/2049

The following may cause a solitary cold

nodule in thyroid scan

A. Lymphoma

B. Parathyroid adenomaC. TB

D W ’ l t

Page 1203: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1203/2049

D. Wegner’s granulomatous

E. Metastatic adenocarcinoma

The following may cause a solitary cold

nodule in thyroid scan

• TTTFT

Page 1204: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1204/2049

The following are true

A. The patient with toxic MNG presenting with pressuresymptoms should be treated with RAI first instance

B. Patients receiving I-131 for thyrotoxicosis should takeapproximately 1 week off work following treatment

C. The absolute of thyroid hormones and TSH beforetreatment with RAI is a useful predictor of the

Page 1205: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1205/2049

treatment with RAI is a useful predictor of the

development of hypothyroidism in Grave’s D. A rise of thyroglobulin level following completeablation for thyroid carcinoma is indicative ofrecurrent malignant disease

E. Uptake of RAI into thyroid carcinoma metastases hasprognostic significance

Page 1206: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1206/2049

What is the origin of lingual and

sublingual thyroid tissue?

Page 1207: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1207/2049

What is the origin of lingual and

sublingual thyroid tissue?

• The main thyroid anlage begins as a

downgrowth from the foramen cecum.• Thyroid tissue may be seen anywhere along

the tract of the thyroglassal duct from the

Page 1208: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1208/2049

y g

foramen cecum to the usual location of thegland.

• However with lingual thyroid tissue, there is

usually a failure of normal development andno tissue in the normal location of the thyroid

What is meant by the organification of

iodine?

Page 1209: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1209/2049

What is meant by the organification of

iodine?

• In thyroid metabolism, iodide is oxidized to

iodine and incorporated into tyrosine to formeither monoiodotyrosine or diiodotyrosine.

• A deficiency in peroxidase which catalyzes the

Page 1210: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1210/2049

y p y

reaction, is cause of congenitalhypothyroidism.

What is the difference in mechanism

of thyroid uptake between Tc-99mpertechnetate and radioiodine?

Page 1211: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1211/2049

What is the difference in mechanism

of thyroid uptake between Tc-99mpertechnetate and radioiodine?

Radioiodine is taken up or extracted (trapped)by the thyroid follicular cell and organified,

binding to tyrosine residues on thyroglobulin

Page 1212: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1212/2049

and stored in colloid in the follicle.

• Tc-99m pertechnetate is trapped but not

organified.

Which are common causes of falsely

low thyroid uptake?

Page 1213: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1213/2049

Page 1214: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1214/2049

What is the difference between

thyroid scan and thyroid uptake?

Page 1215: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1215/2049

What is the difference between

thyroid scan and thyroid uptake?

• A thyroid uptake is usually a nonimaging study

using gamma detector probe.• Thyroid scan results from gamma camera

imaging.

Page 1216: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1216/2049

How can a thyroid uptake test

differentiate two most common causesof thyrotoxicosis, Grave’s and subacute

thyroiditis?

Page 1217: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1217/2049

How can a thyroid uptake test

differentiate two most common causesof thyrotoxicosis, Grave’s and subacute

thyroiditis?• In the initial phase of subacute thyroiditis, thyroid

hormone are released from the inflamed glandcausing thyrotoxicosis.

D t it it f db k TSH i d

Page 1218: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1218/2049

• Due to pituitary feedback, TSH is suppressed.

• Radioiodine or Tc-99m uptake requires TSHstimulation.

• Thus, the uptake of radioiodine or Tc-99mpertechnetate is low or suppressed.

• With Grave’s  disease, TSH is suppressed,however the gland is autonomous and the uptakeis high.

What is the mechanism of action of

antithyroid drugs PTU and CBZ?

Page 1219: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1219/2049

What is the mechanism of action of

antithyroid drugs PTU and CBZ?

• Both PTU and CBZ are thiourea antithyroid

drugs that block the organification of iodine

Page 1220: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1220/2049

Page 1221: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1221/2049

Cold thyroid nodule

1. IV Tc-99m pertechnetate, 140 keV, 6 hours;

oral sodium I-123, 159 keV and 8 hours.2. A single cold nodule has a 15% to 20%

chance of malignancy.

Page 1222: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1222/2049

3. FNA4. Pinhole collimator 4 to 6 mm

Page 1223: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1223/2049

Hyperthyroidism/ thyroiditis1. Grave’s  disease, toxic nodules, thyroiditis,

iatrogenic thyroid hormone ingestion, iodine

induced, trophoblastic tumors, Hashitoxicosisand struma ovarii.

2. Aid in the DD of hyperthyroidism

3 A i i b bt i

Page 1224: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1224/2049

3. A nonimaging gamma probe obtainscounts/time from neck and a phantom countingactivity equal to the orally administered dose toconvert to gamma probe counts µCi % RAIU =neck (µCi) divided by the total administered

dose (µCi) after background correction.4. Subacute thyroiditis based on the history of

neck tenderness, laboratory finding and RAIU.

Page 1225: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1225/2049

Grave’s disease 1. Scan appearance may be similar. With the large goiter the

scan often has a plumper appearance with convex

borders. The pyramidal lobe may be seen as in this case.2. Surgery is seldom performed because of the high risk. PTU

and CBZ sometimes are used initially who require coolingdown most of the patients are treated with RAI after 6 to12 months of antithyroid medication. Many patients are

Page 1226: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1226/2049

12 months of antithyroid medication. Many patients are

treated initially with I-131.3. I-131 uptake (10 µCi), I-123 scan and uptake (300 µCi) andGrave’s disease therapy; I-131 (5-15 mCi)

4. Short term; occasional exacerbation of hyperthyroidismand thyroid storm. Long term; hypothyroidism. There is no

increased incidence of secondary cancers or reduction infertility.

Page 1227: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1227/2049

I-131 star artifact

1. A. Post therapy I-131 WBS shows intense uptake

in the neck with a star effect, diffuse liveractivity and bladder clearance. B, Pinhole image

of the neck with three foci of uptake.

2 Septal penetration of high energy of I 131

Page 1228: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1228/2049

2. Septal penetration of high energy of I-131

gamma rays through the collimator septa.

3. Pinhole collimator centered on the thyroid.

4. Radiolabeled thyroid hormone is metabolized in

the liver. This usually seen only on the posttherapy scan.

Page 1229: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1229/2049

Toxic autonomous thyroid nodule

1. Hot nodule in the mid right of the thyroid

with increasing suppression of the remaininggland at each successive year

2. Toxic autonomous thyroid nodule

Page 1230: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1230/2049

3. Surgery and RAI I-1314. The iodine uptake may be moderately

elevated, but it often is in the normal range.

Normal 24 hour uptake is 10 to 30%

Page 1231: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1231/2049

Lingual thyroid

1. Tc-99m pertechnetate is taken up by thyroid

follicular cells like iodine but not organified. I-123 taken up and organified.

2. Lower radiation exposure to the pediatric

Page 1232: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1232/2049

patient.3. Focal uptake at the base of the tongue.

Normal is submandibular glans and mouth.

No thyroid in the neck.4. Lingual thyroid.

Page 1233: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1233/2049

Left thyroid agenesis1. Uniform uptake in the right lobe. No activity

seen at the left lobe or elsewhere in the neck or

upper chest.2. The uniform activity in the right lobe is more

intense than the salivary glands indirectevidence of an elevated uptake in the absence

Page 1234: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1234/2049

evidence of an elevated uptake in the absence

of intrinsic salivary gland disease.3. Surgical excision, replacement by

hypofunctioning adenoma or carcinoma oragenesis of the left lobe with Grave’s disease of

the solitary right lobe.4. Grave’s disease with agenesis of the left lobe.

Gastrointestinal & Hepatobiliary

Page 1235: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1235/2049

Pearls & Pitfalls

Gastric emptyingstudies

• The study usually are performed

the rate of emptying of solids

from stomach, they are most

commonly performed by Tc-99m

colloid mixed with scramble eggs

before they are cooked.

Page 1236: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1236/2049

• Half of the activity of a solid mealshould be out of the stomach in

about 90 minutes.

•Solids leave the stomach in alinear fashion, liquids

exponentially.

Pearls & Pitfalls

Gastrointestinalbleeding studies

• Usually these are performed byTc-99m labeled RBC, but Tc-99msulfur colloid can also be used.

• A focus of bleeding shouldchange shape and location onsequential images. If the activitydoes not move it may represent

Page 1237: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1237/2049

does not move, it may representa vascular abnormality such asaneurysm or intussusception.

Pearls & Pitfalls

Gastrointestinalbleeding studies

• The best way to pinpoint the

bleeding site is to find an

image in which there is adefinite abnormality and then

to look at the earlier images

and find the first image in

Page 1238: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1238/2049

and find the first image in

which the activity can be seen.

This is necessary because

activity seen as a result of

bleeding can go anterograde orretrograde in the bowel.

Pearls & Pitfalls

Gastrointestinalbleeding studies

• Bladder activity from free Tc-

99m pertechnetate can be

confusing and sometimes it isnecessary for the patients to

void or catheterized.

• If bleeding is intermittent use

Page 1239: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1239/2049

• If bleeding is intermittent, use

Tc-99m RBC. If the bleeding is

active, either Tc-99m RBC or

Tc-99m sulfur colloid can be

used.

Pearls & Pitfalls

Gastrointestinalbleeding studies

• False positives:

Free pertechnetate seen at

stomachRenal excretion of breakdown

products

Page 1240: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1240/2049

Penile blood pool,transplanted kidney and

varices.

Pearls & Pitfalls

Gastrointestinalbleeding studies

• False negatives:

Small bowel bleeding

Rectal bleeding obscured bybladder activity

A stationary abnormal focus

Page 1241: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1241/2049

could represent clotted blood

 

Page 1242: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1242/2049

 

Page 1243: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1243/2049

 

Page 1244: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1244/2049

 

Page 1245: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1245/2049

 

Page 1246: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1246/2049

 

Page 1247: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1247/2049

 

Page 1248: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1248/2049

Gastroesophageal reflux : Milk studyPatient preparation Overnight fasting

Radionuclide Tc-99m SC (0.2 – 1 mCi)

Feeding meal The radionuclide is mixed with half of the

meal and fed the child. The second “cold”

Page 1249: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1249/2049

meal and fed the child. The second cold  

half of the meal is then fed to the child.Orange juice for adults and children

Imaging After blurping infant, place supine with

gamma camera and radioactive marker at

the mouth

Acquire delayed image of the chest

 

Page 1250: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1250/2049

 

Page 1251: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1251/2049

 

Page 1252: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1252/2049

 

Page 1253: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1253/2049

 

Page 1254: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1254/2049

 

Page 1255: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1255/2049

 

Page 1256: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1256/2049

 

Page 1257: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1257/2049

 

Page 1258: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1258/2049

 

Page 1259: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1259/2049

 

Page 1260: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1260/2049

 

Page 1261: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1261/2049

Cimetidine

• Histamine H₂ receptor antagonis 

Increases uptake of Tc-99m pertechnitate• Inhibit releasing of gastric mucosa

• Dose 20 mg/kg orally 2 days prior of the study

Page 1262: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1262/2049

Pentagastrin

• Increases rapidity, duration and intensity of Tc-

99m pertechnitate uptake• Increased mucin producing cells

• Increases intestinal motility

Page 1263: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1263/2049

Glucagon

• Antiperistalsis

Decreased bowel peristalsis• Prevent tracer washout from diverticulum

Page 1264: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1264/2049

 

Page 1265: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1265/2049

 

Page 1266: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1266/2049

 

Page 1267: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1267/2049

 

Page 1268: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1268/2049

Tc-99m RBC

Page 1269: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1269/2049

 

Criteria for

diagnosis of

bleeding site with

Focal activity appears

Activity increases over time

activity movement confirm

to intestinal anatomy

Page 1270: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1270/2049

Tc-99m RBC Movement may beantegrade or retrograde

Tc-99m RBC in vitro

Page 1271: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1271/2049

Tc-99m RBC

Page 1272: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1272/2049

Tc-99m SC

Page 1273: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1273/2049

Tc-99m SC

Page 1274: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1274/2049

Meckel’s Diverticulum 

Page 1275: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1275/2049

Pearls & Pitfalls

Meckel’s diverticulumimaging

• These scan are performed with

Tc-99m pertechnetate which

concentrates in normal and

ectopic gastric mucosa

• Most Meckel’s  diverticula do

not contain ectopic gastric

Page 1276: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1276/2049

mucosa but the ones that

bleed almost always do.

• A Meckel’s  diverticula should

be seen anteriorly, lateral or

oblique.

Pearls & Pitfalls

Meckel’s diverticulumimaging

• Cimetidine can be used to fixthe radiotracer andpentagastrin can increase

uptake in the gastric mucosa,thus increasing the sensitivityof the study.

Page 1277: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1277/2049

Bladder activity from the Tc-99m pertechnetate is normal.The patient may need to voidor be catheterized if there is a

suspicious lesion nearby.

Pearls & Pitfalls

Meckel’s diverticulumimaging

False positives:Confounding urinary system

activity, GI obstruction, tumor

Page 1278: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1278/2049

and inflammation.

Pearls & Pitfalls

Meckel’s diverticulumimaging

• False negatives:Lack of sufficient gastric

mucosa.

Page 1279: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1279/2049

Recent barium study orbladder.

 

Page 1280: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1280/2049

 

Page 1281: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1281/2049

 

Page 1282: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1282/2049

 

Page 1283: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1283/2049

 

Page 1284: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1284/2049

Page 1285: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1285/2049

 

Page 1286: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1286/2049

 

Page 1287: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1287/2049

 

Page 1288: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1288/2049

 

Page 1289: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1289/2049

 

Page 1290: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1290/2049

 

Page 1291: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1291/2049

Meckel’s 

Page 1292: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1292/2049

Tc-99m pertechnitate (Meckel’s) 

Page 1293: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1293/2049

 

Page 1294: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1294/2049

Hepatobiliary

Page 1295: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1295/2049

Pearls & Pitfalls

Hepatobiliary

• The most common indications for

hepatobiliary study are to

differentiate between acute or

chronic cholecystitis, to look forsuspected bile leaks or biliary

obstruction and in the setting of

neonatal jaundice to

Page 1296: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1296/2049

neonatal jaundice, todifferentiate neonatal jaundice or

biliary atresia.

• Tc-99m (IDA) agents are cleared

and excreted by hepatocytes but

not conjugated.

Pearls & Pitfalls

Hepatobiliary

• Cardiac blood pool activity

should clear by 5 to 10 minutes.

Lack of clearance indicates poorly

functioning hepatocytes.

• If there is persistent cardiac

blood pool activity and no biliary

excretion the DD includes

Page 1297: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1297/2049

excretion, the DD includeshepatitis and biliary obstruction.

• Renal and bladder activity may

be seen if the liver cannot

efficiently excrete the

radiotracer.

Pearls & Pitfalls

Hepatobiliary

• Bowel activity should be seen by1 hour. Delayed biliary to boweltransit can be result of a number

of entities, including commonduct calculous, tumor, stricture,morphine, sphincter dyskinesiaand chronic cholecystitis.

• For hepatobiliary scans

Page 1298: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1298/2049

For hepatobiliary scansperformed to differentiate biliaryatresia from neonatal hepatitis,delayed 24 hours images to look

for evidence of excretion intobowel are often necessary.

Pearls & Pitfalls

Hepatobiliary

• The normal GB with patent

cystic duct is usually seen by

30 minutes and should always

be seen by 1 hour.

• Nonvisualization of the GB is

most likely the result of acute

or chronic cholecystitis

Page 1299: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1299/2049

or chronic cholecystitis.

• Nonvisualization of the GB at 4

hours or after given morphine

at 1 hour is most likely due toacute cholecystitis.

Pearls & Pitfalls

Hepatobiliary

• Nonvisualization of the GB at 1hour but visualization at 4hours after morphine is most

likely due to chroniccholecystitis.

• Look for either RIM sign or

cystic duct sign of acuteh l titi if th GB i t

Page 1300: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1300/2049

cystic duct sign of acutecholecystitis if the GB is notseen by 1 hour. A RIM signincreases the likelihood of

complicated cholecystitis(gangrene, abscess or rupture)

Pearls & Pitfalls

Hepatobiliary

• Bile leaks often pool in the regionof the porta hepatis, along rightlateral aspect of the liver. If the

GB was recently removed, thebile may pool in the GB fossa andmimic a GB.

• An unequivocally GBEF after CCK

is more than 50% Borderline 35

Page 1301: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1301/2049

is more than 50%. Borderline 35 – 50% and abnormal < 35%.

• A recent meal may cause GBcontraction and result innonvisualisation of GB,simulating acute cholecystitis.

Pearls & Pitfalls

Hepatobiliary

• False positive

Fasting longer than 24 hours

may cause GB distend withviscous bile. CCK can contract

GB,

Severe illness, pancreatitis,

h i h l titi d id

Page 1302: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1302/2049

chronic cholecystitis and rapid

biliary to bowel transit.

Pearls & Pitfalls

Hepatobiliary

• False negatives:

Mistake with duodenum, renal

pelvis and cystic or common

bile duct

Page 1303: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1303/2049

 

Page 1304: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1304/2049

 

Page 1305: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1305/2049

 

Page 1306: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1306/2049

 

Page 1307: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1307/2049

 

Page 1308: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1308/2049

 

Page 1309: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1309/2049

 

Page 1310: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1310/2049

 

Page 1311: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1311/2049

 

Page 1312: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1312/2049

 

Page 1313: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1313/2049

 

Page 1314: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1314/2049

 

Page 1315: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1315/2049

Left hepatic duct

Right hepatic duct

Common hepatic duct

Common bile duct

Cystic duct

Page 1316: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1316/2049

Gallbladder 

Common bile duct

Spincter of oddi

 

Page 1317: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1317/2049

 

Page 1318: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1318/2049

 

Page 1319: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1319/2049

 

Page 1320: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1320/2049

 

Page 1321: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1321/2049

Patient preparation NBM for 4 hours before study

If fasting longer than 24 hours, infuse sincalide

Radiopharmaceutical Tc-99m HIDA/ mebrofenin/ disofenin

IV

Adults bilirubin < 2mg/dl : 5 mCi

2-10 mg/dl : 7.5 mCi

>10 mg/dl : 10 mCi

Children 200 µCi/kg (no less than 1 mCi)

Patient positioning Supine

Instrumentation Collimator: LEGP

Window : 15% 140 keV

Imaging protocol Inject Tc-99m IDA IVAt 60 min, acquire right lateral and left anterior oblique

Page 1322: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1322/2049

If GB not filled and acute cholecystitis suspected, inject IV

morphine sulfate (0.04 mg/kg over 1 min)

Perform delayed imaging 2 to 4 hour if:

1. Morphine sulfate is not administered and GB has not

filled

2. Hepatic insufficient/ suspected biliary leak/ partialcommon duct obstruction

 

Page 1323: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1323/2049

Page 1324: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1324/2049

 

Page 1325: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1325/2049

 

Page 1326: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1326/2049

 

Page 1327: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1327/2049

 

Page 1328: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1328/2049

 

Page 1329: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1329/2049

 

Page 1330: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1330/2049

Page 1331: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1331/2049

Radiopharmaceutical Mechanism of uptake Indication

Tc-99m sulfur colloid Kupffer cell uptake Focal nodular hyperplasia

Tc-99m HIDA Hepatocyte uptake Cholescintigraphy

Tc-99m RBC Blood pool distribution Cavernous hemangioma

Tc-99m MAA Blood flow & capillary

blockage

Hepatic arterial perfusion

Xe-133 Lipid soluble Focal fatty tumor uptake

Page 1332: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1332/2049

Gallium-67 citrate Lactoferrin transport and

iron binding

Tumor/abscess

F-18 FDG Glucose metabolism tumor

CCK• 33- amino acid polypeptide

• Gallbladder contraction

• Relaxation of sphincter of oddi

• Sincalide = synthetic form of CCK

Page 1333: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1333/2049

 

Gastrointestinalactions of CCK

Contracts gallbladder

Relaxes sphincter of Oddi

Stimulates intestinal

motilityInhibits gastric emptying

Reduces gastrointestinal

sphincter tone

Stimulates hepatic bile

Page 1334: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1334/2049

secretion

Stimulates pancreatic

enzyme secretion

Morphine sulphate• Constricting sphincter of Oddi

• Increases intraluminal biliary pressure

• IV 0.04 mg/kg when GB not filled by 60

minutes

Should not be given to :1 Poor clearance to the bowel

Page 1335: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1335/2049

1. Poor clearance to the bowel

2. Significant retention of radiotracer in biliary

duct

 

False positive of

Acute

Cholecystitis

Fasting < 4 hour

Fasting > 4 hour

concurrent severe illness

Chronic cholescystitis

hepatic insufficient

hyperalimentation

Page 1336: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1336/2049

Alcoholism/pancreatitis (?)

Drugs a/w poor GB

contraction

Diseases a/w poor GB

contractionMorphine DM

Atropine Sickle cells disease

Nifedipine (CCB) IBS

Indomethacin Pancreatic insufficiency

Progesterone Crohn’s disease

Oral contraception Celiac disease

Octreotide Achalasia

Theophylline Obesity

Benzodiazepine Cirrhosis

Page 1337: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1337/2049

Phentolamine Pregnancy

Dyspeptic syndrome

Truncal vagotomy

Differential diagnosis of Primary

Hepatic tumor with Tc-99m HIDA

Lesion Flow Uptake Clearance

Focal

nodular

hyperplasia

Increased Immediate Delayed

Hepaticd

Normal none -

Page 1338: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1338/2049

adenoma

Hepatocellul

ar carcinoma

Increased Delayed Delayed

 

Causes of FocalLiver Defects

Cyst

Benign and malignant

tumor

Abscess

Hematoma

Laceration

Radiation therapy

Infarctionh

Page 1339: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1339/2049

Cirrhosis

Fatty infiltration

Dilated bile duct

 

Increased focal

uptake in Tc-99m SC

Arm injection

Leg injection

focal nodular hyperplasia

Budd-Chiari syndrome

Page 1340: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1340/2049

Cirrhosis

 

Liver heterogeneity

of Tc-99m SC

Metastases

Lymphoma/leukemia

Hepatitis

Chronic passive congestion

Cirrhosis

Parenchymal liver disease

Page 1341: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1341/2049

y

Fatty metamorphosis

Normal HIDA

Page 1342: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1342/2049

Normal HIDA

Page 1343: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1343/2049

HIDA scan, GB visualized after

morphine

Page 1344: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1344/2049

Acute cholecystitis

Page 1345: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1345/2049

What are two FDA approved IDA in use

and how are they different?

Page 1346: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1346/2049

What are two FDA approved IDA in use

and how are they different?• Tc-99m DISIDA and Tc-99m mebrofenin.

Mebrofenin has better hepatic extraction 98%

and renal excretion is 1 %. The higherextraction of mebrofenin is preferable in

patients with hepatic insufficiency.

Page 1347: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1347/2049

What is the most important Q to ask

the patient before startingcholescintigraphy for suspected acute

cholecystitis?

Page 1348: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1348/2049

What is the most important Q to ask

the patient before startingcholescintigraphy for suspected acute

cholecystitis?• When did you last eat. If the patient has eaten

in the last 4 hours, the GB may be contracted

secondary to endogenous stimulation of CCK

and therefore tracer cannot enter into GB.• If the patient has not eaten > 24 hours the GB

Page 1349: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1349/2049

• If the patient has not eaten > 24 hours, the GB

may not have had the stimulus to contract and

will be full of thick, concentrated bile whichmay prevent tracer entry.

What are 5 indication for CCK

infusion?

Page 1350: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1350/2049

Page 1351: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1351/2049

In what clinical settings are false

positive HIDA studies likely to occurwhen performed to rule out acute

cholecystitis.

Page 1352: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1352/2049

In what clinical settings are false

positive HIDA studies likely to occurwhen performed to rule out acute

cholecystitis.

• In patients who have fasted less than 4 hours

or more than 24 hours, patient receiving

hyperalimentation and those who havechronic cholecystitis, hepatic insufficiency or

Page 1353: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1353/2049

y p y

severe illness.

What is the rim sign sometimes seen

with cholescintigraphy and what is itssignificance?

Page 1354: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1354/2049

In what clinical settings are false

positive HIDA studies likely to occurwhen performed to rule out acute

cholecystitis.

• The rim sign is increased uptake and delayed

clearance of activity in the hepatic

parenchyma adjacent to the GB fossa. It hasbeen associated with an increased incidence

Page 1355: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1355/2049

of complications e.g.. perforation and

gangrene.

At what time after HIDA injection is

nonfilling of the GB diagnostic of acutecholecystitis

Page 1356: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1356/2049

At what time after HIDA injection is

nonfilling of the GB diagnostic of acutecholecystitis

• One hour is defined as abnormal. However,

nonfilling of the GB is diagnostic of acute

cholecystitis if delayed images show no filling

by 2 to 4 hours or 30 minutes after morphine

administration.

Page 1357: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1357/2049

What is the mechanism of morphine

augmented cholescintigraphy?

Page 1358: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1358/2049

What is the mechanism of morphine

augmented cholescintigraphy?• Morphine increases tone at the sphincter of

Oddi, resulting in increased intraductal

pressure. This result in bile flow through thecystic duct, if it is patent.

Page 1359: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1359/2049

What is the most common scan finding

in chronic cholecystitis?

Page 1360: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1360/2049

What is the most common scan finding

in chronic cholecystitis?• A normal study. < 5% of patients with chronic

cholecystitis have delayed filling. Other

associated findings include delayed biliary tobowel transit time and rarely nonvisualization

of GB or intraluminal filling defects.

Page 1361: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1361/2049

What is acute acalculous cholecystitis?

Page 1362: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1362/2049

What is acute acalculous cholecystitis?

• Cholecystitis without a stone occluding the

cystic duct. The obstruction may caused by

debris or inflammatory changes or thecholecystitis may be limited to the GB wall

because of infection, ischemia or toxins. It

occurs in hospitalized patients who havesustained trauma, burns, sepsis or other

Page 1363: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1363/2049

sustained trauma, burns, sepsis or other

serious illness.

What are the cholescintigraphic

findings of high grade common ductobstruction?

Page 1364: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1364/2049

What are the cholescintigraphic

findings of high grade common ductobstruction?

Persistent hepatogram with no clearance intobiliary ducts.

Page 1365: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1365/2049

What are the cholescintigraphic

findings of partial common ductobstruction?

Page 1366: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1366/2049

What are the cholescintigraphic

findings of partial common ductobstruction?

• Prominent retention of activity in the common

duct, delayed biliary to bowel clearance and

most important, poor ductal clearance on

delayed imaging or with CCK.

Page 1367: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1367/2049

What is the difference in clinical

presentation and clinical course ofpatients with FNH and hepatic

adenoma

Page 1368: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1368/2049

What is the difference in clinical

presentation and clinical course ofpatients with FNH and hepatic

adenoma

• FNH is asymptomatic and found incidentally,

whereas hepatic adenomas often present with

hemorrhage and can be life threatening.

Adenomas are closely associated with the useof OCP which must be discontinued

Page 1369: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1369/2049

of OCP which must be discontinued.

What are the Tc-99m SC scan findings

in FNH and hepatic adenoma?

Page 1370: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1370/2049

What are the Tc-99m SC scan findings

in FNH and hepatic adenoma?• Hepatic adenomas do not show Tc-99m SC

uptake because they do not usually have

Kupffer cells. FNH is associated with increasedblood flow. Uptake may be increased, normal

or nonexistent. Two thirds of cases of FNH

show some Tc-99m SC uptake.

Page 1371: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1371/2049

What are the characteristic

scintigraphy findings in liverhemangioma?

Page 1372: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1372/2049

What are the characteristic

scintigraphy findings in liverhemangioma?

•Blood flow is normal. Immediate images showa cold defect, whereas delayed images

acquired 1 to 2 hours after tracer

administration show increased uptake withinthe lesion compared with the normal liver,

f l k h l d h

Page 1373: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1373/2049

often equal to uptake in the spleen and heart.

Page 1374: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1374/2049

Beside FNH, what are other causes of

increased focal uptake on Tc-99m SCimaging?

• Superior vena cava syndrome (with arm

injection), inferior vena cava syndrome (withleg injection), Budd-Chiari syndrome and

cirrhosis with a regenerating nodule.

Page 1375: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1375/2049

What is functional asplenia?

Page 1376: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1376/2049

What is functional asplenia?

• Nonvisualization of the spleen on a Tc-99m SC

when the spleen is anatomically present and

when functions other than reticuloendothelialextraction are intact. Functional asplenia is

caused by an acquired dysfunction of the

reticuloendothelial system e.g.. sickle cellanemia or by a disruption of the blood supply

Page 1377: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1377/2049

(splenic artery occlusion).

What is achalasia and how can

radionuclide studies help in makingthe diagnosis and following the

patient’s course? 

Page 1378: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1378/2049

What is achalasia and how can

radionuclide studies help in makingthe diagnosis and following the

patient’s course? 

• Achalasia is characterized by absence ofperistalsis in the distal two thirds of theesophagus, increased lower esophageal sphincter

pressure and incomplete sphincter relaxationafter swallowing. The diagnosis can be confirmedby esophageal manometry Radionuclide

Page 1379: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1379/2049

by esophageal manometry. Radionuclideesophageal transit studies have a high sensitivity

for making the diagnosis and evaluate theeffectiveness of esophageal dilatation.

In regard to reflux and aspiration

studies?A. The milk study is a sensitive method for

diagnosing gastroesophageal reflux.

B. The milk study is a sensitive method for

diagnosing aspiration.

C. Frequent image acquisition improves the

sensitivity of milk study.

D The salivagram is a sensitive method for

Page 1380: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1380/2049

D. The salivagram is a sensitive method for

diagnosing aspiration.

In regard to reflux and aspiration

studies?• TFTT

Page 1381: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1381/2049

Which anatomical portion of the

stomach are responsible for solid

emptying and which for liquid

emptying

Page 1382: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1382/2049

Which anatomical portion of the

stomach are responsible for solid

emptying and which for liquid

emptying

• Liquid emptying is largely caused by the slow

contractions of the proximal fundus whereas

the distal stomach or antrum is responsible for

the grinding and sieving solid food.

Page 1383: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1383/2049

Which of these factors will affect the

rate of gastric emptying?A. Meal content

B. Time of day

C. Gender

D. Position

E. StressF. Exercise

Page 1384: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1384/2049

Which of these factors will affect the

rate of gastric emptying?• TTTTTT

Page 1385: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1385/2049

Regarding gastric emptying studies?

A. Attenuation results in an underestimation ofgastric emptying when performed in the

anterior viewB. A solid gastric emptying time activity curve

shows a rise in activity after ingestion in theanterior view

C. The geometric mean method of attenuationcorrection is considered the reference standard

Page 1386: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1386/2049

D. The left anterior oblique method of attenuationcorrection is superior to the geometric mean.

Regarding gastric emptying studies?

• TTTF

Page 1387: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1387/2049

When might the use of Tc-99m SC

offer advantages over Tc-99m RBCs forthe diagnosis of acute GI bleeding?

Page 1388: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1388/2049

When might the use of Tc-99m SC

offer advantages over Tc-99m RBCs forthe diagnosis of acute GI bleeding?

With very rapid GI bleeding and vascularinstability, the radiotracer can be injected and

the study completed in 15 to 20 minutes. It is

likely to be positive with the rapid

hemorrhage when transfusion cannot keep up

with the bleeding rate The patient can then

Page 1389: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1389/2049

with the bleeding rate. The patient can then

go directly for angiography.

List in increasing order the labeling

efficiency for method to label Tc-99m

RBCs; in vivo, in vitro or in vivtro

Page 1390: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1390/2049

List in increasing order the labeling

efficiency for method to label Tc-99m

RBCs; in vivo, in vitro or in vivtro

• In vivo 75%, in vivtro 85% and in vitro 98%

Page 1391: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1391/2049

Why is the Tc-99m RBC for detecting GI

bleeding more sensitive than the Tc-

99m SC?

Page 1392: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1392/2049

Why is the Tc-99m RBC for detecting GI

bleeding more sensitive than the Tc-

99m SC?

• Delayed images can be performed up to 24

hours with RBC labeling

Page 1393: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1393/2049

What are the criteria needed to

diagnose confidently the site of

bleeding on a radionuclide study?

Page 1394: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1394/2049

What are the criteria needed to

diagnose confidently the site of

bleeding on a radionuclide study?

a. Hot spot appears where there was none and

conforms to bowel activity

b. Activity increases over time

c. Activity moves antegrade and retrograde

Page 1395: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1395/2049

Ectopic mucosa is most often seen

clinically in Meckel’s diverticulum.

What other gastric abnormalities may

contain gastric mucosa?

Page 1396: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1396/2049

Ectopic mucosa is most often seen

clinically in Meckel’s diverticulum.

What other gastric abnormalities may

contain gastric mucosa?

• Duplication of GI tract

• Barrett’s esophagus 

Page 1397: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1397/2049

What is the origin of Meckel’s

diverticulum?

Page 1398: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1398/2049

What is the origin of Meckel’s

diverticulum?• Failure of closure of the omphalomesentric

duct of the embryo, which connects the yolk

sac to the primitive foregut via the umbilicalcord

Page 1399: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1399/2049

Concerning Meckel’s diverticulum 

A. Ectopic gastric mucosa in a Meckel’s diverticulum can be reliably distinguished fromectopic mucosa elsewhere in the small intestine

B. Cimetidine given before the scan to blocks thesecretion of pertechnetate from gastric mucosa

C. Children are more likely to have a positive testthan adults

D. Diverticulitis is a common cause of false positiveresult

Page 1400: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1400/2049

E. A false negative result may be obtained if therehas been a recent barium study

Concerning Meckel’s diverticulum 

• FTTFT

Page 1401: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1401/2049

Concerning GI bleeding studies

A. Hepatic hemangioma is a recognised cause offalse positive Tc-99m RBS study

B. A rejecting transplanted kidney is a recognisedcause of a false positive Tc-99m tin colloid study

C. Anemia is a cause of visualization of the GB inlabeled RBC study

D. Diffuse colonic activity in a labeled RBC studyindicates colonic bleeding

E. When reporting a study. It is not necessary to

Page 1402: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1402/2049

view the dynamic images that provide allinformation

Concerning GI bleeding studies

• TTTFF

Page 1403: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1403/2049

GI bleeding studies

A. Tin colloid studies are better at detecting bleedingsites proximal to the ligament of Treitz than distal to it

B. Delayed images on a tin colloid scan may be of valuein separating liver and spleen activity from bowelactivity

C. In vitro labeling of RBC gives fewer false positive teststhan in vivo

D. Bleeding must be continuous to be detected on alabeled RBC study

Page 1404: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1404/2049

E. 51 Cr-chromate labeled RBC can detect bleedingdown to 1-2 mls per day

GI bleeding studies

• FFTFT

Page 1405: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1405/2049

Concerning cholescintigraphy

A. Failure to visualize the GB by 4 hr with normal activityappearing in the bowel is highly suggestive of GBdisease

B. Chronic Cholecystitis can be distinguished fromacalculous cholecystitis

C. Giving CCK before isotope is more likely todemonstrate the GB than giving morphine

D. Common duct obstruction should be excluded ifvisualization of bowel activity is delayed beyond 1h

Page 1406: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1406/2049

hour

E. GB emphysema has a typical rim sign appearance

Concerning cholescintigraphy

• TFTTT

Page 1407: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1407/2049

Concerning cholescintigraphy

A. Cholescintigraphy has greater specificity thanultrasound at detecting bile duct obstruction

B. Following cholecystectomy, an abnormalaccumulation of HIDA outside biliary tree likelydue to bile leak

C. US is more sensitive than cholescintigraphy atdetecting bile leak

D. Cholescintigraphy can diagnose afferent loopobstruction after gastroenterostomy

i b d d

Page 1408: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1408/2049

E. Ascites can be detected

Concerning cholescintigraphy

• TTFTT

Page 1409: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1409/2049

In pediatric cholescintigraphy

A. Phenobarbitone is used to maximise hepatic oftracer

B. Neonate hepatitis can be distinguished fromRotor syndrome

C. Choledocal cyst can be distinguished frompancreatic cyst

D. Cholescintigraphy is more accurate in diagnosingbiliary atresia in children > 3 months than inneonates

E Dil d i h i d f i

Page 1410: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1410/2049

E. Dilated intrahepatic ducts are often seen inpatients with biliary atresia

In pediatric cholescintigraphy

• TTTFF

Page 1411: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1411/2049

Concerning GI transit studies

A. It is easier to detect abnormalities of gastricemptying for solids than for liquids

B. DM is a common cause of delayed gastricemptying

C. Hyperthyroidism is the commonest of rapidgastric emptying

D. Scleroderma affects esophageal transit throughthe whole esophagus

E. Achalasia has a specific appearance on adi lid h l t it ti

Page 1412: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1412/2049

radionuclide esophageal transit time

Concerning GI transit studies

• TTFFF

Page 1413: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1413/2049

Concerning Milk Studies

A. Reflux is more likely to be detected if the infantis placed prone

B. The longer the test the more sensitive itbecomes

C. Labeled milk studies are better at detectingpost-prandial reflux than 24 hour pH monitoring

D. A normal study excludes significant lungaspiration

E. Reflux detected by scintigraphy is more likely tob i ifi t

Page 1414: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1414/2049

be significant

Concerning Milk Studies

• FTTFF

Page 1415: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1415/2049

 

Page 1416: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1416/2049

 

Page 1417: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1417/2049

 

Page 1418: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1418/2049

 

Page 1419: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1419/2049

 

Page 1420: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1420/2049

3. False positive for Tc-99m RBC

• TTTFF

Page 1421: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1421/2049

 

Page 1422: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1422/2049

 

Page 1423: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1423/2049

 

Page 1424: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1424/2049

6. Tc-99m HIDA

• TTTTF

Page 1425: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1425/2049

 

Page 1426: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1426/2049

 

Page 1427: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1427/2049

 

Page 1428: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1428/2049

8. Sulphur colloid scan

• FFFFT

Page 1429: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1429/2049

 

Page 1430: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1430/2049

9. Colloid shift is seen in

• TTTTF

Page 1431: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1431/2049

 

Page 1432: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1432/2049

 

Page 1433: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1433/2049

 

Page 1434: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1434/2049

 

Page 1435: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1435/2049

 

Page 1436: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1436/2049

12. Focal defect in sulphur colloid scan

is seen in• TTTTT

Page 1437: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1437/2049

What physiologic molecules does Tc-

99m IDA most closely mimic?

Page 1438: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1438/2049

What physiologic molecules does Tc-

99m IDA most closely mimic?• Bilirubin

Page 1439: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1439/2049

What is the main difference between

Tc-99m IDA and bilirubin?

Page 1440: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1440/2049

What is the main difference between

Tc-99m IDA and bilirubin?• Tc-99m IDA is not conjugated

Page 1441: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1441/2049

What level of bilirubin is required to

interfere with the quality of HIDAscan?

Page 1442: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1442/2049

What level of bilirubin is required to

interfere with the quality of HIDAscan?

> than 20 to 30 mg/dl

Page 1443: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1443/2049

How does prior CCK administration

affect the biliary to bowel transit time?

Page 1444: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1444/2049

How does prior CCK administration

affect the biliary to bowel transit time?• CCK delays biliary to bowel transit time

Page 1445: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1445/2049

How can one distinguish acute from

chronic cholecystitis as a cause of non

visualization of the GB at 1 hour ?

Page 1446: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1446/2049

How can one distinguish acute from

chronic cholecystitis as a cause of non

visualization of the GB at 1 hour ?

• Obtain delayed image and perform morphine

augmentation

Page 1447: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1447/2049

What 2 findings on scan increased

likelihood that nonvisualisation of GB

is caused by acute cholecystitis ?

Page 1448: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1448/2049

What 2 findings on scan increased

likelihood that nonvisualisation of GB

is caused by acute cholecystitis ?

1. Hyperemia in GB fossa on early images

2. Rim sign on later images

Page 1449: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1449/2049

What is the prognostic implication of

rim sign in scan?

Page 1450: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1450/2049

What is the prognostic implication of

rim sign in scan?• It is associated with GB gangrene and

perforation

Page 1451: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1451/2049

How does morphine augmented

cholescintigraphy work?

Page 1452: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1452/2049

How does morphine augmented

cholescintigraphy work?• Morphine increases the tone of sphincter of

oddi

• Raising common bile duct pressure• Facilitating GB filling if cystic duct is patent

Page 1453: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1453/2049

How does one perform morphine

augmented cholescintigraphy?

Page 1454: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1454/2049

How does one perform morphine

augmented cholescintigraphy?• If GB does not fill by 60 minutes

• Give 0.04 mg/kg IV morphine

• If GB does not fill by 30 minutes means thepatient has cystic duct obstruction

Page 1455: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1455/2049

What is the major cause of a false

negative scan for acute cholecystitis in

scan ?

Page 1456: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1456/2049

What is the major cause of a false

negative scan for acute cholecystitis in

scan ?

• Acute acalculous cholecystitis

Page 1457: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1457/2049

How does one perform GB ejection

fraction?

Page 1458: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1458/2049

How does one perform GB ejection

fraction?• Administer IV sincilide 0.02 µg/kg

• Normal GB ejection fraction = 35%

Page 1459: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1459/2049

What patient preparation is requires

before scan for biliary atresia?

Page 1460: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1460/2049

Page 1461: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1461/2049

Page 1462: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1462/2049

Tc-99m colonic bleeding

1. Tc-99m labeled RBCs.

2. A. left colon, rectosigmoid region

3. B. Right colon, hepatic flexure. It movesrapidly to the left colon.

4. RBC scintigraphy, 0.1 mil/min; contrast

angiography 1 ml/min.

Page 1463: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1463/2049

Page 1464: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1464/2049

Meckel’s Diverticulum 

1. Meckel’s  can. The radiopharmaceutical is taken up andsecreted by gastric mucosa.

2. Pentagastrin increases rapidity, intensity and duration ofuptake. It is used with glucagon, which is antiparistalticthat inhibits rapid dispersion effect of pentagastrin.Cimetidine, a histamine antagonist, increases andprolonged uptake because of inhibition of Tc-99mpertechnetate secretion from gastric mucosal cells.

3. Increasing focal uptake in the mid abdomen suspicious forMeckel’s diverticulum, however, atypical timing of uptakelessens the certainty. The uptake should be coincidentwith gastric uptake in cases of Meckel’s diverticulum. Thismay be false positive scan.

Page 1465: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1465/2049

4. Acid and pepsin secretion by the gastric mucosa producesinflammation and ulceration of adjacent bowel mucosa.

Page 1466: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1466/2049

Diabetic gastroparesis

1. Consistent with severe diabetic gastroparesis. Obstructioncannot be ruled out.

2. Normal values are meal specific and depend on itsvolume/composition, the method of acquisition,attenuation correction, processing and quantification.Normal values must be determines in each clinic or resultsof a published method should be followed closely.

3. Solid or semisolid gastric emptying meals are moresensitive for detection of mild to moderate delay inemptying than studies conducted after a liquid meal.

4. Activity is detected with greatest efficiency close to thecamera. The anterior view alone underestimates emptyingand posterior view overestimates it because of variable

Page 1467: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1467/2049

attenuation as the meal moves through the stomach fromthe posterior gastric fundus to the more anterior gastricantrum.

Page 1468: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1468/2049

Gastroesophageal reflux

1. Vomiting, pulmonary symptoms, asthma,

pneumonia, sudden death, failure to thrive

and anemia.2. 24 hours pH monitoring.

3. Tc-99m sulfur colloid 1 mCi in the child’s 

usual feeding, formula or milk4. 5 to 10 second/frame.

Page 1469: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1469/2049

Page 1470: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1470/2049

Gastrointestinal bleeding

1. Tc-99m labeled RBC study. Abnormal focaluptake appearing simultaneously at two sitesin the right abdomen, increasing in intensityand changing in pattern with time.

2. Caecum and ascending colon.

3. Review images an a computer in cinematic

mode.4. Acute bleeding due to angiodisplasia,

diverticula, neoplasm, IBD and ischemia.

Page 1471: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1471/2049

Page 1472: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1472/2049

Axillobifemoral bypass graft

1. Tc-99m labeled RBC or sulfur colloid

2. Evidence of current or recent bleeding

3. Tc-99m RBCs4. The vascular flow and delayed static images

show no active bleeding seen. Labeled RBCsare shown in a tubular shape in the rightabdomen that connects after a Y bifurcationto the two iliac vessels as a result of anaxillobifemoral vascular bypass graft. The

Page 1473: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1473/2049

patient has prominent splenomegaly.

Page 1474: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1474/2049

Free pertechnetate vs gastric bleeding

1. Tc-99m RBC

2. In both studies the stomach visualize

promptly. The chest and neck image showsthyroid and salivary gland uptake in study Abut not in study B

3. A. Free pertechnetate. Negative for

gastrointestinal bleeding. B. Active bleedingoriginating from the stomach

4. In vitro

Page 1475: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1475/2049

Page 1476: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1476/2049

Rectal bleeding

1. Abnormal activity accumulate early in the lowermidline pelvis. The appearance is changing overtime and seems to decrease and then increase

again.2. To differentiate activity in the rectum from

bladder and penis, in this patient the activity isseen in the rectum.

3. Positive for gastrointestinal bleeding is not theanswer. Localization is critical. The 90 minutelateral view confirms that this is rectal bleeding.

4. New activity, increases in amount over time and

Page 1477: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1477/2049

moves intraluminally.

Page 1478: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1478/2049

Small bowel bleeding

1. Tc-99m RBCs. The in vitro method of labelingwas used.

2. Evidence of active bleeding, first seen at 5minutes, starting in the left upper abdomenand moving across the mid to lowerabdomen to the right lower and then right

mid abdomen.3. Small bowel bleeding originating from the

region of the jejunum.

Page 1479: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1479/2049

4. Arteriovenous malformation or tumors

Page 1480: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1480/2049

Pulmonary aspiration

1. Recurrent pneumonia, cough, asthma, apnea orsudden infant death.

2. Tc-99m sulfur colloid in a small volume of fluid

placed on the tongue and allowed to mix withoral secretion and swallowed.

3. Poor bolus progression noted in the dynamicesophageal swallow study with entrance into

the main bronchi bilaterally and then into theright lower lobe.

4. The milk study is very sensitive for reflux,however it is insensitive for aspiration. The

Page 1481: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1481/2049

salivagram is sensitive for small amounts ofpulmonary aspiration.

Page 1482: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1482/2049

Choledocal cyst

1. A. Good hepatic uptake and clearance into thegallbladder, common hepatic and proximal commonbile duct at 60 minutes. No biliary to bowel transit. B.the gallbladder contracts with sincalide infusion,however focal increasing accumulation of radiotracer

occurs just medial to the proximal portion of thecommon bile. The proximal common duct activityempties into the duodenum.

2. Likely choledocal cyst. Partial biliary obstruction alsowould cause radiotracer retention within the moreproximal biliary duct.

3. Cholangitis, sepsis, pancreatitis or obstruction.

4. Congenital anomaly. Localize dilatation of the biliarytract, either fusiform or diverticular outpouching.

Page 1483: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1483/2049

, p g

Surgery is the appropriate therapy.

Page 1484: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1484/2049

Chronic acalculous cholecystitis

1. CAC is clinically and pathologically identical to chroniccalculous cholecystitis, except for absence ofgallstone.

2. Anatomical imaging diagnosis depends heavily onvisualization of gallstones. CCK cholescintigraphyallows quantification of gallbladder contraction.Diseased gallbladders do not contract.

3. Findings consistent with chronic acalculouscholecystitis in patient B but not A.

4. A low GBEF has a positive predictive value of morethan 90% that cholecystectomy will cure the patient’s 

Page 1485: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1485/2049

symptoms and that diagnosis will be confirmed bypathological gallbladder examination.

Page 1486: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1486/2049

Post cholecystectomy syndrome

1. Prompt hepatic uptake, clearance into biliary ducts by 15to 30 minutes, retention of activity in ducts, apparentlydilated proximal hepatic and common ducts, biliary tobowel clearance but prominent retention in common duct

with apparent cutoff distally.2. 60 minutes: partial common duct obstruction versus post

biliary duct obstruction surgery with nonobstructedpersistent bile duct dilatation. 120 minutes: suspectedpartial obstruction.

3. Common duct stone, inflammatory stricture of thecommon duct, sphincter of Oddi dysfunction, inflamedcystic duct remnant.

4. Sphincter of Oddi dysfunction is a partial biliaryobstruction at the level of the sphincter of Oddi not

Page 1487: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1487/2049

obstruction at the level of the sphincter of Oddi not

caused by atones or stricture.

Page 1488: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1488/2049

Focal nodular hyperplasia

1. Increased uptake that corresponds to the lesionseen on CT. the uptake is retained after liverwashout.

2. Benign and malignant tumors that havehepatocytes e.g.., hepatic adenoma, hepatomaand FNH. The letter is the correct diagnosis.

3. FNH usually requires no specific therapy. Hepaticadenoma requires discontinuation of oralcontraceptives and surgical removal andhepatoma requires resection.

Page 1489: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1489/2049

4. Tc-99m sulfur colloid.

Page 1490: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1490/2049

Hot spot Tc-99m sulfur colloid imaging

1. Uptake by reticuloendothelial system.

2. 85% by Kupffer cells, 10% by the spleen and

5% by the bone marrow.3. A. the central large cold region may becaused by an intrahepatic mass but thepattern has been stable and CT shows

cirrhosis. B. increased uptake in the region ofthe quadrate lobe, consistent with FNH.

4. Superior vena cava syndrome, inferior vena

Page 1491: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1491/2049

cava obstruction, Budd-Chiari syndrome.

Page 1492: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1492/2049

Cholescintigraphy – normal study

1. No oral intake for 3 to 4 hours before

injection.

2. Tc-99m disofenin or Tc-99m brida.3. Both are iminodiacetic acid analogues,

extracted and excreted by hepatocytes into

biliary system. Mebrofenin has higherhepatocyte extraction (98%)

4. Yes. Acute cholecystitis is ruled out with a

Page 1493: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1493/2049

high degree of certainty.

Page 1494: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1494/2049

Acute cholecystitis

1. A. Abnormal. B. No. C, yes

2. A. Sensitivity 98%, specificity 95%, B greater

than 90%.3. The few direct comparisons published have

shown cholescintigraphy superior to US.

4. Prolonged fasting, hyperalimentation, chroniccholecystitis and hepatic insufficiency.

Page 1495: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1495/2049

Page 1496: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1496/2049

Morphine augmented

cholescintigraphy

1. Morphine produces contraction of the sphincterof Oddi, which increases intraluminal commonbile duct pressure. Bile and excreted radiotracer

then preferentially flow through the cystic ductinto the GB if the cystic duct is pattern.

2. Exclude drug allergy. Do not give if evidence ofcommon duct obstruction.

3. The accuracy is at least as good, if not betterthan the delayed imaging method.

4. IV 0.04 mg/kg morphine. Images are acquired

Page 1497: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1497/2049

for an additional 30 minutes.

Page 1498: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1498/2049

Biliary leak

1. Rapid bile leakage probably originating fromthe region of the ligated cystic duct andextending toward the right colonic gutter

with time, over the dome of the liver.

2. Rapid biliary leak.

3. Cystic duct ligature after cholecystectomy,

surgical anastomosis, trauma andinflammatory processes.

4. Confirm that fluid collection seen by

Page 1499: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1499/2049

anatomical imaging modalities are biliary innature.

Page 1500: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1500/2049

Cavernous hemangioma of the liver

1. Tc-99m RBCs

2. Immediate images show no definite

abnormality. Delayed images show increasedfocal uptake in the left lobe consistent with

cavernous hemangioma.

3. At least 2 cm4. Very specific (>99%) for hemangioma. Poor

sensitivity for small lesions.

Page 1501: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1501/2049

Page 1502: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1502/2049

Biliary atresia

1. Phenobarbital, 5mg/kg/day for 3 to 5 daysbefore study.

2. Inflammatory, infections and metabolic causes

for neonatal hepatitis and biliary atresia.3. A. delayed blood pool clearance as the result of

hepatic insufficiency. Biliary clearance at 50minutes and increasing through 120 minutes. B.

good liver function. No secretion into biliaryduct during the initial 120 minutes or at 5 and24 hours. Case B consistent with biliary atresia.Case A with neonatal hepatitis.

Page 1503: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1503/2049

4. Sensitivity 97% and specificity 82%.

Page 1504: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1504/2049

RIM sign

1. Increased incidence of false positive in patients whohave been fasting more than 24 hours

2. Nonvisualization of GB after 60 minutes. After

morphine, no filling of the GB occurs. Increaseduptake is seen in the region of the GB fossa, whichpersists after most of the liver has washout (RIM sign)

3. Nonvisualization of the GB after morphine is

consistent with acute cholecystitis. The RIM sigh isvery specific for acute cholecystitis and confirmsdiagnosis.

4. The RIM sign indicates severe acute cholecystitis

Page 1505: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1505/2049

which is associated with an increased incidence of GBgangrene and perforation.

Genitourinary scan

Page 1506: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1506/2049

Pearls & Pitfalls

General

The common indications forradionuclide scan for kidneys

include allergy to iodinated

contrast material, assessment

of possible renal artery

stenosis and differentiation of

obstruction from collecting

system. In children corticalscanning agents are used for

evaluation of pyelonephritis.

Page 1507: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1507/2049

Pearls & Pitfalls

General

Tc-99m DTPA reflects glomerularfiltration, Tc-99m MAG3 isessential a tubular agent.

• Tc-99m DMSA is renal cortical

agent.• Tc-99m glucoheptonate is used

to evaluate both renal corticaland collecting system.

• Maximum parenchymal activity isseen at about 3 to 5 minutes andbladder activity is seen by 4 to 8

Page 1508: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1508/2049

minutes.

Pearls & Pitfalls

General

Half of the renal activity shouldbe cleared in about 8 to 12minutes.

• On a postcaptopril renogram

using Tc-99m MAG3 , the kidneythat has delayed clearance withsignificant renal cortical retentionshould be the one with the renal

artery stenosis.• Bilateral delayed clearance can

be caused by bilateral stenosis,obstruction, renal disease,

Page 1509: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1509/2049

dehydration or hypotension.

Pearls & Pitfalls

General

ATN perfusion is usuallynormal with bilaterally

increased renal cortical activity

and rising renogram curves

when Tc-99m MAG3 is used.

• When faced with abnormal

time activity curves, look at the

images to see if the problem is

parenchymal or related to the

collecting system.

Page 1510: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1510/2049

Pearls & Pitfalls

Renal transplant

Common indication are todifferentiate rejection from

ATN.

ATN is usually seen within thefirst week after

transplantation. It usually has

preserved renal perfusion with

progressive accumulation of

tubular agents (Tc-99m MAG3)

in the renal parenchyma. It

Page 1511: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1511/2049

should improved with time.

Pearls & Pitfalls

Renal transplant

Severe ATN can present withenough edema immediatelyafter surgery to have reducedperfusion and therefore look

similar to acute rejection.• Cyclosporin toxicity can look

like ATN but is usually not seen

in the immediatepostoperative period.

• Rejection usually has poorperfusion and poor tubular

Page 1512: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1512/2049

excretion.

Pearls & Pitfalls

Renal transplant

Look for photopenic defectsaround the transplant on the

blood pool image that may be

caused by urinomas,

hematomas and lymphoceles.

Page 1513: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1513/2049

Pearls & Pitfalls

Testicularimaging

Common indications are todifferentiate between

epididymitis and acute or

delayed torsion.

• The initial problem is to

determine whether blood flow

is increased or decreased.

• The best way to determine

which side is abnormal is to

obtain a patient history.

Page 1514: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1514/2049

Pearls & Pitfalls

Testicularimaging

Epididymitis should bediffusely hot on all images and

frequently focal hot in the

region of the epididymitis.

• Increased flow to one

hemiscrotum and a rim of

testicular activity with a cold

center (halo sign) can be a

delayed torsion but also can be

testicular abscess, hematoma

Page 1515: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1515/2049

or tumor

 

Page 1516: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1516/2049

 

Page 1517: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1517/2049

Glomerular filtration 100 % DTPA

Tubular secretion 100% MAG 3

Tubular secretion 80%Glomerular filtration 20%

HIPPURAN

Cortical binding 40% DMSA

Glomerular filtration 80%

Cortical binding 15%

GLUCOHEPTONATE

Page 1518: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1518/2049

Tc-99m DTPA Tc-99m MAG 3

Glomerular filtration 100% -

Tubular secretion - 100%

Extraction fraction

20% 40 – 50%Target to back ground

ratioPoor Good

Protein bound No Yes

Time for imaging Immediate Immediate

Heating for labeling No Yes

Page 1519: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1519/2049

 

Page 1520: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1520/2049

 

Page 1521: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1521/2049

 

Page 1522: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1522/2049

 

Page 1523: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1523/2049

 

Page 1524: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1524/2049

 

Page 1525: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1525/2049

 

Page 1526: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1526/2049

 

Page 1527: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1527/2049

 

30 – 60 SECONDS

1-3 MINUTES

COLLECTING

SYSTEMCORTICAL

Page 1528: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1528/2049

 

Page 1529: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1529/2049

 

Page 1530: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1530/2049

 

Page 1531: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1531/2049

 

Page 1532: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1532/2049

 

Page 1533: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1533/2049

 

Page 1534: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1534/2049

 

Page 1535: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1535/2049

 

Page 1536: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1536/2049

 

Page 1537: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1537/2049

 

Page 1538: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1538/2049

 

Page 1539: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1539/2049

 

Page 1540: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1540/2049

 

Page 1541: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1541/2049

 

Page 1542: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1542/2049

 

Page 1543: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1543/2049

 

Page 1544: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1544/2049

 

Page 1545: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1545/2049

 

Page 1546: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1546/2049

 

Page 1547: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1547/2049

 

Page 1548: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1548/2049

 

Page 1549: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1549/2049

 

Page 1550: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1550/2049

 

Page 1551: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1551/2049

 

Page 1552: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1552/2049

 

Page 1553: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1553/2049

 

Page 1554: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1554/2049

 

Page 1555: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1555/2049

 

Page 1556: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1556/2049

 

Page 1557: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1557/2049

 

Page 1558: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1558/2049

 

Page 1559: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1559/2049

 

Page 1560: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1560/2049

 

Page 1561: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1561/2049

 

Page 1562: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1562/2049

 

lungs

LIVER

KIDNEY

ADRENAL

Page 1563: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1563/2049

 

Page 1564: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1564/2049

 

Page 1565: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1565/2049

 

Page 1566: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1566/2049

 

Page 1567: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1567/2049

 

Page 1568: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1568/2049

 

Page 1569: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1569/2049

 

Page 1570: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1570/2049

 

Page 1571: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1571/2049

 

Page 1572: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1572/2049

RVH with DTPA

Page 1573: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1573/2049

RVH with MAG 3

Page 1574: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1574/2049

Renogram pattern with ACE

Page 1575: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1575/2049

Renogram pattern with ACE

• A = normal TAC curve (grade 0)

• B = peak mildly delayed but greater than 5 minand with delayed excretion (grade 1)

• C = very delayed uptake but some wash out(grade 2A)

• C = extremely delayed uptake with no wash out

(grade 2B)• D = complete renal failure where blood pool

moves through the kidney without an extractionphase

Page 1576: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1576/2049

 

Page 1577: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1577/2049

 

Page 1578: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1578/2049

 

Page 1579: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1579/2049

 

Page 1580: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1580/2049

 

Page 1581: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1581/2049

 

Page 1582: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1582/2049

 

Page 1583: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1583/2049

 

Page 1584: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1584/2049

 

Page 1585: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1585/2049

 

Page 1586: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1586/2049

 

Page 1587: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1587/2049

 

Page 1588: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1588/2049

 

Page 1589: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1589/2049

 

Page 1590: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1590/2049

 

Page 1591: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1591/2049

 

Page 1592: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1592/2049

 

Page 1593: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1593/2049

 

Page 1594: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1594/2049

 

Page 1595: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1595/2049

 

Page 1596: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1596/2049

 

Page 1597: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1597/2049

 

Page 1598: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1598/2049

 

Page 1599: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1599/2049

 

Page 1600: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1600/2049

Complication of

renal transplant

Pre surgical

insult

Autoimmune

rejection

Surgical

Vascular

Vasomotor nephropathy

resolution ATNMinutes to hours

Hyperacute rejection

Accelerated rejection

Acute rejection

Chronic rejection

Cyclosporine rejection

Urine leak

Hematoma 

Infection 

Lymphocyle 

Renal artery stenosis

Vascular occlusion

Infarct 

Renal obstruction

Vesicoureteroreflux

Minutes to hours

1 – 5 hours

After 5 days – first 3/12

Months to years

Months 

Days or weeks

1st few days

1st few days

2 – 4 months

After 1st months

Days/months/years

Page 1601: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1601/2049

 

Page 1602: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1602/2049

 

Page 1603: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1603/2049

 

Page 1604: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1604/2049

 

Page 1605: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1605/2049

 

Page 1606: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1606/2049

 

Page 1607: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1607/2049

Page 1608: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1608/2049

 

Page 1609: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1609/2049

 

Page 1610: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1610/2049

 

Page 1611: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1611/2049

 

Page 1612: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1612/2049

 

Page 1613: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1613/2049

 

Page 1614: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1614/2049

 

Page 1615: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1615/2049

1. Static radionuclide imaging of

kidney

A. Tc 99m DMSA is the radionuclide of choice

B. Tc 99m DMSA is the best for imaging

pseudotumor of kidney

C. DMSA can measure relative tubular mass

D. DMSA can detect of areas of renal ischemia

E. Optimum time for DMSA scanning is oneweek after onset of symptoms in infection

Page 1616: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1616/2049

1. Static radionuclide imaging of

kidney

• TTFFF

Page 1617: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1617/2049

2. MAG 3 scintigraphy

A. Best method for assessment of scarring in

children

B. Prolonged transit time in dilated system

C. Reliable for diagnosis of obstruction in renal

failure

D. Prolonged parenchymal transit time in renal

artery stenosis

E. Patients are dehydrated before study

Page 1618: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1618/2049

2. MAG 3 scintigraphy

• FTFTF

Page 1619: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1619/2049

3. Renal scintigraphy

A. For captopril test, ACE inhibitors should on

the day of the test

B. MAG 3 is used for assessing renal scarring

C. DMSA is superior to MAG 3 for both dynamic

and structural assessment

D. Radiation is lower for MAG 3

E. 100% of MAG 3 is excreted by tubular

secretion

Page 1620: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1620/2049

3. Renal scintigraphy

• FTFTF

Page 1621: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1621/2049

4. Renal scintigraphy

A. DMSA images are acquired within one hourof injection to avoid artifacts

B. DTPA is isotope of choice for dynamic renal

scansC. Kidney/background ratio is better for MAG 3

than DTPA

D. I 123 can be produced only by cyclotronE. Hippuran is completely cleared by glomerular

filtration

Page 1622: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1622/2049

4. Renal scintigraphy

• FFTTF

Page 1623: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1623/2049

5. Renal scintigraphy

A. The glomerular filtration rate of DTPA is 500ml/min

B. DTPA is completely cleared by tubular

filtrationC. The maximum diuresis occurs within 2

minutes of diuretic administration

D. Images are acquired between 5-10 minutesfor perfusion in transplants

E. Post void film is indicated in cases of stasis

Page 1624: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1624/2049

5. Renal scintigraphy

• FFFFT

Page 1625: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1625/2049

6. Static renal scans are indicated in

the following instances

A. Horseshoe kidney

B. Renal agenesis

C. Column of bertin

D. Individual renal function

E. UTIs

Page 1626: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1626/2049

6. Static renal scans are indicated in

the following instances

• TTTTT

Page 1627: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1627/2049

7. Recognised indication of dynamic

nuclear scanning

A. Hypertension

B. Renal transplantation

C. Renal trauma

D. Reflux

E. Tumor

d d f d

Page 1628: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1628/2049

7. Recognised indication of dynamic

nuclear scanning

• TTTTF

Page 1629: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1629/2049

9. Abnormal bone uptake in kidney

A. Radiation

B. Chemotherapy

C. Papillary necrosis

D. Multiple myeloma

E. Amyloidosis

Page 1630: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1630/2049

9. Abnormal bone uptake in kidney

• TTFTF

Page 1631: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1631/2049

10. In urinary tract obstruction

A. A DMSA scan always estimates renal function moreaccurately than DTPA scan

B. Evan if a kidney contributes less than 10% to the totalGFR, it’s  function will usually improve if the

obstruction is relievedC. Failure of the collecting systems to empty on standingconfirms the presence of obstruction

D. Lower urinary tract obstruction may be missed on aDTPA study

E. Giving furosemide during a DTPA study results in agreater specificity for diagnosing PUJ obstruction thangiving it at the start of the study

Page 1632: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1632/2049

10. In urinary tract obstruction

• FFFFTF

Page 1633: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1633/2049

11. Concerning radionuclide studies

A. DMSA gives an accurate assessment of overallrenal function in renal tubular acidosis

B. DTPA studies can reliably exclude obstruction indehydrated patient

C. A tissue injection can give a false positive resultfor obstruction

D. An aortic aneurysm can be excluded if a dilatedaorta is not seen on the blood flow renogram

imagesE. Visualization of a ureter on a renogram is

abnormal

Page 1634: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1634/2049

11. Concerning radionuclide studies

• FFTFF

12 C i di lid t di i

Page 1635: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1635/2049

12. Concerning radionuclide studies in

acute renal failure

A. ATN typically can be distinguished from othercauses of acute renal failure

B. On a DTPA study in pre renal failure, there isimpaired renal blood flow, poor uptake, delayed

intrarenal transit and little or no excretionC. A rising T/A curve on DTPA study confirms

obstruction

D. In ATN , a horizontal third phase to the T/A curve

in a DTPA study indicates that recovery isoccurring

E. MAG 3 is agent of choice

12 C i di lid t di i

Page 1636: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1636/2049

12. Concerning radionuclide studies in

acute renal failure

• TFFTT

13 C i d l

Page 1637: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1637/2049

13. Concerning renogram and renal

transplants

A. On a DTPA scan, rejection can be distinguished fromcyclosporine A toxicity

B. Arterial thrombosis can be distinguished from venousocclusion

C. A high perfusion index means that there is a good bloodsupply to the transplant

D. Arterial occlusion can be detected on a DTPA study even ifan earlier one has shown ATN from which the patient hasnot yet recovered

E. Vesicoureteric reflux is the commonest cause ofpelviureteric dilatation

F. A urinary leak can be excluded if it is not shown in earlyimages

13 C i d l

Page 1638: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1638/2049

13. Concerning renogram and renal

transplants

• FFFTTF

Page 1639: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1639/2049

14. Concerning MAG 3

A. A kit reconstituted first thing in the morningremains usable until the 99m-Tc decays

B. MAG 3 has a smaller volume of distribution

than DTPAC. Liver and biliary activity may be seen

D. MAG 3 measures GFR more accurately than

DTPAE. The radiation dose from a MAG 3 study is

less than from DTPA

Page 1640: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1640/2049

14. Concerning MAG 3

• FTTFF

Page 1641: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1641/2049

15. In renal tract infections

A. In acute pyelonephritis, there may be area ofdecreased perfusion on the flow study

B. In a patient with UTI, a small smooth kidney is unlikelyto be due to chronic pyelonephritis alone

C. The overall sensitivity of DMSA is increased by SPECTD. A recognised feature of established scars is that they

become more prominent with time

E. Renal parenchymal involvement can be predictedfrom clinical and lab parameters

F. Most acute parenchymal defects develop into corticalscars

Page 1642: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1642/2049

15. In renal tract infections

• TFFTFF

Page 1643: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1643/2049

16. Concerning vesicoureteric reflux

A. In patients who reflux, 20% reflux only during micturitionB. Reflux seen on direct scintigraphy cystography correlates

closely with the results of an MCUG

C. Any reflux is a risk factor for pyelonephritis

D. Renal scarring occurring after an episode of acutepyelonephritis is independent of continued reflux

E. A recognised appearance on a DMSA scan of a kidneydamaged by infection is a normal size kidney with reducedfunction

F. Reflux occurring after the age of 3 yrs in patients withnormal DMSA scans is probably irrelevant

G. A 1 yr old with their first proven UTI and hydronephrosison US should have a DMSA and an MCUG

Page 1644: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1644/2049

16. Concerning vesicoureteric reflux

• TFFFTTF

Page 1645: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1645/2049

17. In ACE I renography

A. With longstanding total occlusion of the renalartery, there can be no uptake in the affectedkidney

B. Branch arterial stenosis can be detected

C. In a patient with solitary kidney, ACE Irenography may result in acute renal failure

D. Furosemide is recommended at the start of thetest to improve specificity

E. In a MAG 3 study, a continually rising curveindicates a haemodynamically significantstenosis

Page 1646: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1646/2049

17. In ACE I renography

• FTTTT

Page 1647: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1647/2049

18. Renal radionuclide imaging

A. Can distinguish between renal contusion andinfarction

B. Can detect radiation nephritis 3 wks aftertreatment

C. Can detect central cysts more easily thanperipheral ones

D. A phantom kidney may be seen afternephrectomy

E. A phantom kidney, if due to mesenteric vesselsmore commonly occurs on the right

Page 1648: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1648/2049

18. Renal radionuclide imaging

• TTFTF

19 The following are causes of a

Page 1649: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1649/2049

19. The following are causes of a

flattened DTPA curve

A. Hypovolaemia

B. Hypoplastic kidney

C. Recent contrast angiogram

D. After extracorporeal shock wave lithotripsy

E. Severe cyclosporine toxicity

19 The following are causes of a

Page 1650: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1650/2049

19. The following are causes of a

flattened DTPA curve

• TTTTT

Page 1651: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1651/2049

20. In DTPA renal scan

A. The examination is contraindicated in renalfailure

B. Fluid restriction is mandatory

C. Vascular phase is acquired immediately afterinjection

D. The acquisition is performed with patient

facing the cameraE. Calculation of GFR takes the background into

consideration

Page 1652: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1652/2049

20. In DTPA renal scan

• TFTFT

What percentage of renal plasma flow

Page 1653: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1653/2049

p g p

is filtered through the glomerulus and

what percentage is secreted by thetubules

What percentage of renal plasma flow

Page 1654: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1654/2049

p g p

is filtered through the glomerulus and

what percentage is secreted by thetubules• 20% of renal plasma flow is cleared by

glomerular filtration.• 80% by tubular secretion.

Which radiopharmaceuticals are most

Page 1655: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1655/2049

often used clinically for measurement

of GFR and ERPF?

Which radiopharmaceuticals are most

Page 1656: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1656/2049

often used clinically for measurement

of GFR and ERPF?

• GFR : Tc-99m DTPA

• ERPF : I-131 OIH (iodohippurate) or Tc-99m

MAG3• However Tc-99m MAG3 does not actually

measure ERPF and a correction factor based

on proportional clearance compared with I-131 OIH must be applied.

Page 1657: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1657/2049

What is the percentage of cortical

Page 1658: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1658/2049

binding of Tc-99m DMSA and Tc-

99mGH?

• Tc-99m DMSA :40-50%

• Tc-99m GH : 10-20%

Page 1659: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1659/2049

What is Webster’s rule? 

Page 1660: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1660/2049

What is Webster’s rule? 

• Pediatric radiopharmaceutical doses can beestimated using the formula (age + 1)/(age +

7) x adult dose.

The time to peak activity of a renal

Page 1661: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1661/2049

The time to peak activity of a renal

time activity curve (TAC) represents:

A. The end of extraction

B. The beginning of renal clearance

C. The time point at which the amount of

cortical uptake of the radiopharmaceutical is

equal to clearance

The time to peak activity of a renal

Page 1662: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1662/2049

The time to peak activity of a renal

time activity curve (TAC) represents:

• FFT

What are the general method for

Page 1663: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1663/2049

What are the general method for

calculating absolute GFR?

What are the general method for

Page 1664: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1664/2049

What are the general method for

calculating absolute GFR?

• Blood sampling, blood sampling and urinecollection and camera based methods.

At what step in the renin-angiotensin-ld d d il

Page 1665: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1665/2049

aldosterone cascade does captopril

work?

At what step in the renin-angiotensin-ld d d il

Page 1666: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1666/2049

aldosterone cascade does captopril

work?

• Captopril blocks the conversion of angiotensin

I to angiotensin II in the lung.

Which of these factors effects the

Page 1667: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1667/2049

Which of these factors effects the

accuracy of diuresis renography?

A. State of hydration

B. Renal function

C. Dose of diuresis

D. Radiopharmaceutical

E. Bladder capacity

Which of these factors effects the

Page 1668: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1668/2049

accuracy of diuresis renography?

• TTTTT

What is the most sensitive technique

Page 1669: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1669/2049

q

for diagnosing scarring secondary to

reflux?

What is the most sensitive technique

Page 1670: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1670/2049

q

for diagnosing scarring secondary to

reflux?• Tc-99m DMSA

How can radionuclide imaging

Page 1671: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1671/2049

g g

differentiate upper from lower UTI?

How can radionuclide imaging

Page 1672: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1672/2049

g g

differentiate upper from lower UTI?

• Upper UTI or pyelonephritis , Tc-99m DMSAshows tubular dysfunction, manifested bydecreased uptake.

This is a reversible process.• With appropriate therapy, tubular will return

in 3 – 6 months.

• Upper UTI has prognostic implication becauseit may lead to subsequent renal scarring, HPTand renal failure.

What is meant by direct vs indirect

Page 1673: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1673/2049

cystography and which is the preferred

method in detecting VUR?

What is meant by direct vs indirect

Page 1674: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1674/2049

cystography and which is the preferred

method in detecting VUR??• Direct cystography is sensitive, requiring

urinary tract catheterization and infusion of

radiotracer into the bladder. Reflux can bedetected during bladder filling and voiding.

• Indirect method, where a routine renogram is

initially performed, cannot be used to detectreflux during the bladder filling stage becauseradiotracer is flowing through the collectingsystem antegrade.

What is the common development

Page 1675: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1675/2049

p

abnormality leading testicular torsion?

What is the common development

Page 1676: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1676/2049

p

abnormality leading testicular torsion?

• The bell-clapper testis

What is the difference in blood supply

Page 1677: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1677/2049

pp y

to the testis and scrotum?

What is the difference in blood supply

Page 1678: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1678/2049

to the testis and scrotum?

• The testes receive the blood from testicularartery.

• Scrotum receives supply from the pudendal

vessels.

Page 1679: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1679/2049

Urinoma

Page 1680: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1680/2049

Urinoma

1. A photopenic region, best seen on early images, involvesmost of the left renal fossa. Only the upper pole isfunctioning. Urinary clearance into the left renal pelvisappears displaced medially by the photopenic defect. Theright pelvic and uppe2/3 of the ureter fill. Poor clearance

bilaterally. Delayed images show increased uptake in theregion of the initial cold defect and inferior to it.

2. The cold defect is a urinoma with an attenuating masseffect. Over time the radioactive urine enters this spaceand mixed with the nonradioactive urinoma. Activity in

the region of the urinoma increases over time while theearlier seen kidney and background activity have cleared.

3. Activity urinary leak and urinoma.

4. Urinary tract obstruction.

Page 1681: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1681/2049

Bilateral obstruction

Page 1682: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1682/2049

Bilateral obstruction

1. Left kidney; delayed and decreased cortical uptake, noclearance into the calyces or pelvis. Right kidney;prompt uptake and clearance into the collectingsymptom, faint persistent visualization of the rightureter and, poor response to furosemide.

2. Before furosemide; high grade obstruction on the leftand HN on the right, suspicious of obstruction. Afurosemide high grade obstruction on the left andobstruction on the right.

3. Filling of the renal collecting system.4. Percent radiopharmaceutical uptake by each kidney

divided by total renal uptake between 1 and 3minutes (before clearance into the pelvicalycialsystem)

Page 1683: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1683/2049

Torsion of testicular appendage

Page 1684: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1684/2049

Torsion of testicular appendage

1. A, Mildly increased flow and mild focal left upperscrotal uptake on the static image. B, Increased flowand increased distribution on the left hemiscrotum. C,Increased flow and delayed halo sign of the right

hemiscrotum.2. A, Torsion of a testicular appendage. B, Acute

epididymitis/orchitis. D, Delayed testicular torsion.

3. A, Loss of blood supply to the appendage of the

testicle. B, Infection, viral or bacterial. C, Infarction ofthe testicle caused by torsion more than 24 hoursduration.

4. Testicular torsion, 35%; torsion of the appendix testis,

35%; acute epididymitis, 25%.

Page 1685: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1685/2049

Radionuclide cystography

Page 1686: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1686/2049

Radionuclide cystography

1. Tc-99m DTPA and Tc-99m SC2. Radionuclide cystography is more sensitive in detection of

VUR and results in 50 to 200 times less radiation exposureto gonads compared with the contrast study.

3. The direct method is commonly used and requires urinary

catheterization and installation of radiotracer into thebladder through catheter. The indirect method isperformed after routine DTPA/MAG3. when the bladder isfull, a prevoiding image is obtained, followed by dynamicimages during and after voiding.

4. Grading criteria are similar to those used with contrastcystography, however the radionuclide study’s  limitedresolution does not permit assessment of calycealmorphology. Mild reflux; confined to the ureter.Moderate; reaches the pelvicalyceal system. Severe;

distorted collecting system and dilated tortuous ureter.

Page 1687: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1687/2049

Unilateral obstruction

Page 1688: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1688/2049

Unilateral obstruction

1. Good symmetrical cortical uptake and promptexcretion into collecting systems bilaterally.Retention of activity in left renal collectingsystem, apparent cutoff in the upper ureter and

very poor response of furosemide. The right sideshows a prominent collecting system but washesout spontaneously before furosemide.

2. HN of the left kidney. TRO obstruction.

3. Consistent with significant obstruction of the leftkidney.

4. Dehydration, renal insufficiency, inadequatediuretic dose, full bladder and large collecting

system.

Page 1689: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1689/2049

Renal scan

Page 1690: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1690/2049

Renal scan

1. Tc-99m DTPA, Tc-99m MAG3 and I-131 hippuran.2. DTPA; glomerular filtration, MAG3; tubular secretion

and hippuran; 20% glomerular and 80% tubular.

3. DTPA is inexpensive, provides a good image quality

but has low extraction efficiency (10-20%) and poorpoor quality images with renal insufficiency. MAG 3has a high extraction rate (60%), good target tobackground and good quality images with renalinsufficiency. Hippuran has good extraction efficiency,

high target to background, poor image quality, poorcortical/collecting system differentiation and deliversa high radiation dose in renal insufficiency.

4. No . A dose of 5 mCi is needed for good blood flowimages.

Page 1691: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1691/2049

Diuretic renography

Page 1692: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1692/2049

Diuretic renography

1. Bilateral cortical uptake and excretion into collectingsystems. Retention in the right collecting system at 30minutes with good post furosemide washout.

2. Good response to surgical correction with no obstruction.

3. Not with certainty. Ureteral nonvisualization is not

diagnostic of ureteropelvic junction obstruction because astanding column of ureteral urine can prevent radiotracerentry.

4. It measures pressure flow relationships and requiresfluoroscopically guided trocar or spinal needle insertion

into the renal pelvis. Basal and pressure measurementsduring infusion of a contrast solution at a rate arerecorded. Obstruction pressure is defined as greater than15cm water, no obstruction as less than 10 to 12 cmwater.

Page 1693: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1693/2049

Transplanted kidney

Page 1694: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1694/2049

Transplanted kidney

1. Rapid leakage of urine just inferior to thetransplanted kidney and extravasating into the

scrotum.

2. Urinary leak caused by disruption of surgicalanastomosis.

3. Hematomas and abscess occur in the early

postoperative course, whereas lymphoceles

generally are noted 4 to 8 weeks after surgery.

4. ATN, acute rejection or obstruction. Cyclosporin

toxicity usually occurs months after transplant.

Page 1695: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1695/2049

Non viable kidney after

Page 1696: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1696/2049

transplantation

1. No blood flow to the transplanted kidney. Norenal uptake. A photopenic region in the

shape of the transplanted kidney.

2. Nonviable kidney3. Arterial or venous thrombosis, severe

irreversible rejection and acute cortical

necrosis.4. Removal of nonviable transplanted kidney

Page 1697: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1697/2049

ATN

Page 1698: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1698/2049

ATN

1. ATN, accelerated acute rejection, urinary leakand urinary obstruction.

2. The second postoperative week. Acceleratedrejection may occur during the first week in

patients who have had previous transplants orreceived multiple transfusion.

3. Normal blood flow, very poor function, no

excretion. Base of penis seen inferiorly.4. The pattern of normal blood flow but poor

function during the first week aftertransplantation is typical of ATN

Page 1699: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1699/2049

Testicular torsion

Page 1700: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1700/2049

Testicular torsion

1. Tc-99m pertechnetate, initial blood flow andthen tracer distributes in the extracellular fluidspace.

2. Acute epididymitis, testicular torsion or torsion

of the testicular appendage.3. Developmental abnormality of testicular

descent and attachment predisposes tospermatic cord torsion. The most common

anatomical abnormality is “bell clapper” testis.4. Decreased blood flow to the right testicle and aphotopenic right testicle consistent with acutetesticular torsion.

Page 1701: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1701/2049

Acute renal transplant rejection

Page 1702: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1702/2049

Acute renal transplant rejection

1. Very decreased and delayed blood flow andpoor transplant function.

2. Acute rejection.

3. Fever, transplant tenderness andenlargement, decreased urinary output and

rising serum creatinine level.

4. Biopsy.

Page 1703: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1703/2049

Captopril renography

Page 1704: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1704/2049

Captopril renography

1. With renal artery stenosis, glomerular filtration decreasesand GFR drops. Renin released from juxtaglomerularconvert angiotensin I to angiotensin II. Angiotensin IIcauses vasoconstriction of the glomerular efferentarterioles, rising filtration and maintaining GFR. ACE

inhibitor blocks conversion of angiotensin I to II resultingin decreased in a decrease GFR.

2. The right kidney is small but with good function. Withcaptopril cortical retention persists, consistent with renindependent renovascular HPT of the right kidney. This isconfirmed by the renal cortical time activity curves.

3. Yes. The accuracy of I-131 hippuran, Tc-99m DTPA and Tc-99m MAG 3 are similar.

4. Sensitivity 90% and specificity 95%. Sensitivity is less fordetection of renin dependent HPT if the patient has been

taking an ACE inhibitor chronically or renal insufficiency.

Page 1705: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1705/2049

Pyelonephritis

Page 1706: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1706/2049

y p

1. 40% of DMSA binds and fixes to functioningproximal cortical renal tubules.

2. Diagnosis of pyelonephritis or renal scarring.

3. Decreased uptake in the lower half of theright kidney on initial imaging (A). RepeatSPECT show normalization of uptake. A,Pyelonephritis. B, Renal scarring

4. DMSA in the early stages of infection is thebest predictor of renal sequalae.Identification of pyelonephritis will increase

the duration of antibiotic therapy

Page 1707: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1707/2049

Lung scintigraphy

Pearls & Pitfalls

Page 1708: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1708/2049

Lungs perfusion

• Unless it is completely and

absolutely normal, neverinterpret a V/P scan without a

recent chest radiograph.

•A normal perfusion lung scanessentially excludes clinically

significant PE.

An abnormal ventilation scanor chest radiograph will not

change this assessment.

Pearls & PitfallsOth f f i

Page 1709: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1709/2049

Lungs perfusion

• Other causes of perfusiondefects are COPD, asthma,tumor, mediastinitis, mucousplug, fat emboli and vasculitis.

• Most perfusion defects caused

by PE are wedge shaped andextend to the periphery,usually bilateral and multiple.

An unmatched defects refers toone that is seen on theperfusion scan withoutventilation abnormality.

Pearls & Pitfalls

Page 1710: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1710/2049

Lungs perfusion

• Even a low probability scan has

a 15% to 20% probability of PE.• A very low probability scan has

a positive predictive value of

less than 10%.• Asthma, mucous plugs and

COPD can cause segmental

defects, but they should nothave normal ventilation scans.

Pearls & Pitfalls

Page 1711: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1711/2049

Lungs perfusion

• A stripe sign of peripheral activity

around a perfusion defect isfrequently seen with COPD and

indicates a very low probability

defect.

• When there is an infiltrate on the

CXR and a small perfusion defect,

pneumonia is a common cause.

• When there is a small infiltrateand a relatively larger perfusion

defect, PE should be considered.

Pearls & Pitfalls

Page 1712: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1712/2049

Lungs perfusion

• If there is ventilation of one

whole lung but no perfusion, thedifferential diagnosis includescongenital absence of thepulmonary artery, massive

central PE, mediastinal fibrosis orhilar neoplasm.

• A focal hot spot in the lung is dueto an injected labeled clot that

was either formed in the syringeor dislodged from the end of thecentral line through which Tc-99m MAA was injected.

Pearls & Pitfalls

Page 1713: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1713/2049

Lungs perfusion

• On an aerosol ventilation scan,

collection of activity in thecentral bronchi is an indication ofCOPD.

• Poor perfusion to the lung apices

may be normal after lungtransplantation.

• Large segmental V/Q mismatchesare more likely to represent PE

than the small ones.

• Multiple irregular tiny perfusiondefects can be due to COPD, fat

emboli and vasculitis

Pearls & Pitfalls

Page 1714: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1714/2049

Lung perfusion

• Parenchymal renal activity on a

Tc-99m MAA scan indicates apossible right to left shunt.

• This can be confirmed by

noting activity in the brain.• V/Q scans remain useful for

renal failure patients and

contrast allergies.

Lungs

Page 1715: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1715/2049

Lungs

Perfusion ventilation

Radioactive

gasesRadioaeresols

Tc-99m human

Albumin microspheres

Tc-99m MAA

Macroaggregated

albumin

Xenon 133 Xenon 127 Krypton 81m Tc-99m DTPA Tc-99m

technigas

Xenon 133 Tc-99m DTPA

Mode of decay Beta minus Isometric

Page 1716: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1716/2049

Mode of decay Beta minus Isometric

Half life 5.5 days 6 hours

Biological half life 30 seconds 45 minutes

Photo energy 81 keV 140 keV

Multiple view imaging No Yes

Useful for severe

COADYes -/+

Used after perfusion

scan

No No

Tc-99m MAA

Page 1717: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1717/2049

Size 10 – 90 µm

Minimum number of particles to

be used in adults

100000 unless pulmonary

hypertension and right to left

shunt

Ideal number of particles 200000 - 500000

Biological half life 4 – 8 h

Injection Care should be taken not to

cause particle aggregates that

can produce hot spot

Safety Particles block <1/1000 of thecapillaries and precapillary

arterioles

Terminology

Page 1718: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1718/2049

V/Q match defect Both scans abnormal in same area

and equal size

V/Q mismatch Abnormal perfusion

Normal ventilation

Triple match

V/Q matching with CXR

Segmental defect

Wedge shape and pleural base

Large > 75%

Moderate 25 -75%

Small < 25%

Reversed mismatch Abnormal ventilation

Normal perfusion

Xenon-133 ventilation scintigraphyPatient preparation None

Page 1719: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1719/2049

Patient preparation None

Dosage 10-20 mCi inhale

Collimator LEGP

Photopeak 20% window centered at 81 keV

Positioning Patient is seated

Place nose clamps on patient and connect

mouthpiece for several minutesCenter camera over chest posteriorly

Patient breathes continuously through

mouthpiece for several minutes

Acquisition First breath- patients exhales fully and is ask to

minimally inspire and hold it long enough to

obtain 100000 count or 10-15 secondsEquilibrium-obtain 2 sequential 90 seconds

images while patient breath normally

Washout-turn system to exhaust

Obtain 3 sequential 45 seconds posterior

images then right and left posterior oblique

and final posterior image

Tc-99m DTPA ventilation scintigraphy

Page 1720: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1720/2049

Patient preparation None

Dosage 30 mCi Tc-99m DTPA nebulizer

Collimator LEGP

Photopeak 20% window centered at 140 keV

Positioning Place nose clamps on patient and connect

mouthpiece for several minutes

Center camera over chest posteriorly

Patient breathes continuously through

mouthpiece for several minutes

Acquisition Acquire posterior image for 250k and

mark time

Views: posterior/anterior/right and left

lateral/right and left posterior oblique

Tc-99m MAA perfusion scintigraphy

Page 1721: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1721/2049

Patient preparation None

Patient precaution Pulmonary hypertension : reduces

particle to 100000

Right to left cardiac shunt : reduced

particle number

Dosage 2-5 mCi IV over several respiratory cycle

with patient supine

Collimator LEGP

Photopeak 20% window centered at 140 keV

Acquisition Acquire posterior image for 500k

counts/image

Views: posterior/anterior/right and left

lateral/right and left posterior oblique

Understanding the report

Page 1722: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1722/2049

Mismatched or matched V/Q scan

Mismatched  –  decreased perfusion with

normal ventilation

Matched  –  abnormal perfusion and

abnormal ventilation

Ventilation abnormal image shows  – 

slow to wash in/ slow to wash out (wash

in images are obtained in all ventilation

agent but wash out only with xenon gas)

Understanding probability

Normal scan- low probability of PE (0-5%)

Low probability scan -PE (10-15%)

Intermediate probability -PE (25-30%)

High probability –PE (80-100%)

Qualitative lung scan

Describe the percent contribution to

global perfusion of each lung

Combined with pulmonary function test

Potential problemsFalse positive Conditions that can mimic high probability-

Page 1723: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1723/2049

pvasculitis / pulmonary arterial anomalies i.e.

hypoplasia and stenosis

Clinical pretest probability of PE Useful for deriving post test probability

Interpretations of defect size High probability  –  2 moderate / large

mismatched perfusion defects

If patient with cardiopulmonary disease- 4

mismatched defects

Moderate – 25-27% area lung segment

Large 75% segment2 defects each 50% of segment can be counted

as 1 large defect

Widespread ventilatory abnormalities Widespread ventilatory abnormalities =

intermediate probability of PE

i.e. pulmonary infarction or pneumonia showedmatched V/Q and matched CXR infiltrate

Right to left shunt Number of particle can be reduced for

patients with right to left shunt i.e.

children.

 

V/Q scan

b bili f

Clinical pre scan probability

Page 1724: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1724/2049

probability for

PE High Intermediate Low

High 97% 88% 56%

Intermediate 66% 28% 16%

Low 40% 16% 4%

Page 1725: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1725/2049

Page 1726: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1726/2049

Page 1727: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1727/2049

Page 1728: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1728/2049

Technegas (ventilation)

Page 1729: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1729/2049

DTPA (perfusion)

Patient with COPD

Page 1730: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1730/2049

Page 1731: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1731/2049

  Primary vascular lesionPE

Vasculitis

Page 1732: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1732/2049

Causes of perfusion

defect

Septic/fat/air emboli

Pulmonary artery hypoplasia or atresia

Primary ventilation

abnormalityPneumonia

Atelectasis

Pulmonary edema

Asthma

COPD

Bullae

Mass effectTumor

AdenopathyPleural effusion

IatrogenicSurgery

Radiation fibrosis

Acute PE

Page 1733: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1733/2049

 

V/Q mismatched

defect

Chronic PE

Vasculitis

Mediastinal or hilar

adenopathy

hypoplasia or aplasia ofpulmonary artery

Post radiation therapy

Bronchogenic carcinoma

Septic/drug abuse

Page 1734: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1734/2049

 

V/Q matched defect

COPDAir space disease

Tumor

Pleural effusion

Asthma

Lung infarction

Page 1735: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1735/2049

 

V/Q reversed

mismatched defect

Pneumonia

Mucus plugging

Alveolar pulmonary edema

Page 1736: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1736/2049

 

Unilateral lung

perfusion

abnormality

Pneumonectomy

Mediastinal fibrosis

Pneumothorax

Tumors

Mucous plug

Pulmonary embolus

Pulmonary artery stenosis

Swyer-James syndrome

Massive pleural effusion

  Pacemaker

Page 1737: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1737/2049

Non segmental

defect

Bullae

Trauma

Tumors

Hemorrhage

CardiomegalyHilar adenopathy

Atelectasis

Pleural effusionPneumonia

Perfusions defect ventilation CXR Probability category

Moderate to large

≥ 2 segments Mismatch clear high

Page 1738: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1738/2049

≥ 2 segments  Mismatch clear high

< 2 Mismatch clear Intermediate

Match LL zone Intermediate

Match UL zone Low

Multiple Match Clear Low

Small (<25% of a segments)

> 3 N/A Clear Low

1 - 3 N/A Clear Very low

Non segmental

N/A Shows anatomicalreason for perfusion

abnormality

Very low

None

N/A N/A Normal

Wells clinical prediction rule for the diagnosis of pulmonary embolism (PE)

Page 1739: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1739/2049

Variable Points

Clinical signs and symptoms of DVT 3

Alternative diagnosis is less likely than PE 3

Heart rate > 100 bpm 1.5

Immobilization or surgery in the previous 4 weeks 1.5

Previous DVT or PE 1.5

Hemoptysis 1

Malignancy 1

Risk categories based on Wells score

(version used in PIOPED II)

Page 1740: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1740/2049

Risk category Cumulative score

Low <2

Intermediate 2-6

High >6

Risk categories based on Wells score

(version used in Christopher study)

Page 1741: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1741/2049

Risk category Cumulative score

PE unlikely ≤4 

PE likely >4

Page 1742: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1742/2049

Page 1743: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1743/2049

Page 1744: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1744/2049

Page 1745: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1745/2049

 Most common symptoms of

PE (PIOPED study)

Dyspnea (73%)

Pleuritic chest pain (66%)

Coughing (37%)

Hemoptysis (13%)

Abdominal/ pelvic pain

Page 1746: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1746/2049

 

Atypical

presentations of PE

bdo a / pe c pa

Decreasing level ofconsciousness

Fever

Productive cough

Seizures

Syncope

Wheezing

  AMI

Acute stroke

DIC

Page 1747: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1747/2049

Conditions

associated with D-

Dimer production

Advanced age

Heart failure

Connective tissue disease

Infection

Malignancy

Post operative

Pregnancy

Renal failure

Trauma

Sickle cells

DVT

The following associated with matchedventilation/perfusion defects of lung

Page 1748: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1748/2049

scans

A. IV drug abuse

B. Congenital rubella syndrome

C. Histoplasmosis

D. Thymolipoma

E. Haematogenous metastases

The following associated with matchedventilation/perfusion defects of lung

Page 1749: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1749/2049

scans

• TFTFF

The following may cause perfusion

defects on lung scan

Page 1750: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1750/2049

A. SLE

B. TB

C. SarcoidosisD. Retrosternal goitre

E. Radiation pneumonitis

F. Anomalous pulmonary artery

G. Bronchial carcinoma

H. Congenital lobar emphysema

I. Haemangioendoliomatosis

The following may cause perfusion

defects on lung scan

Page 1751: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1751/2049

•TTTTTTTTT

Concerning PE

Page 1752: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1752/2049

A. A single perfusion defect separated from thepleural surface by a rim of normal perfusion israrely due to embolus

B. Normal perfusion exclude clinically significant PE

C. The combination of clinical impression and lungscan results is a better predictor of PE thaneither taken alone

D. Patients with a low probability scan and no

evidence of venous thrombosis may be safelyleft untreated

E. He particle count of Tc-99 MAA may need to beincreased in patients with pulmonaryhypertension to achieved diagnostic images

Concerning PE

Page 1753: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1753/2049

•TTTTF

Total loss of perfusion to one lung

occurs in

Page 1754: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1754/2049

A. Bullous emphysemaB. Beckwith-Wiedmann syndrome

C. Following a Blalock-Taussig shunt

D. Pleural effusion

E. Swyer-James syndrome

Total loss of perfusion to one lung

occurs in

Page 1755: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1755/2049

•TFTTT

Regarding V/Q scanning in the

following up of confirmed PE

Page 1756: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1756/2049

A. Perfusion defects may clear at 24 hoursB. A perfusion defect still present at three

months is likely in persist indefinitely

C. A persistent defect implies lung infarctionD. Underlying heart failure may enhance the

resolution f perfusion defects

E. A repeat V/Q scan should be performed priorto stopping anticoagulation

Regarding V/Q scanning in the

following up of confirmed PE

Page 1757: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1757/2049

•TTFFT

The fissure sign occurs in

Page 1758: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1758/2049

A. Sub pulmonic effusionB. Cystic fibrosis

C. Sarcoidosis

D. PE

E. Emphysema

The fissure sign occurs in

Page 1759: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1759/2049

•TTFTT

Reverse V/Q mismatched occurs in

Page 1760: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1760/2049

A. Pulmonary atelectasisB. PE

C. Alveolar proteinosis

D. Bronchogenic carcinoma

E. Pleural effusion

Reverse V/Q mismatched occurs in

Page 1761: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1761/2049

•TFFTT

The visualization of the kidneys on Tc-99m MAA perfusion scan can be

caused by:

Page 1762: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1762/2049

caused by:

A. Right to left shunt

B. Free Tc-99m

C. MAA particle less than 10 µm in sizeD. Kidney obstruction

E. Less dehydration

The visualization of the kidneys on Tc-

99m MAA perfusion scan can be

Page 1763: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1763/2049

caused by:

• TTTFF

A. Low probabilityB. Intermediate probability

Page 1764: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1764/2049

C. High probability1. Clear CXR with multiple matched V/Q defects

2. Single large segmental V/Q mismatch

3. Perfusion defect < radiological infiltrate

4. Multiple small perfusion defect

5. Perfusion defects equal to radiographic

infiltrate

6. Lobar V/Q mismatch

A. Low probabilityB. Intermediate probability

Page 1765: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1765/2049

C. High probability1. Clear CXR with multiple matched V/Q

defects. A

2. Single large segmental V/Q mismatch. B

3. Perfusion defect < radiological infiltrate. A

4. Multiple small perfusion defect. A

5. Perfusion defects equal to radiographic

infiltrate. B

6. Lobar V/Q mismatch. C

Stripe sign generally is reflective of

Page 1766: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1766/2049

A. PEB. Non embolic disease such as COPD

C. Pulmonary hypertension

D. Pleural fluid

E. Asthma

Stripe sign generally is reflective of

Page 1767: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1767/2049

FTFFF

Matched absence or near absence ofperfusion and ventilation in the entire

lung may be associated with?

Page 1768: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1768/2049

lung may be associated with?

A. Lung carcinoma

B. Aspirated foreign body

C. Swyer James syndrome

Matched absence or near absence ofperfusion and ventilation in the entire

lung may be associated with?

Page 1769: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1769/2049

lung may be associated with?

• TTT

Regarding V/Q

Page 1770: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1770/2049

A. Kr-81m is generator producedB. Rb-81 is cyclotron produced

C. Albumin macroaggregates remain in thepulmonary capillary bed for weeks, limiting the

number of follow up perfusion scans that can besafely performed.

D. The biologic half life of MAA is longer thanalbumin microspheres

E. A patient with high pretest probability of PE, thenegative predictive value of a normal scanexceeds 95%

Regarding V/Q

Page 1771: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1771/2049

TTFFT

Regarding V/Q

Page 1772: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1772/2049

A. In a patient with low pretest probability of PE,the positive predictive value of positive scanexceeds 95%

B. The presence of the triad has a positive

predictive value of PE exceeding 95%C. V/Q scan is nondiagnostic in most patients with

pulmonary edema

D. Most patients with PE show infiltrate or effusionon properly exposed CXR

E. Absence of perfusion to an entire lung iscommon with PE

Regarding V/Q

Page 1773: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1773/2049

FFFFF

What are two commonly used

radiopharmaceuticals for ventilation

Page 1774: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1774/2049

imaging? What are their advantagesand disadvantages

What are two commonly used

radiopharmaceuticals for ventilation

Page 1775: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1775/2049

imaging? What are their advantagesand disadvantages

• Xenon-133 and Tc-99m DTPA aerosol. Xenon-133

demonstrates more clearly the physiology ofrespiration and is very sensitive to detection ofobstructive airways disease manifested by slowwashout. The disadvantages is the rapid washout, itssuboptimal view due to low photopeak (81 keV) andpoor count rate image.

• Tc-99m DTPA aerosol allows high count images in allprojections, however the images are comparable onlyto the inspiratory phase of xenon-133.

What is minimum number of particlesrecommended for pulmonary

perfusion imaging?

Page 1776: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1776/2049

perfusion imaging?

What is minimum number of particlesrecommended for pulmonary

perfusion imaging?

Page 1777: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1777/2049

perfusion imaging?

• This requires at least 100,000 particles in

normal adults and many authorities

recommend a minimum of 200000  –  500000

particles.

What is the size range of MAAparticles?

Page 1778: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1778/2049

What is the size range of MAAparticles?

Page 1779: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1779/2049

In commercial preparations the majority ofparticles are 20 to 40 υm with a range of 10 – 

90 υm.

What is the biological fate of MAAparticles?

Page 1780: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1780/2049

What is the biological fate of MAAparticles?

Page 1781: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1781/2049

MAA particles are easily broken down in thelung. Delayed imaging performed several

hours after pharmaceutical administration

demonstrates activity in the

reticuloendothelial system because of

phagocytosis of the breakdown particles.

Pearl

Page 1782: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1782/2049

One way to determine whether radioactivityoutside of the lungs is caused by free Tc-99m

or shunted Tc-99m MAA is to image the brain.

Free pertechnetate should localize in the

brain, whereas Tc-99m MAA particles that gain

access to the systemic circulation will lodge in

the first capillary bed that they encounter,

including the capillary bed in the brain.

What is the preferred patient positionduring administration of Tc-99m MAA?

Page 1783: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1783/2049

What is the preferred patient positionduring administration of Tc-99m MAA?

Page 1784: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1784/2049

Administering Tc-99m MAA with the patientsupine results in a more homogenous

distribution of particles in the lung than when

the patient is sitting or standing.

What is the stripe sign?

Page 1785: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1785/2049

What is the stripe sign?

Page 1786: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1786/2049

Stripe sign refers to a stripe or zone of activityseen between a perfusion defect and the

closest pleural surface. Because PE are

typically pleura based, the stripe sign suggests

another diagnosis, often emphysema.

What is physiological basis forperfusion defects in areas of poor

ventilation?

Page 1787: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1787/2049

ventilation?

What is physiological basis forperfusion defects in areas of poor

ventilation?

Page 1788: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1788/2049

ventilation?

• The classic response to hypoxia at the alveolar

level is vasoconstriction. Shunting a blood

away from the hypoxic lung zone maintains

oxygen saturation.

What is the shrunken lung sign?

Page 1789: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1789/2049

What is the shrunken lung sign?

Page 1790: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1790/2049

The lung may appear smaller than usual inpatient sustaining multiple small emboli, such

as fat emboli, that distribute uniformly around

the lung periphery

What is the classical appearance ofmultiple PE on lung perfusion

scintigraphy?

Page 1791: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1791/2049

scintigraphy?

What is the classical appearance ofmultiple PE on lung perfusion

scintigraphy?

Page 1792: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1792/2049

scintigraphy?

• Multiple pleura-based, wedged shaped areas

of significantly diminished or absent

perfusion. The size of the defect may varyfrom subsegmental to segmental or may

involve an entire lung or lobe.

What is the sensitivity of the highprobability scan category for detecting

Page 1793: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1793/2049

pulmonary embolism?

What is the sensitivity of the highprobability scan category for detecting

Page 1794: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1794/2049

pulmonary embolism?• In the PIOPED study, 41 % of patients with PE

had a high probability scintigraphy pattern.

What are the most common clinical

signs and symptoms in patients with

Page 1795: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1795/2049

confirmed PE?

What are the most common clinical

signs and symptoms in patients with

Page 1796: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1796/2049

confirmed PE?• In PIOPED, the three most common presenting

symptoms, dyspnea 80%, pleuritic chest pain

60% and cough 40%.• On physical examination, lung crackles 60 %,

leg swelling 30% or pleural friction rub 5%.

Page 1797: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1797/2049

High probability of PE

1 Perfusion is decreased in the right lower lobe

Page 1798: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1798/2049

1. Perfusion is decreased in the right lower lobeexcept for the superior segment. Ventilation istruncated in the right lower lobe consistent withsubpulmonic effusion

2. High probability for PE. Mismatch between

perfusion and ventilation is evident in the basalsegment. The perfusion defect is considerablylarger than the effusion on the X-ray

3. > 90%

4. Most common : Normal5. Next most common : atelectasis

Page 1799: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1799/2049

Hot spots on lung scan

1 Multiple hot spot are present in the upper and lower

Page 1800: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1800/2049

1. Multiple hot spot are present in the upper and lowerlobes, predominately in the right lung field

2. Radioactive emboli as a result of poor techniquecaused by drawing back blood into the syringecontaining the Tc-99m MAA before injection of the

radiotracer, causing clumping

3. The lungs, the target organ, received 5 mCi from Tc-99m MAA. Approximately 0.2 rads to the lung from a20 mCi xenon study

4. The biological half life is brief. The patient breathesXe-133 gas to equilibrium, then expels it into a trap.Only Xe-133 absorbed as a result of fat solubility hasany appreciable biological half life

Page 1801: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1801/2049

Ventilation perfusion stripe sign,emphysema

1 Decreased upper lobe ventilation is seen on the

Page 1802: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1802/2049

1. Decreased upper lobe ventilation is seen on thesingle breath with air trapping in both upperlobes and the right lower lobe on washoutimages

2. Decreased perfusion to the majority of bothlungs, with preserved perfusion in thesubpleural lung, most evident at the lung basesand medial aspect of both upper lobes

3. Low probability4. Stripe sign

Page 1803: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1803/2049

Hampton’s Hump – intermediateprobability

1. Posteroanterior and lateral chest radiographs

Page 1804: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1804/2049

1. Posteroanterior and lateral chest radiographsdemonstrate a pleural based opacity in the lateralright lung base

2. A single wedge shape, pleural based defect in thesame location as the radiographic abnormality,

probably the anterobasal segment of the right lowerlobe. Normal Xe-133 ventilation study

3. Intermediate probability for PE

4. CXR findings in PE without infarction are uncommon.When present, they are usually associated with alarge, central embolus. Discoid atelectasis is the nextmost common finding

Page 1805: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1805/2049

Emphysema caused by alfa 1antitrypsin deficiency

1. Single breath or wash in, equilibrium and wash out phase

Page 1806: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1806/2049

g , q p

2. Single breath : patient breathes in and holds a singlemaximum deep inspiration while a 100000 count image isacquired. Equilibrium : patient breathes a mixture of airand xenon while serial images are obtained every 60  – 90seconds for 3 minutes. Washout : patient breathes room

air and exhales xenon while serial images are obtained3. Ventilation : nonuniform in the upper lung zones

bilaterally, initial near absent at the bases. As upper lobeswash out, xenon fills and is retained in both basesindicating severe air trapping. Perfusion : heterogeneous

to both upper lung zones that match the early ventilationimages. The extensive perfusion abnormalities in bothlower lung zones are matched with areas of washout airtrapping

4. Low probability for PE, alfa 1 antitrypsin deficiency

Page 1807: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1807/2049

Tc-99m DTPA ventilation study withaerosol clumping

1. Multiple perfusion defects in upper and lower lung fields. Many appear

Page 1808: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1808/2049

segmental e.g.., the lateral of the right lower lobe, superior segment ofthe left lower lobe. Ventilation shows extensive diffused clumping withinthe air ways throughout both lung fields making determination ofmatching or mismatching difficult. The study was interpreted asintermediate probability since ventilation study could not be interpreted,however the segmental perfusion defect pattern is suspicious forembolus

2. Tc-99m DTPA aerosol provide (0.1  –  0.5 υm) normally distribute on firsimpact within alveoli. With airway turbulence e.g.., asthma or COPD,particles impact proximally within bronchi and appear as focal hot spot

3. Tc-99m DTPA aerosol ventilation is performed first. The patient breathesin less than 1 mCi at tidal volume until an adequate count rate isobtained the sixfold larger Tc-99m MAA perfusion dose (5 mCi)

overwhelms the retained ventilation dose, allowing the two consecutiveTc-99m studies

4. Xe-133 an inert gas, is advantageous for patients with COPD and asthma.Delayed filling and clearance in regions of obstructive disease can beseen. Disadvantage : only posterior views are possible because of rapidexhalation

Page 1809: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1809/2049

Low probability V/Q scan

1. Bilateral inhomogeneous distribution. Matched

Page 1810: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1810/2049

gperfusion and ventilation abnormalities throughoutthe upper and lower lobes, especially in the rightlower lobe basal segments. Minimal atelectasis in thelower lobes in chest x-ray. Low probability for PE

2. < 20%3. < 1 %

4. Large (segmental): > 75% of a segment

Moderate (subsegmental): 25% to 75% of a segmentSmall (small subsegmental):< 25% of a segment

Page 1811: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1811/2049

Intermediate probability andpregnancy

1. Bronchodilator therapy before V/Q scan as an asthmatic

Page 1812: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1812/2049

therapeutic trial2. PE are life threatening to the patient and fetus. The radiation

dose to the patient and fetus is low (< 2 rads). The benefit/riskratio is high. No change in procedure is required. In young,nonsmoking patients without cardiopulmonary disease, one

might reduce the dose, conduct only a perfusion study or both3. Hypoperfusion of the left lower lobe, except the superior

segment. Better ventilation than perfusion with mismatching inthe anterior basal and part of the lateral basal segments. Noventilation in the posterior basal and part of the lateral basal.

Costrophenic angle loss seen in the left lateral and LPO views.CXR: atelectasis/ infiltrate with elevation of the left diaphragm

4. Intermediate probability for PE. One large/ one moderatesegmental mismatch and one large and one moderate segmentalmatch corresponding to the x-ray atelectasis/infiltrate

Page 1813: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1813/2049

High probability of PE

1. Perfusion: decreased right lower lobe except for

Page 1814: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1814/2049

the superior segment. Ventilation: normalexcept for mildly truncated right lower lobeconsistent with subpulmonic effusion

2. High probability of PE. Mismatch between

perfusion and ventilation in the basal segments.The perfusion defect is considerably larger thanthe pleural effusion on the radiograph

3. > 80%

4. Most common: normal, next most common:atelectasis

Page 1815: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1815/2049

Stripe sign

1. Decreased perfusion in the right upper lobe

Page 1816: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1816/2049

(apical and anterior segment). Stripe sign of theposterior segment of the right upper lobe. Normalventilation

2. Two segmental mismatched. High probability of PE

3. Its presence signifies perfused lung tissuebetween a perfusion defect and the adjacentpleural surface. Its presence can be use to classifya segment as not related to PE.

4. Usually a manifestation of airway obstruction. Thesign has been correlated with CT and PET showingspared perfusion of the cortex of the lung inasthma and emphysema

Page 1817: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1817/2049

Unilateral matched V/Q abnormality

1. Perfusion: global decreased perfusion to the

Page 1818: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1818/2049

g pentire left lung, more striking than theventilation. Xe-133 ventilation images:decreased and delayed ventilation of the entireleft lung. Washout images show no significantair trapping

2. Low probability

3. Hilar mass, severe unilateral parenchymal lung

disease, prior shunt for congenital heart disease4. Lung cancer

Page 1819: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1819/2049

PET and oncology

Page 1820: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1820/2049

 

Page 1821: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1821/2049

 

Page 1822: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1822/2049

 

Page 1823: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1823/2049

 

 

Page 1824: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1824/2049

• A : without

attenuation

corrected

• B : with attenuation

corrected

Page 1825: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1825/2049

 

Page 1826: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1826/2049

 

Page 1827: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1827/2049

 

 

Page 1828: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1828/2049

 

HG = high grade

If spleen > liver = post chemo

Page 1829: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1829/2049

 

Page 1830: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1830/2049

 

Page 1831: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1831/2049

Page 1832: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1832/2049

Ur Metser, MD, Einat Even-Sapir, MD, PhD, Semin Nucl Med 37:206-222 © 2007

Page 1833: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1833/2049

Page 1834: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1834/2049

Ur Metser, MD, Einat Even-Sapir, MD, PhD, Semin Nucl Med 37:206-222 © 2007

Page 1835: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1835/2049

Ur Metser, MD, Einat Even-Sapir, MD, PhD, Semin Nucl Med 37:206-222 © 2007

Page 1836: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1836/2049

Ur Metser, MD, Einat Even-Sapir, MD, PhD, Semin Nucl Med 37:206-222 © 2007

Page 1837: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1837/2049

Ur Metser, MD, Einat Even-Sapir, MD, PhD, Semin Nucl Med 37:206-222 © 2007

Page 1838: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1838/2049

Ur Metser, MD, Einat Even-Sapir, MD, PhD, Semin Nucl Med 37:206-222 © 2007

Page 1839: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1839/2049

Ur Metser, MD, Einat Even-Sapir, MD, PhD, Semin Nucl Med 37:206-222 © 2007

Page 1840: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1840/2049

 

Page 1841: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1841/2049

 

Page 1842: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1842/2049

 

Page 1843: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1843/2049

 

Page 1844: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1844/2049

Brown Fat

• Sedation

Page 1845: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1845/2049

• Adrenergic blocking agents

  Higher tumor grade

Large number of variable

cells

Increased tumor blood flow

Page 1846: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1846/2049

High FDG uptake

Increased tumor blood flow

Inflammation

Tumor hypoxia

Acute radiation

Recent chemotherapy

Recent surgery

  Benign lesion

Necrosis

Mucinous bronchoalveolar

Page 1847: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1847/2049

Low FDG uptake

Mucinous , bronchoalveolar

carcinoma

Hyperglycemia

High insulin

Chronic radiation

Scar

Prior chemotherapy

History Course of action

Prior surgery Delay scan 4-6 weeks

Chemotherapy Delay scan several weeks or schedule

scan just before next cycle

Page 1848: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1848/2049

scan just before next cycle

Radiation therapy Delay scan at least 3 months

Colony stimulating factor Delay scan for 1 week for short actingagents or several weeks for long

acting agents

Serum glucose > 200 Reschedule scan

Insulin administration Wait at least 2 hours

Breastfeeding Discontinue scan at least 6 hours

 

Page 1849: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1849/2049

 

Page 1850: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1850/2049

 

Page 1851: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1851/2049

 

Page 1852: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1852/2049

Which of these statements is trueregarding F-18 FDG PET?

A. F-18 FDG uptake is normally high in brain and

heart

Page 1853: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1853/2049

heart

B. The mechanism of F-18 FDG uptake and

metabolism is identical to that glucose

C. Oncology patients should fast for at least 4

hours prior to injection

D. Unlike glucose, F-18 FDG is excreted through

the genitourinary system

Which of these statements is trueregarding F-18 FDG PET?

• TFTT

Page 1854: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1854/2049

The sensitivity of FDG PET is high fordetection of many malignancies. For

which of the following tumors is the

sensitivity of FDG PET not high?

Page 1855: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1855/2049

sensitivity of FDG PET not high?

A. Colorectal cancer

B. MelanomaC. Hepatocellular carcinoma

D. Renal cell carcinoma

E. Lymphoma

The sensitivity of FDG PET is high fordetection of many malignancies. For

which of the following tumors is the

sensitivity of FDG PET not high?

Page 1856: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1856/2049

sensitivity of FDG PET not high?

FDG PET has poor sensitivity for primary

hepatocellular carcinoma, renal cell carcinomaand prostate cancer.

This is less true of metastatic disease than

primary tumors.

Concerning F-18 FDG PET in lungcancer staging

A. The sensitivity for detection is high for

tumors of 5mm and greater size

Page 1857: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1857/2049

tumors of 5mm and greater size.

B. Sensitivity and specificity of FDG PET is

higher than CT for mediastinal staging for

lung cancer.

C. False negatives may be seen with

hyperglycemia.

D. False negatives may occur with

bronchoalveolar carcinoma

Concerning F-18 FDG PET in lungcancer staging

• FTTT

Page 1858: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1858/2049

What are the advantages CT PET overPET alone?

A. Automated hardware and software fusion for

anatomical fusion

Page 1859: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1859/2049

anatomical fusion

B. Diagnostic CT at the same time as the PET

scan.

C. CT is used for more rapid attenuation

correction.

D. Eliminates false positive interpretation.

What are the advantages CT PET overPET alone?

• TFTF

Page 1860: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1860/2049

What are some limitations of FDG PETin tumor staging?

Page 1861: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1861/2049

What are some limitations of FDG PETin tumor staging?

• PET imaging does not detect microscopic

metastases tumor involvement in local LNs

Page 1862: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1862/2049

metastases, tumor involvement in local LNs

may be obscured by activity in an adjacent

tumor, concurrent infection/inflammatory

process may cause false positive andsensitivity for intracranial metastases is low.

What are limitations of tumorrestaging by PET?

Page 1863: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1863/2049

What are limitations of tumorrestaging by PET?

• Posttherapy effect of surgery, chemotherapy

and radiation therapy may cause increased F-

Page 1864: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1864/2049

and radiation therapy may cause increased F-

18 FDG uptake, which can be confused activity

from active tumor.

• Even patients scheduled for imaging after an

appropriate delay after therapy may require

follow up imaging.

What are some differences between

nonattenuation corrected and

attenuation corrected PET images?

Page 1865: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1865/2049

What are some differences between

nonattenuation corrected and

attenuation corrected PET images?

Nonattenuation

Page 1866: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1866/2049

• Structures near surface more intense

• The skins more intense

• The lungs more intense

Nonattenuationcorrected

Lung carcinoma

• PET sensitivity in 1 node is 75%

• Pet sensitivity for mediastinal involvement is

Page 1867: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1867/2049

• Pet sensitivity for mediastinal involvement is

91%

• Adrenal is most common metastasis site

Lung carcinoma

Epidemiology 

Page 1868: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1868/2049

UK = 38000 cases

22000 men and 16000 women Death = 34000 per annum

Peak incidence in Europe 60-70 years

3 x more common in men

Lung carcinoma

Small cell carcinoma Non small cell carcinoma

Page 1869: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1869/2049

25% 75%

Oat cell Intermediate cell Squamous cell

50%

Adenocarcinoma

15%

Large

Cell

Anaplastic

10%

Bronchoalveolar Acinar

Papillary

Solid

Bronchial derived

Lung carcinoma

Symptoms 

Page 1870: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1870/2049

Cough

Hemoptysis Dyspnea

Chest pain

Recurrent chest infection

Lung carcinoma

Signs

Page 1871: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1871/2049

Finger clubbing

Nicotine staining Cervical sympathetic (Horner’s  syndrome)=

partial ptosis/ miosis (pupil constriction)/

enopthalmos/ anhydrosis Wasting of hand

Lung carcinoma

Differential diagnosis

Page 1872: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1872/2049

Benign tumors-papilloma/ carcinoid/

leiomyoma

Metastasis

Primary malignant-mesothelioma/ soft tissue

sarcoma Chronic lung abscess

Radiographic artifact-nipple shadow

Lung carcinoma

Investigation

Page 1873: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1873/2049

CXR

Sputum cytology

Bronchoscopy CT

MRI

Bone scan Indirect laryngoscopy

Lung function test

Page 1874: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1874/2049

Page 1875: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1875/2049

Page 1876: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1876/2049

Page 1877: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1877/2049

Stage TNM

Ia T1 N0 M0

Ib T2 N0 M0

Staging lung carcinoma based on TNM classification scheme

Page 1878: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1878/2049

IIa T1 N1 M0

IIb T2 N1 M0

T3 N0 M0

IIIa T3 N1 M0

T1-3 N2 M0

IIIb T4 N0-2 M0

T1-4 N3 M0

IV Any T Any N M1

Based on AJCC staging system 1997

Page 1879: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1879/2049

Page 1880: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1880/2049

Page 1881: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1881/2049

Page 1882: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1882/2049

Page 1883: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1883/2049

Page 1884: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1884/2049

Page 1885: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1885/2049

Page 1886: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1886/2049

Single pulmonary nodule

1. Only 20% to 30% are malignant. Higher for

smoker 50%.

Page 1887: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1887/2049

2. CXR/CT criteria, 30% - 40% are

indeterminate, 50% are benign.

3. High.

4. False negative: lesion < 1cm, bronchoalveolar

carcinoma and carcinoid tumors. False

positive: benign tumor, inflammatory,

infection (TB).

Page 1888: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1888/2049

Lung carcinoma staging

1. Focal increased uptake corresponding to the

nodule on CT. abnormal uptake is seen in thei ht d l ft t h l i th i ht

Page 1889: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1889/2049

right and left paratracheal regions, the rightand left hilum and mediastinum.

2. FDG PET has preoperatively upstaged thepatient, who is no longer a surgicalcandidate.

3. 65%

4. 85%

Breast carcinoma

Epidemiology

Page 1890: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1890/2049

UK = 45000 cases

325 arising in men

12000 death per annum

Peak age incidence 50-70 years

Breast carcinoma

Etiology

Page 1891: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1891/2049

Family history

Menstruation > 12 or stop >55 years

On HRT

Women with no borne children

Women have had children late > 30 years

Overweight

Alcohol

Breast carcinoma

Classification

Page 1892: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1892/2049

Ductal carcinoma in situ

Lobular carcinoma in situ

Inflammatory breast carcinoma

Paget’s disease of the breast 

Basal cancers

Male breast cancer

Breast carcinoma

Differential diagnosis

Page 1893: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1893/2049

Fibroadenoma

Breast abscess

Fat necrosis

Galactocoele

Breast carcinoma

Investigations

Page 1894: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1894/2049

Mammography

FNA

Ultrasound

MRI

Excision biopsy

Page 1895: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1895/2049

Page 1896: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1896/2049

(ipsilateral mobile axillary nodes)

(ipsilateral fixed axillary nodes)

(ipsilateral internal mammary nodes metastasis)

GIST

Mesenchymal neoplasm

70% arise from stomach

Page 1897: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1897/2049

25% arise from small intestine

Express growth factor receptor with tyrosinekinase activity (c-kit) – detect by CD117

Highly malignant

Resistant to conventional treatment

Staging TNM(Gastrointestinal)

Tis – carcinoma in situ

T0 – no evidence of primary TX – primary cannot be assessed

Page 1898: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1898/2049

p y

T1 – involving lamina propria/submucosa

T2 – involving muscularis propria/subserosa

T3 – penetrates serosa T4 – involving adjacent structures

N0 – 1 – 6 nodes involved

N2 – 7 -15 nodes involved

N3 - > 15 nodes M0 – no distant metastasis

M1 – distant metastasis

Colon carcinoma

Epidemiology

Page 1899: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1899/2049

UK = 36000 cases, 22000 men and 16000

women

3rd commonest

16000 deaths per annum

Occur 50 years of age

Colon carcinoma

Etiology

Page 1900: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1900/2049

Diet – high meat/fat/calorie/alcohol

First degree

Polyps

Chronic Crohn’s colitis 

Colon carcinoma

Symptoms

Page 1901: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1901/2049

Change in bowel habit

Blood per rectum

Mucus per rectum

Tenesmus

Obstructive symptoms

Iron deficiency anemia

Colon carcinoma

Investigations

Page 1902: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1902/2049

Digital PR examination

Double contrast barium enema

Colonoscopy

CT

MRI

Colon carcinoma

DUKES Staging

Page 1903: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1903/2049

Dukes’  A/ stage A  –  invasion into but not

through bowel wall

Dukes’  B/ stage B  –  involving bowel wall but

not lymph nodes

Dukes’ C/ stage C – involvement of nodes

Dukes’ D/ stage D - metastasis

TNM colorectal carcinoma

Page 1904: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1904/2049

TNM colorectal carcinoma

Page 1905: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1905/2049

Page 1906: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1906/2049

Colorectal carcinoma

1. Increased uptake consistent with tumor in the

liver corresponding to CT mass. No other liverlesions or metastases are seen elsewhere.

Page 1907: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1907/2049

2. Surgical resection is planned. The preoperativeFDG PET scan is used to determine the presence

of any other metastases in the liver orelsewhere.

3. a. increased serum CEA with normalconventional imaging. b. equivocal lesion withconventional imaging. c. preoperative stagingbefore curative resection.

4. Negative scan. No evidence of tumor.

Page 1908: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1908/2049

Colorectal carcinoma

1. Large abnormal region of increased uptake in

the pelvis consistent with recurrent tumor. Alarge tumor is present in the left pelvis adjacentt th bl dd i dditi t lti l ll it

Page 1909: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1909/2049

to the bladder in addition to multiple small sitesof tumor uptake.

2. Tc-99m CEA is superior to CT in extrahepaticabdomen and pelvis but equal to CT in detectingtumor in the liver.

3. Rising serum CEA level with negative CT findings.Potentially resectable recurrent disease, usuallyin the liver, done to exclude other metastasesthat would preclude surgery.

4. In-111 Oncoscint and FDG PET

Prostate carcinoma

Epidemiology

Page 1910: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1910/2049

UK = 35000 cases = 12% cancer cases and

10000 deaths per annum

Age over 70 years

2nd most common after lung carcinoma

Prostate carcinoma

Symptoms

P t ti tfl b t ti t

Page 1911: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1911/2049

Prostatic outflow obstructive symptoms: poorstream/ frequency/ terminal dribble/ nocturia

Erectile dysfunction Haematospermia

Bone pain

Hypercalcemia

Prostate carcinoma

Investigations

PSA l 4 / l

Page 1912: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1912/2049

PSA = normal 4 ng/ml

Blood test = hypercalcaemia

Biopsy

IVU

CT scan

Bone scan

MRI

Page 1913: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1913/2049

Page 1914: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1914/2049

Prostate carcinoma

1. In-111 labeled monoclonal antibody directed

against the prostate specific membrane antigen,a glycoprotein expressed by normal and prostatecancer cells

Page 1915: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1915/2049

cancer cells.

2. CT and MRI sensitivity ranges from 5% - 20%.

Accuracy of In-111 ProstaScint is 70%.3. Paraaortic upper abdominal uptake consistentwith tumor adenopathy. Focal uptake in the leftupper chest consistent with tumor.

4. Recurrent tumor limited to the prostate bed ormetastatic pelvic nodes require radiation ports.Extrapelvic metastases require systemic therapy.

Cervical carcinoma

Epidemiology

Page 1916: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1916/2049

UK = 2700 cases, 900 deaths per annum

Age 40 – 50 years

24000 carcinoma in citu (CIN III)

Cervical carcinoma

Etiology

HPV

Page 1917: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1917/2049

HPV

Intercourse at early age

Lower socioeconomic group

Oral contraceptive

Miscarriage

Smoking

Cervical carcinoma

Symptoms

Page 1918: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1918/2049

Vaginal bleeding

Vaginal discharge

Hematuria

Low back pain

Renal failure due to bilateral ureteralobstruction

Cervical carcinoma

Investigations

Page 1919: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1919/2049

Cervical cytology

Biopsy

CT scan

MRI

Cervical carcinoma

Page 1920: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1920/2049

Cervical carcinoma

Page 1921: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1921/2049

Ovarian carcinoma

Epidemiology

Page 1922: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1922/2049

UK = 6600 cases

2.3 % of all cancer cases

4400 cases deaths per annum

Ovarian carcinoma

Pathology

Common appearance

Page 1923: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1923/2049

Common appearance

• Psedomucinous cyst

• Serous cyst

Microscopic appearance

• Epithelial adenocarcinoma• Germ cell tumors

Ovarian carcinoma

Investigation

S CA 125

Page 1924: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1924/2049

Serum CA 125

CXR

Ultrasound

CT scan

Ovarian carcinoma staging

Page 1925: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1925/2049

Hodgkin’s Lymphoma

Epidemiology

UK 1500 850 d 650

Page 1926: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1926/2049

UK = 1500 cases, 850 men and 650 women

with 350 deaths per annum

Two peak incidence in young 20  –  30 years

and over 70 year

Hodgkin’s Lymphoma

Etiology

E t i B i

Page 1927: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1927/2049

Epstein Barr virus

Hodgkin’s Lymphoma

Symptoms

B t

Page 1928: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1928/2049

B symptoms:

1. Fever > 38⁰C 

2. Weight loss > 10%

3. Night sweat

Hodgkin’s Lymphoma 

Sign

E l d t k

Page 1929: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1929/2049

Enlarge nodes at neck

Hepatospleenomegaly

Abdominal mass

Inguinal nodes

Hodgkin’s Lymphoma 

Differential diagnosis

I f ti i / TB i l

Page 1930: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1930/2049

Infection: pyogenic/ TB or viral

Leukemia

carcinoma

Hodgkin’s Lymphoma 

Investigations

Bl d t

Page 1931: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1931/2049

Blood count

ESR

Serum LDH

Alkaline phosphatase

Marrow

CXR

CT/ MRI

PET scan

Biopsy

Non Hodgkin’s lymphoma 

Epidemiology

UK 10000 cases 5300 for men and 4800 for

Page 1932: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1932/2049

UK = 10000 cases, 5300 for men and 4800 for

women with 4500 deaths per annum

Occurs equally in men and women

More 50 years of age

Non Hodgkin’s lymphoma 

Epidemiology

UK 10000 cases 5300 for men and 4800 for

Page 1933: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1933/2049

UK = 10000 cases, 5300 for men and 4800 for

women with 4500 deaths per annum

Occurs equally in men and women

More 50 years of age

Non Hodgkin’s lymphoma 

Etiology

Infective agents : EBV/ helicobacter/ human T

Page 1934: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1934/2049

Infective agents : EBV/ helicobacter/ human T

cell lymphotropic virus/ HIV

Altered immune status

Irradiation

Non Hodgkin’s Lymphoma 

Sign

Enlarge nodes at neck

Page 1935: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1935/2049

Enlarge nodes at neck

Hepatospleenomegaly

Abdominal mass

Inguinal nodes

Non Hodgkin’s Lymphoma 

Investigations

Blood count

Page 1936: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1936/2049

Blood count

ESR

Serum LDH

Alkaline phosphatase

CSF - DLBCL

Marrow

CXR

CT/ MRI

PET scan

Biopsy

Hodgkin’s Lymphoma 

Classic HD

Nodular Lymphocyte rich

Page 1937: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1937/2049

Nodular sclerosis

Mixed cellularity

Lymphocyte depleted

Nodular

lymphocyte

predominant

Lymphocyte rich

Non Hodgkin’s lymphomaLow grade

Indolent

High grade

CurableAggressive and urgent

treatmentFollicular

Lympho

plasmacytoid

DLBCLBurkitt’s 

Lymphoblastic

Sezary syndrome

Page 1938: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1938/2049

Non Hodgkin s lymphoma Indolent

Respond well to chemo but

difficult to cure

T cellMantle cell

MALT

Lymphocytic

Peripheral T cell

Anaplasticlarge cell

Angiocentric

Adult T cellleukemia

Angioimunoblastic

Mycosis fungoides

Page 1939: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1939/2049

Page 1940: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1940/2049

Page 1941: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1941/2049

Page 1942: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1942/2049

Hodgkin’s disease 

1. FDG is glucose analog. Increased FDG uptake occurs

with increased glucose metabolism. Is taken upintracellularly and phosphorylated similar to glucose,however, unlike glucose, it can not be metabolized

Page 1943: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1943/2049

further and is intracellularly trapped.

2. a. intense multifocal uptake bilaterally in the neck,upper chest and parasternal regions. b. uptake limitedto the left neck. Study a. abnormalities are caused bymuscle tension. Diazepam 5 mg was take just beforestudy b.

3. 110 minutes. 2. 10 and 20 minutes. It is important toremember that the half life of positron are very short.

4. 3.2 rads/ 5 mCi to urinary bladder. Brain and heart.

Page 1944: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1944/2049

Intracranial lymphoma

1. Tl-201 was used. Tc-99m sestamibi also can

be used, however it is taken up by choroidplexus and could pose diagnostic problems in

Page 1945: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1945/2049

some cases.

2. Tumor, particularly lymphoma, versusinfection, usually toxoplasmosis or infection

e.g.. CMV or herpes simplex.

3. Malignant lymphoma.4. 90% sensitivity and false negative < 10%.

Page 1946: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1946/2049

Lymphoma

1. CT scan is in indeterminate, but FDG PETdemonstrates a complete response.

2. CT assessment of tumor response is based on adecreased in the size of the mass or completeresolution Post therapy residual masses are common

Page 1947: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1947/2049

resolution. Post therapy residual masses are commonand CT cannot differentiate residual tumor from post

therapy fibrosis and necrosis.3. Multiple high energy photopeak: 185, 300, 394

resulting poor image resolution, need delayed imagesfrom 2 to 3 days.

4. Study completed 2 hours after injection. FDG PETtarget to background ratio higher and image qualitysuperior to Ga-67.

Page 1948: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1948/2049

Hodgkin’s disease 

1. The bone scan shows mild increased uptake

at L3. The Ga-67 scan shows abnormaluptake in the L3 vertebral body, bilateralneck mediastinum right paratracheal

Page 1949: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1949/2049

neck, mediastinum, right paratrachealregions, posterior thorax, right lung base and

liver.2. Bone scan.

3. Hodgkin’s  disease, TB or atypical

mycobacteria; Hodgkin’s disease likely.4. Stage IV.

Page 1950: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1950/2049

Non Hodgkin’s lymphoma 

1. Adult dose is 10 mCi. Imaging performed 48 to

72 hours after injection.2. CT provides better sensitivity for initial staging.

Ga-67 is superior to CT after therapy and

Page 1951: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1951/2049

Ga-67 is superior to CT after therapy andresidual masses after therapy.

3. a, large mass in the anterior mediastinumextends to supraclavicular regions. b. completeresponse to therapy. The residual chest mass onCT caused by necrosis and fibrosis, not tumor.

4. Laxative may be given, and imaging may bedelayed as needed at 4 to 7 days after injection.

Axillary LNs

Page 1952: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1952/2049

Sentinel node

• Is the first lymph node bed which a tumor cell

would come if it penetrated into lymphaticfluid.

Page 1953: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1953/2049

• If axillary sentinel node is tumor free < 3%

chance of any tumor metastasis• Radiopharmaceutical= Tc-99m SC injected

subdermally/ periareolar/ intradermal or

peritumoral

Page 1954: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1954/2049

Scintimammography

1. Tc-99m sestamibi lipophilicity allows it to enter thecell where it is concentrated in the mitochondrialregion related to charge.

2. Patient A has prominent focal uptake in a right breastmass Patient B has definite focal uptake at the

Page 1955: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1955/2049

mass. Patient B has definite focal uptake at theperiphery of the breast prosthesis.

3. Accuracy of conventional mammography: sensitivity,70% to 95%; positive predictive value for cancer, 20%- 30%. Scintimammography trial: sensitivity/specificity, 75%/83%

4. Most false negative findings are in lesions less than 1cm. False positive findings occur in fibroadenomasand benign and malignant tumors other than breastcancer

Page 1956: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1956/2049

Scintimammography

1. The 5 year survival rate for breast cancerdecreases with axillary node involvement.Adjuvant chemotherapy is indicated.

2. A sentinel node biopsy drained by thel h i i d l b i

Page 1957: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1957/2049

lymphatics in a nodal basin.

3. If the sentinel node biopsy is tumor negative, noaxillary dissection is needed. If positive, axillarydissection is performed.

4. Tc-99m sulfur colloid is often used. It is injectedaround the lesion or biopsy site. Imaging usuallyis performed. At surgery a gamma probe is usedto help locate the sentinel node.

Head and neck carcinoma

• PET sensitivity for recurrence is 76-96%

• Negative predictive value > 90%

Page 1958: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1958/2049

Thyroid carcinoma

• PET sensitivity for poorly differentiated

carcinoma > 90%• Benefits for: anaplastic and Hurtle cell variant

Page 1959: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1959/2049

of follicular

Medullary thyroid carcinoma

• Arises from parafollicular cells

• Does not accumulate I-131• PET sensitivity 78% and specificity 79%

Page 1960: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1960/2049

• Can evaluate with :1. Somatostatin

2. DMSA pentavalent

3. Thallium 2014. Tc-99m sestaMIBI

Esophageal carcinoma

• PET sensitivity 95%

• LNs involvement sensitivity >70%

• LNs involvement specificity >90%

Page 1961: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1961/2049

p y

• Distant metastasis accuracy 83%

Colorectal carcinoma

• Primary sensitivity >90% : CT 60%

• LNs involvement sensitivity 85 – 99%

• LNs involvement specificity 71 – 87%

Page 1962: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1962/2049

• Alter management 29 – 36%

Melanoma

• PET sensitivity > 90% and specificity 87%

• PET alter treatment 20 – 26%

Page 1963: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1963/2049

• Α feto protein for hepatocellular carcinoma

• Ca 19-9 for pancreatic carcinoma

• PET less sensitive for hepatocellular carcinoma

Page 1964: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1964/2049

Breast carcinoma

• PET sensitivity 88% and specificity 79%

• > 2-5 cm PET sensitivity 92%• < 2 cm PET sensitivity 68%

Page 1965: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1965/2049

• LNs involvement sensitivity 79-100% and

specificity 66-100%

• False negative:

1. Well differentiated2. Slow growing : lobular/tubular/DCIS

Page 1966: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1966/2049

 

PET false – ve in

Mucinous

cystadenocarcinoma

Well differentiated

cystadenocarcinoma

Di i d i l

Page 1967: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1967/2049

PET false   ve in

ovarian carcinoma

Disseminated peritoneal

carcinomatosis

Borderline tumors

Stage I tumors confined to

the ovary

Testicular carcinoma

• PET sensitivity 84%

• PET negative predictive value is 94%

Page 1968: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1968/2049

Neuroendocrine tumor

Page 1969: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1969/2049

 

Page 1970: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1970/2049

 

Page 1971: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1971/2049

 

Page 1972: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1972/2049

 

Page 1973: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1973/2049

 

Page 1974: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1974/2049

 

Page 1975: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1975/2049

 

Page 1976: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1976/2049

 

Page 1977: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1977/2049

 

Page 1978: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1978/2049

 

Page 1979: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1979/2049

 

Page 1980: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1980/2049

 

Page 1981: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1981/2049

 

Page 1982: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1982/2049

 

Page 1983: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1983/2049

 

Page 1984: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1984/2049

 

Page 1985: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1985/2049

 

Page 1986: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1986/2049

 

Page 1987: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1987/2049

 

Page 1988: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1988/2049

 

Page 1989: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1989/2049

 

Page 1990: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1990/2049

 

Page 1991: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1991/2049

 

Page 1992: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1992/2049

 

Page 1993: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1993/2049

 

Page 1994: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1994/2049

 

Page 1995: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1995/2049

 

Page 1996: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1996/2049

 

Page 1997: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1997/2049

 

Page 1998: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1998/2049

 

Page 1999: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 1999/2049

 

Page 2000: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2000/2049

 

Page 2001: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2001/2049

 

Page 2002: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2002/2049

 

Page 2003: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2003/2049

 

Page 2004: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2004/2049

 

Page 2005: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2005/2049

 

Page 2006: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2006/2049

 

Page 2007: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2007/2049

 

Page 2008: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2008/2049

 

Page 2009: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2009/2049

 

Page 2010: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2010/2049

 

Page 2011: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2011/2049

 

Page 2012: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2012/2049

 

Page 2013: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2013/2049

 

Page 2014: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2014/2049

Radionuclide therapy

Bone metastasis

Intra articular therapy

Intra vascular therapyHepatocellular ca

Phosphorus 32 phosphate

Rhenium 188 lipiodol

Rhenium 188

Rhenium 188 HEDP

Phosphorus 32 phosphate

Phosphorus 32 phosphate

Yittrium 90 microsphere

I-131 lipiodol

Samarium 153 EDTMP

Page 2015: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2015/2049

Non Hodgkin’s LymphomaIntra cavity therapy

Polycythemia vera

Hyperthyroid / thyroid ca

Phosphorus 32 phosphatePhosphorus 32 phosphate colloid

I-131 NaI

Yittrium 90 citrate

I-131 anti CD 20 antibody

Strontium 89 chloride

PeptideNon specific

Tumor specific

Tumor imaging

Monoclonal

Thyroid ca

Tc-99m

Thallium-201

FDG

Gallium - 67

MIBI/tetrofosmin

MTC

Breast

MTC

Breast

Brain

Bone

MTC

Karposi sarcoma

I-131

HD

NHD

Hepatocellular

Melanoma

LungsHead & neck

Soft tissue sarcoma

Abd & pelvic tumors

MIBG

Adrenal medulla

NP-59

Adrenal cortex

DMSA(V)

MTC

Tc-99m CEA

Colorectal

I-111 pentreotide

Somatostatin

MTC

Tc 99m Neo Tect

Page 2016: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2016/2049

Organ specific

HotCold

ThyroidBone Brain

I-123

Tc-99m pertechnetate

Tc-99m SC Tc-99m DTPA

Tc-99m glucoheptonate

Hepatocyte

Tc-99m MDP

Tc-99m HDPTc-99m HIDA

In-111 satumomab (onco scint)

Ovarian

colorectal

In-111 capromab

Prostate

Liver

I-111 zevalin

NHD

Tc-99m Neo Tect

Somatostatin

Lungs ca

What is the mechanism of G-67 uptake

in tumors?

Page 2017: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2017/2049

What is the mechanism of G-67 uptake

in tumors?

• It’s binds to serum iron transport molecules suchas transferrin, which transport Ga-67 to thetumors.

• Ga-67 enters the extracellular fluid space via thetumor’s leaky capillary endothelium.

Page 2018: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2018/2049

• It’s bound to the tumor cell surface by transferrinreceptors and then transported into the cell,where it binds to proteins such as ferritin andlactoferrin, which are increased concentration in

tumors.

Ga-67 uptake is normally seen in which

of the following organs: salivaryglands, lacrimal glands, thymus,

spleen, breast and heart?

Page 2019: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2019/2049

Ga-67 uptake is normally seen in which

of the following organs: salivaryglands, lacrimal glands, thymus,

spleen, breast and heart?

• Normal uptake : salivary glands and lacrimal

glands. Spleen has uptake but is low level.

B t t k i i bl d t i t

Page 2020: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2020/2049

Breast uptake is variable and most prominent

in post partum.

• Children after chemo : thymus

Not normal : heart due to myocarditis andpericarditis.

Which malignant tumors useful for Ga-

67 for diagnosis, staging and restaging?

Page 2021: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2021/2049

Which malignant tumors useful for Ga-

67 for diagnosis, staging and restaging?

• Hodgkin’s disease• Lymphoma

• Hepatoma

Page 2022: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2022/2049

Hepatoma

• Melanoma

Which of the following statement

associated with Hodgkin’s and nonHodgkin’s lymphoma? 

A. Contagious spread of LN involvement in youngpatients.

B. Multicentric disease with a highly variable clinicalcourse and high incidence of extranodal tumorinvolvement

Page 2023: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2023/2049

involvement.

C. Mediastinal masses are common.D. Abdominal involvement of mesenteric and

retroperitoneal nodes is common.

E. High cure rate.

F. Variable clinical course that can be indolent or rapidlethal

Which of the following statement

associated with Hodgkin’s and nonHodgkin’s lymphoma? 

HD

• Contagious spread of LN

involvement in young

patients.

Non HD• Multicentric disease with a

highly variable clinical course

and high incidence of

Page 2024: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2024/2049

p

• Mediastinal masses arecommon.

• High cure rate.

extranodal tumorinvolvement.

• Abdominal involvement of

mesenteric and

retroperitoneal nodes is

common.• Variable clinical course that

can be indolent or rapid lethal

Tc-99m sestamibi has been used for

determination of malignancy of breastmasses.

A. Its accuracy is higher for palpable than fornon palpable masses.

B. Its sensitivity is poor for lesions less than 1

Page 2025: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2025/2049

cm in size.C. Fibroadenomas are always negative.

D. Useful for dense breast patients, previous

surgery, radiation therapy and breastimplants.

Tc-99m sestamibi has been used for

determination of malignancy of breastmasses

TTFT

Page 2026: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2026/2049

Regarding In-111 capromab pendetide

(ProstaScint)

A. Murine monoclonal antibody against aprostate specific membrane antigen expressby more than 95% of prostateadenocarcinomas.

B. Its main indication is for localization of soft

Page 2027: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2027/2049

tissue metastases after prostactomy inpatients with a rising PSA and negative bonescan.

C. Elevated human murine antibody (HAMA)titers are observed in 50% of patients.

D. SPECT is mandatory for the pelvis.

Regarding In-111 capromab pendetide

(ProstaScint)

• TTFT

Page 2028: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2028/2049

Regarding In-111 Octreoscan

A. It is somatostatin receptor imaging agent.

B. The sensitivity for all NET is very high.C. Highest uptake is seen in the spleen and

kidneys.

Page 2029: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2029/2049

D. Only NET have somatostatin receptors.

Regarding In-111 OctreoScan

• TFTF

Page 2030: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2030/2049

Lacrimal drainage study

Inner canthus

Page 2031: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2031/2049

Using 2 - 4 MBq Tc-99m pertechnetate

Face in front collimator

Imaging time 5,10, 15, 20 minutes

Page 2032: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2032/2049

Dacryoscintigram : Normal drainage on the left eye with obstruction on

the right eye at the level of common canaliculus

Radiosynovectomy

Page 2033: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2033/2049

Page 2034: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2034/2049

Page 2035: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2035/2049

Page 2036: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2036/2049

Page 2037: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2037/2049

Page 2038: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2038/2049

Page 2039: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2039/2049

Page 2040: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2040/2049

Page 2041: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2041/2049

Page 2042: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2042/2049

Page 2043: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2043/2049

Page 2044: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2044/2049

Page 2045: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2045/2049

Page 2046: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2046/2049

Page 2047: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2047/2049

Page 2048: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2048/2049

Page 2049: AZIMAT NUCLEAR PDF .pdf

8/10/2019 AZIMAT NUCLEAR PDF .pdf

http://slidepdf.com/reader/full/azimat-nuclear-pdf-pdf 2049/2049